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Abstract 
Background and aims: Homocysteine (Hcy), C-reactive protein (CRP), and Lipoprotein- 
associated phospholipase A2 (Lp-PLA2) have been associated with a high risk of cardiovascular 
disease. If casual, they are expected to provide additional tools for prevention. Utilising the unique 
properties of genetic variants (randomly allocated and unmodifiable), they could be used as 
unconfounded proxies of environmental exposures to investigate disease aetiology, known as 
Mendelian randomisation. Herein I conduct a series of Mendelian randomisation experiments to: 
(i) investigate the role of Hyc in stroke; (ii) judge causality of CRP in cardiovascular disease; (iii) 
investigate the validity of Lp-PLA2 as a therapeutic target in coronary heart disease (CHD) and; 
(iv) describe how the integration of cis-acting variants and their cognate proteins can be used to 
dissect causal pathways. 
Methods: For aim (i), I conducted synthesis research of published and unpublished studies 
investigating the MTHFR/C677T variant, Hcy and stroke. For aims (ii) to (iv), a series of 
prospective collaborations conducting de novo genotyping for CRP and PLA2G7 genes, were 
established using European-based cardiovascular genetic studies of adults. 
Results: The meta-analyses of studies on MTHFR/C677T-Hcy-Stroke to 2003, showed that 
subjects with the TT genotype had on average 1.93 µmol/L higher levels of Hcy compared with 
subjects with CC genotype, and an odds ratio (OR) of stroke of 1.26 (95%Cl: 1.14,1.40). An 
update analyses to 2008 showed that in both MTHFR-Hcy and MTHFR-stroke associations, 
studies in Asia had the largest effect, followed by Europe with intermediate effect, and lower or 
negligible effect in the Americas and Australasia. Analysis on CRP, indicated that subjects 
homozygous for the T-allele of CRP/+1444C>T variant despite having 0.68 mg/L higher levels of 
CRP, had no increase in risk of myocardial infarction (OR of 1.01 [95CI: 0.74,1.38]). A tagging- 
haplotype approach showed a gradual increase on CRP levels by haplotype, but no effect on 
CHID, diabetes or stroke. Analysis of the seven PLA2G7 tagging-SNPs showed that the best 
variant (rs1051931) had small to moderate effects on the Lp-PLA2 activity (up to 7% relative 
differences). No genetic signal with CHD was observed for any PLA2G7 variant, despite some 
comparisons including up to 8412 CHID cases. A description of the proof of principle, illustrating 
how to utilise cis-acting variants and their cognate proteins to distinguish causal from non-causal 
effects among correlated blood proteins was presented, using as an example 6 proteins that have 
been associated with CHD risk. 
Conclusions: Genetic evidence reported in this document suggested that the MTHFR effect is 
more pronounced in geographic regions associated with low folate intake. Genetic studies on 
CRP presented in this document indicated that CRP is unlikely to be causal in cardiovascular 
disease. A genetic approach using common variants in PLA2G7 had a reduced ability to confirm 
or reject Lp-PLA2 as a valid drug target. Finally, integration of cis-acting variants with their 
cognate proteins seems to be an effective way of dissecting biological pathways. 
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Chapter 1 Background and Aims 
1.1 Risk factors for cardiovascular disease, with focus on coronary heart disease and 
stroke 
Cardiovascular diseases (CVD) account for 20.3% of disability-adjusted life years lost in more 
developed countries and already 8.1% in less-developed countries. [1] Cardiovascular diseases as 
a group are the leading cause of death in the European Union, accounting for over 1.5 million 
deaths each year. Nearly half (42%) of all deaths in the European Union are from CVD. [2] In the 
United Kingdom (UK) although the age-adjusted CVD mortality has decreased in the last three 
decades, [3] it remained the primary cause of mortality responsible for 39% of all deaths in 
2002. [3] Coronary heart disease (CHD), the main form of CVD, causes over 170,000 deaths a 
year in the UK: approximately one in five deaths in men and one in six deaths in women. In 2003 
the prevalence estimated in UK adult population of CHD was 2.65 million, and it is expected that 
every year about 85,000 British individuals under 65 living in UK will have a new heart attack. [3] 
Coronary heart disease and stroke, the most common disorders within the CVD group, have both 
been associated with similar environmental and behavioural risk factors. [4) Smoking, 
hypertension, elevated blood cholesterol, diabetes, are considered well-accepted risk factors for 
CHD. [51 For stroke, hypertension, smoking, diabetes and atrial fibrillation are considered well- 
established risk factors, while in contrast to CHD, the role of cholesterol remains controversial. [61 
Despite a great advance in the understanding of the causes of CVD, mainly CHD, it is known that 
30% of cardiovascular events occurring in middle age subjects take place in individuals within the 
lowest portion (in quintile terms) of the continuous distribution of the established cardiovascular 
risk factors. [7] In addition, a considerable proportion of subjects with high levels of those 
established risk factors do not develop a cardiovascular event. Between 58% to 85% of subjects 
with at least one established risk factor within the clinically elevated range fail to develop a 
cardiovascular event after long follow-up (range from 14.4 to 24.4 years). [7,8] This has motivated 
the search for additional risk factors for CVD that might enhance disease prediction, and offer the 
prospect of new therapies. As a consequence, in recent years increasing attention has focused 
on the so-called emerging risk factors such as infection, [9] homocysteine (Hcy), [10] and markers 
of the inflammatory response (e. g. C-reactive protein [CRP], and Lipoprotein-associated 
phospholipase A2 [Lp-PLA2]). [11,121 However the precise causal role of these putative factors on 
the natural history of different types of cardiovascular disorders remains to be established. 
To date, the main disciplines contributing to the identification of possible new risk factors for CVD 
are the laboratory research and the traditional observational epidemiology. Despite its inherent 
limitations, observational epidemiology has played an important role in our understanding of the 
established risk factors for CVD, and has had a considerable impact in public health and clinical 
practice. However, in recent years well-known discrepancies between the findings from 
18 
observational studies and randomised clinical trials in cardiovascular disease, (and also cancer), 
has brought to focus the need for careful design to control for the main threats of validity in 
observational research. [13,141 Spurious associations in observational epidemiology may be the 
result of uncontrolled confounders and reverse causation, but such studies are also prone to other 
types of bias. Assessing the likelihood and magnitude of such biases or systematic errors is 
complicated because some confounding factors may be unknown or difficult to measure and 
ascertaining the starting time for exposure and disease may not be possible raising the potential 
for reverse causation [151 
In contrast, randomised trials, although aimed to at evaluating the efficacy of interventions and the 
reversibility of an exposure, arise as a better design in the hierarchy of research to help in 
determine causal role of environmental exposures. The basic concept behind that superiority of 
clinical trials over observational studies is the randomisation process, which makes the groups 
being evaluated comparable for any known and unknown characteristics, which abolishes the 
possibility of spurious results due to confounding. [16] If high levels of a certain exposure are 
associated with an increase in disease risk, an intervention that specifically reduces the levels of 
that exposure in subjects randomised to that intervention should lead to a lower event rate if that 
exposure is causal. That has been the case for blood pressure and cholesterol, in which 
randomised clinical trials have provide strong evidence of a causal role on coronary heart 
disease, which was previously suggested by prospective cohort studies. [17] However, because of 
the lack of specific interventions, or because the conduct of a clinical trial may be unethical or 
logistically unachievable, randomised trials to evaluate causality may not be practical. Inference 
on causality then mainly resides on non-randomised observations (on humans: classic 
observational epidemiology) or experimentation (in animal models, systems, or cells/tissues). An 
emerging genetic approach offers an opportunity to substantially reduce some of the limitations 
from observational studies, when inference on causality from environmental risk factors is 
evaluated, that might help to prioritise the development of new therapies, which is a costly 
endeavour. 
1.2 Limitation of observational epidemiology for aetiological studies, with a focus on 
biomarkers in cardiovascular disease 
In an ideal setting, to evaluate causality a study should compare individuals with themselves in 
both an exposed and unexposed state over the same time. Such as approach is clearly not 
realistic and is referred to as counterfactual. [18] Since we cannot achieve the counterfactual ideal, 
we strive to come as close to it as possible. The aim would be to find an unexposed population 
that would give a result close to, if not identical, with that, of the counterfactual companson. [18] 
An strategy that attempts to generate comparable groups is the "randomisation" process involved 
in a clinical trial, in which two generated groups are comparable for any characteristic, with the 
exception of the intervention to which they are randomised. Because of the impossibility of 
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generating comparable groups fulfilling the counterfactual ideal, results from any epidemiologic 
study deviate from the truth, due to the presence of systematic and random errors. [181 The 
systematic error is what is left after an study became infinitely large in which the random error 
disappears. Systematic error affects the validity of the results from an epidemiologic study. There 
are three main groups of systematic error or biases that affect the results of an observational 
epidemiology: selection bias, information bias and confounding. [18] 
Case-control and prospective cohort studies are the main designs used to identify associations in 
terms of relative risks between certain biomarkers (a term used to reflect uncertainty regarding 
their aetiological role) and later cardiovascular events such as myocardial infarction (MI) or stroke. 
These biomarkers include representatives from lipid, inflammatory, metabolic and pro-oxidant 
pathways e. g. lipoprotein (a), high-density lipoprotein, Hcy, CRP, and interleukin-6, among many 
others. However, the validity of these associations is often called into question due to the 
presence of systematic error which will compromise the causal inference on the role of a certain 
biomarkers as a relevant therapeutic targets for which a specific intervention and then a 
randomised trials need to be developed. In the cardiovascular arena, systematic error is mainly 
due to the possibility of residual confounding and reverse causation, among the many possible 
biases. Since several novel biomarkers are often associated with one or more exposures that 
causally affect risk of CVD such as blood pressure, smoking, obesity, diabetes and physical 
activity, confounding becomes an important issue. [19] Despite, several existing strategies to 
reduce confounding by matching, restriction or statistical adjustment, not all the relevant 
confounders are measured in every single study as some of them are unknown at the time of 
conducting the study. Also a problem is the presence of unavoidable errors in measurement of 
potential confounders. [14,15,181 An additional limitation, that is becoming more relevant with the 
ample use of biomarkers is that for a variable to be classified as a confounder of the exposure 
(biomarker) of interest, it should not lie in the causal pathway of linking the biomarker of interest 
with the outcome. If it does inappropriate adjustment will arise and it will tend to bias the results. 
For example, if the association between a biomarker and CVD is mediated through blood 
pressure, or a second biomarker, rather than confounded by them, adjustment for these factors 
will lead to an inappropriate loss of association. 
Many biomarkers studied (e. g. CRP, Hcy and LpPLA2) are also higher in subjects with 
established CVD which makes reverse causation a possible explanation. This is because, the 
natural history of the atherosclerotic process, the key factor in CHD and ischaemic stroke, begins 
in the early adulthood with the presence of fatty streaks that, with time, accumulates leading to 
the development of the atherosclerotic plaque. Therefore, even in prospective studies of usually 
middle-age populations there is a potential, though reduced compared to case-control studies, for 
reverse causation is not abolished and could still lead to an observed association of biomarker 
and CHD risk. 1201 
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On the other hand, regression dilution bias, which arises due to biological variability in the level of 
the biomarker and measurement error, can lead to an underestimation of the association between 
a biomarker and disease. [211 Dealing with these potential sources of error to distinguish causal 
from non-causal associations is of critical importance, because, if CRP, Hey, or other biomarkers 
were causal in CVD, they would represent legitimate therapeutic targets, and provide additional 
opportunities for disease prevention. 
1.3 Advantages and limitations of the genetic approach, Mendelian randomisation to 
establish unbiased biomarker-outcome associations 
Because of the random assortment of paternal and maternal alleles at conception, according to 
Mendel's 2nd law, the carriage by an individual of a certain allele, genotype or haplotype that 
directly governs the circulating level of a biomarker of interest will be a random process 
independent of any other characteristic that may confound the plasma biomarker-disease 
association. This mimics the random allocation operating in a clinical trial (Figure 1.1). [22,231 
Therefore, a genetic approach might allow unbiased insight into the link between biomarkers and 
high-risk phenotypes (e. g. high blood pressure, diabetes) and cardiovascular outcomes. 
Figure I. I. Parallel of the Mendelian randomisation approach with a randomised clinical trial. 
Figure adapted from the Figure of the manuscript: Hingorani A, Humphries S. Nature's 
randomised trials. Lancet. 2005; 366: 1906-8. 
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If we consider the case of a specific circulating biomarker associated with CVD in observational 
studies, where the concentration of the biomarker is influenced by common polymorphisms in a 
gene X. Let alleles X and x be associated with high and low levels of biomarker, if the circulating 
biomarker were a true cause of disease, individuals with genotype XX should have an increased 
risk of CVD commensurate with the effect of this genotype on its intermediate phenotype free 
from confounding (Figure 1.2). [24] Because genotype is a non-modifiable characteristic, and 
determined far in advance of disease, any gene-disease association should also be free of 
reverse causation and regression dilution bias. [22,23] 
Figure 1.2. Components of the Mendelian randomisation strategy. 
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This concept, is highly attractive since it is well known that many (if not all) circulating biomarkers 
are highly heritable. Genes contributing to their regulation are therefore plausible candidates for 
CVD susceptibility. 
Although, in contrast to the biomarker-cardiovascular outcome association, a genetic approach 
that uses a gene variant that reliably affects the concentration of such biomarker in a direct 
manner should not be affected by confounding and reverse causation, for reasons mentioned 
above, it may suffer from other limitations. Although confounding is reduced in genetic studies, it 
may not be abolished because specific type of confounding can affect even this design. The first 
one is confounding by linkage disequilibrium (LD). If the gene variant of interest (gene-1) is in LD 
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with a second gene variant (gene-2) in an adjacent gene, the association of gene-1 with disease 
might not be mediated through its direct biomarker (biomarker-1), but rather it may be the result of 
confounding by LD with the adjacent gene, that modifies disease risk through a second 
biomarker. In this way, spurious evidence on causation could be obtained for biomarker-1. [22] 
The second source of confounding, could arise when the genotype (or allele) frequency differs in 
groups of differing ancestral origin, when ancestry is associated with disease risk, and when the 
case and control groups in an association study differ in their ethnic composition. This is referred 
to as population stratification. [25] However, population stratification, to an extent large enough to 
distort results, has been considered unlikely to occur in well-designed studies, [25,26] and 
moreover, nowadays it is possible to adjust for this type of confounding . 
[27,281 
Other theoretical limitations of Mendelian randomisation have also been described. It is also 
possible that lifelong, genetically determined, differences in an intermediate phenotype 
(biomarker) will lead to compensatory changes in other systems to inhibit the initial effect, a 
phenomenon referred to as canalization. This concept arose from animal studies in which a 
complete deletion of a certain gene results in a functional compensation by other genes, restoring 
the balance into the organism and limit the development of a phenotype. [221 Also, it is 
theoretically possible that a gene may exhibit pleiotropic effects, though sometimes used loosely, 
this term is perhaps best reserved for the specific (and possible rare) situation where there is 
alternative splicing of the mRNA which results in two gene products that may have different 
functions within the organism. A final limitation is that because most common gene variants only 
exhibit an small effect on their respective intermediate phenotypes really large sample sizes for a 
gene-disease association will be required to confirm or refute the causal role of a biomarker of 
interest, and therefore to legitimate it as a valid therapeutic target. 
The concept of Mendelian randomisation was first introduced in the literature in 1986 by Martijn B. 
Katan in its letter to the Lancet when presenting the option of using the APOE gene as instrument 
for cholesterol to help to clarify the controversial role (at the time) of low levels of cholesterol on 
cancer. [29] Later, some of the principles of Mendelian randomisation were sporadically mentioned 
by other investigators, [241 but it was not until recent years when Professors G. Davey-Smith and 
S. Ebrahim, formally introduce the theoretical grounds of this novel approach as way to 
understand the environmental determinants of disease. [22,23] Part of the results presented in this 
thesis actually constitutes some of the pioneers examples of Mendelian randomisation 
experiments to help to clarify a possible causal role of several biomarkers in CVD. As the 
development of this thesis occurred, there has been immense interest in this approach, that not 
only lies in the generation of empirical evidence for this approach in different diseases, [30,31,32] 
but also in the development of more adequate statistical tools to overcome some of the 
challenges that this strategy brought. [33,341 
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1.4 Thesis aims and objectives 
1.4.1 Aim 1: Homocysteine and stroke 
Aim: To conduct a series a systematic reviews and meta-analyses of genetic studies 
investigating the MTHFR/C677T variant, Hcy and stroke, and contextualize the findings 
with evidence derived from observational studies in Hcy and stroke and clinical trials 
using Hcy-lowering therapies. 
Objectives: 
  To synthesised genetic evidence from published and unpublished studies evaluating the 
MTHFR effect on Hcy. 
  To synthesised genetic evidence from published and unpublished studies investigating the 
MTHFR effect on Stroke. 
" To synthesised the results from clinical trials using Hcy-lowering therapies in stroke. 
  To investigate, whether the MTHFR-Hcy-Stroke association is modified by geographical 
location, used as proxy of the different policies for folic acid fortification. 
1.4.2 Aim 2: C-reactive protein and cardiovascular disease 
Aim: To investigate the potential causal role of CRP in CHD, stroke, and diabetes adopting the 
CRP gene (using de novo genotyping on a single-variant or a tagging-haplotype) as 
unconfounded proxy of plasma CRP. 
Objectives: 
  To evaluate the effect of the CRP/+1444C>T variant on CRP levels, and to generate 
empirical evidence of the random distribution by genotype of variables considered as 
confounders of the plasma CRP associations. 
" To evaluate the effect of CRP/+1444C>T variant on the risk of MI. 
" To evaluate the effect of the CRP tagging-haplotypes on CRP levels, and to obtain 
evidence of a random distribution by haplotype of variables that act as confounders of the 
plasma-CRP associations. 
  To evaluate the effect of the CRPtagging-haplotypes on risk of CHD, stroke and diabetes. 
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1.4.3 Aim 3: Lp-PLA2 and coronary heart disease 
Aim: To investigate the validity of Lp-PLA2 enzyme as a therapeutic target in CHD by using de 
novo data on the Lp-PLA2 gene (known as PLA2G7) as an unbiased tool for Lp-PLA2 
activity. 
Objectives: 
  To evaluate the shape of the association between Lp-PLA2 activity and CHD risk, and to 
investigate the potential for confounding on that association. 
  To evaluate the effect of the PLA2G7 tagging-SNPs on Lp-PLA2 activity, and on 
cardiovascular traits that act as confounders of Lp-PLA2 activity-CHD association. 
  To evaluate the effect of the PLA2G7 tagging-SNPs on CHD risk. 
1.4.4 Aim 4: Mendelian randomisation and biological pathways 
Aim: To describe how the integration of protein quantitative trait SNPs (pQTSNPs) and their 
cognate proteins can be used to dissect biological pathways among blood proteins. 
Objectives: 
" To evaluate the degree of correlations present among 6 blood proteins (CRP, fibrinogen, 
Lp-PLA2, Factor VII, apo-A1, and apo-B) that have been associated with high risk of 
cardiovascular disease. 
  To select the most potent cis-acting variant to be used as unconfounded tool of its 
respective cognate protein (e. g. CRP variants on CRP levels) 
  To quantify the effect of each one of the selected genetic-tool on its respective cognate 
protein (e. g. CRP-variant on CRP levels), as well as on the other 5 blood proteins (e. g. 
CRP-variant on fibrinogen, Lp-PLA2, Factor VII, apo-Al, and apo-B) 
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Chapter 2 Homocysteine and Stroke 
2.1 Homocysteine and stroke: use of Mendelian randomisation to support a causal role 
Stroke is the third most common cause of death in developed countries, [1] and approximately 80 
percent of strokes are ischaemic in origin and the remainder haemorrhagic. [35,361 In the United 
Kingdom, stroke is the largest single cause of severe disability with more than 125,000 incident 
strokes annually, and approximately 60,000 deaths due to stroke each year. [35] The best 
approach to reduce mortality and morbidity from the disease is by primary prevention through 
modification of acquired risk factors. [36] 
Data derived from non-genetic observational studies (cohort and case-control studies), suggest 
that a prolonged increase in total Hcy (sum of homocysteine, homocysteine-homocysteine, and 
homocysteine-cysteine disulfide and that now on will be referred in this document as Hcy) levels 
is associated with a higher risk of stroke. [37-39] However, since Hcy concentration is also related 
to smoking status, blood pressure, and social class, and is also higher in subjects with existing 
atherosclerosis, this relationship, may be subject to residual confounding, reverse causation or 
both. [40,41 ] 
Homocysteine is a sulphur-containing aminoacid that is formed during the methionine metabolism 
and is regulated by the B vitamins: folate, B6 and B12. [42] The first evidence for a vascular effect 
of Hcy in humans was derived from anecdotal reports from individuals suffering from 
homocystinuria, a metabolic disorder associated with very high levels of Hcy consequence from a 
homozygous deficiency of the cystathionine beta-synthase. [431 In 1985, Mudd et al. [44] reported 
the natural history of 629 subjects with homocystinuria before treatment with Hcy-lowering 
therapies was established. A time-to-event analysis indicated that by age 29 the probability of 
suffering a thromboembolic event was 50%. During the follow up, a total of 253 thromboembolic 
events in 158 patients (1 event per 25 patient-years of follow up) were observed, distributed as 
follow: 130 (51%) peripheral venous events, of which 32 were pulmonary embolism, 81 (32%) 
cerebrovascular accidents, 28 (11%) peripheral arterial events, 10 (4%) MI and 4 (2%) events did 
not fall into none of those categories. Of interest, there were 8 times more cerebrovascular events 
than coronary events. The evidence derived from this rare genetic disorder associated with very 
high levels of Hcy, is in a manner analogous to the inference that in past was derived for LDL 
cholesterol in CHD, using to individuals suffering from familial hypercholesterolemia. [22] 
In 1995, Frost et al, [45] reported the existence of a C-to-T substitution at nucleotide 677 
(rs1801133) in the gene encoding methylenetetrahydrofolate reductase (MTHFR), an enzyme 
involved in Hey metabolism. This substitution that converts an alanine to a valine residue at 
position 222 (A222V) has been associated with a decrease enzyme activity (35% to 40% in 
subjects with the TT genotype compared with subjects with the CC genotype) and differences in 
Hcy concentration. [46,47] Since carriage of this variant is subject to the random assortment of 
maternal and paternal alleles at the time of gamete formation, [48] associations between MTHFR 
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genotype and Hcy or stroke should not be subject to reverse causality bias and should also be 
largely free from confounding by other determinants of Hcy or risk factors for stroke. [22,23] 
Therefore, if the Hcy-stroke association is unbiased, carriage of the MTHFR polymorphism, that 
exposes individuals to a long term elevation in Hcy, should confer an increased risk of stroke 
proportional to the difference in Hcy attributable to variant and the risk observed in non-genetic 
observational studies. 
The evaluation of consistency between unbiased risk estimates obtained from genetic studies 
with those from non-genetic observational studies, to provide insight into the nature of the 
observed associations, as described in Chapter 1 has been referred to as Mendelian 
randomisation approach. This approach was used previously to test the nature of the association 
between Hcy and CVD. [37] However, in the prior genetic analyses of the MTHFR polymorphism 
and stroke, the number of available studies was relatively small. Also, information on the relative 
effect of the MTHFR polymorphism on Hcy level in different geographical locations, ethnic groups 
and age bands was limited. [37] 
If Hcy is shown to be causally related to the development of stroke this would have important 
implications in primary prevention, since folic acid is known to reduce Hcy levels, [49] and a policy 
of fortification of cereal and flour with folic acid to reduce the incidence of neural tube defects has 
been initiated since 1996 in United States, Canada, Australia and New Zealand and more recently 
in Ireland, Brazil, Chile, Jordan and South-Africa. Indirect evidence derived from two non- 
randomised intervention studies in subjects with homocystinuria indicated that uses of Hcy- 
lowering therapies during 18 years was associated with a substantially lower than expected 
(compared with event-rate observed in the study by Mudd et al in 1985) number of vascular 
events, including stroke. [50,51] Using a quasi-experimental intervention Yang et al, [52] observed 
an accelerated decline in stroke mortality in post-fortification period (1998-2002) compared with 
the pre-fortification period (1990-1997). In contrast there was not a significant change in the 
decline of stroke mortality, for the same period in England and Wales where fortification is not 
required. [52] 
I have now performed two up-dated and comprehensive meta-analyses. In the first, I evaluated to 
what extent Hcy levels are determined by the MTHFR/C677T polymorphism. I also evaluated the 
effect of pre-existing CVD, geographical location, ethnic background and age on this association. 
In the second, I estimated the odds of stroke conferred by this variant. Compared to a previous 
meta-analysis, my meta-analysis of MTHFR/C677T polymorphism and Hcy concentration 
includes data from 48 additional studies and extends the observations to subjects without 
CVD. [37] Compared to a previous meta-analysis by Wald et al, [37] my meta-analysis of the 
MTHFR/C677T polymorphism and stroke includes data from 23 additional studies and evaluates 
the robustness of the results by sensitivity analysis. 
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2.2 Systematic review and meta-analysis of the effect of the MTHFR/C677T 
polymorphism in homocysteine and stroke 
2.3 Methods 
Two electronic databases [MEDLINE and EMBASE] were searched up to June 2003 for all 
studies evaluating the association between the MTHFR/C677T polymorphism and homocysteine 
levels, and up to December 2003 for studies on the association between the MTHFR/C677T 
polymorphism and stroke. For the first search, I used the text words, which were also MeSH 
terms, "polymorphism", "mutation", "genes", and "cardiovascular disease" in combination with 
"homocysteine". For the second search, the terms used were "stroke", "brain infarction", "cerebral 
ischaemia", "hemorrhagic stroke" and "silent brain infarction" in combination with "genetic", 
"polymorphism", "mutation" or "genes". Both, literature searches were limited to "human", and 
"English Language". I searched for any additional studies in the references of all identified 
publications, including previous relevant meta-analyses. [37] 
2.3.1 Selection Criteria 
2.3.1.1 Homocysteine levels and MTHFR Polymorphism 
For inclusion, studies had to have an analytical design and examine the association between Hcy 
levels and the MTHFR/C677T polymorphism. Studies were included only if they were published 
as full-length articles or letters in peer-reviewed journals. For duplicate publications the smaller 
dataset was excluded. 
2.3.1.2 MTHFR and Stroke 
For inclusion, studies had to involve unrelated subjects, and examine the associations between 
ischaemic or hemorrhagic stroke and the presence of the MTHFR/C677T polymorphism. For the 
main comparison, only studies published as full-length articles or letters in peer-reviewed journals 
in English language were included. A sensitivity analysis was conducted which included silent 
brain infarction as an outcome, non-full text papers, and non-English language publications. In all 
searches, when relevant information was not reported, or there was doubt regarding duplicate 
publications, the authors were contacted to obtain the required information. 
2.3.2 Data Extraction 
I extracted and entered the data for analysis into two databases. The results were compared and 
disagreements resolved by consensus with Prof Aroon D Hingorani and Dr Pankaj Sharma. The 
data extracted and entered for the analysis was country of origin, study design, mean age of 
participants, frequency of genotypes, and alleles, Hcy and serum folate levels, ethnic background, 
and frequency of cardiovascular risk factors. 
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2.3.3 Statistical Analysis 
I obtained a summary estimate of the effect of raised plasma Hcy on risk of stroke from a recently 
published meta-analysis. [37] In this analysis, an increase of 5 µmol/L in plasma Hey was 
associated with an OR for stroke of 1.59 (95%Cl: 1.29-1.96). [37] I conducted a meta-analysis to 
obtain the weighted mean difference (WMD) in plasma Hcy levels between individuals 
homozygous for the T allele and subjects homozygous for the C allele. The WMD was obtained 
separately for subjects with and without known cardiovascular disease and for both groups 
combined. For these analyses a random effect model was used. [531 Then, I conducted a second 
meta-analysis of all published studies to obtain a OR for all strokes for individuals homozygous for 
the T allele compared with homozygotes for the C allele. Fixed effect ORs and 95% confidence 
intervals (CI) were calculated using the Mantel-Haenszel method, [541 while the DerSimonian and 
Laird method[53] was used to calculate random effects ORs and their 95%Cl. Also, to evaluate 
the robustness of our findings I calculated different ORs according to outcome sub-type, ethnic 
background, publication language and type of publication. 
The DerSimonian and Laird Q test[55] was used to evaluate the degree of heterogeneity between 
studies, and funnel plots and the Egger regression asymmetry test to evaluate small-study 
bias. [56] Meta-regression was also used to evaluate the extent to which different variables 
explained heterogeneity in WMD and in the summary ORs. [571 Finally, I used the WMD in Hey 
concentration by MTHFR/C677T polymorphism to estimate an expected increase in the risk of 
stroke (non-genetic OR) assuming that an increase of 5 µmol/L in plasma Hey would be 
associated with an OR for stroke of 1.59 (95%C1: 1.26-1.96), and that this association follows a 
log-linear relationship. [371 The uncertainty surrounding the estimate of the non-genetic OR is a 
function of the variability of the WMD in Hey by genotype and the variability of the summary OR 
from Wald's meta-analysis, [37] and cannot be directly calculated. Therefore, to obtain a 95%Cl 
for this OR, 1 generated one million values from a normal distribution with mean and standard 
deviations equal to the WMD and its standard error, and one million values from a normal 
distribution with mean and standard deviation equal to the natural logarithm of the summary OR 
from Wald's meta-analysis [37] and its standard error (calculated from its 95%Cl). I used the 
simulated values to calculate one million estimates of the non-genetic OR and took the 2.5% and 
97.5% percentile values of the so created empirical distribution as 95% confidence limits. The 
original do-file program in Stata for the simulations was generated by Dr. Leonelo Bautista from 
Department of Population Health Sciences at University of Wisconsin School of Medicine and 
Public Health. [58] 
Then, the non-genetic OR was compared with the summary OR obtained from the meta-analysis 
of genetic studies by means of an interaction test. [59] Consistency between the two ORs would 
indicate that the association between plasma Hey and stroke seen in non-genetic epidemiological 
studies is unlikely to be the result of confounding or reverse causality bias. Data were analysed 
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using the Review Manager software (version 4.2) from the Cochrane Collaboration 2003 and 
Stata B. O. 
2.4 Results 
2.4.1 Homocysteine and MTHFR/C677T polymorphism 
The primary search generated 104 potentially relevant studies of which 81 met the selection 
criteria. w'-w8' From the 23 articles excluded, 16 did not provide sufficient data to calculate the 
WMD between the genotypes, W82-w97 and the relevant information could not be obtained from the 
authors. Two were discarded as likely duplication "98, w99 and five only reported the Hey levels for 
TT subjects and C-allele carriers, but not for the CC genotype alone. w'oo-wI04 Of the 81 studies 
included (31,355 subjects), information for the main comparison (TT vs. CC genotype) was 
available for 15,635 subjects without known CVD, w'-w4' for 6312 subjects with 
CVD, w2'w4, w7, w11, w16, w21, w26, w27, w29, w32, w37, w39-w55 and for 9408 subjects reported only as the 
W56 combination of individuals with and without CVD. _w8' 
Among subjects without CVD, the WMD in plasma Hcy between subjects homozygous for the T 
allele compared with homozygotes for the C allele was 1.93 µmol/L (95%CI: 1.38,2.47; p<0.001, 
Figure 2.1). "''-"'41 Significant inter-study heterogeneity was observed (P-value for heterogeneity; 
PHet <0.001). 
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Figure 2.1. Weighted mean differences in plasma Hcy (µmol/L) according to the MTHFR/C677T 
genotype (TT vs. CC) among subjects without known cardiovascular disease. 
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WAj Val 39 12.00(4.12) 135 10.13(5.00) 1.87 10.33,3.411 
Vj? Z FriedmanG 55 11.67(6.66) 150 9.76(3.89) 1.91 10.04,3.781 
HusemoenLLN00 246 9.800.591 1361 7.80(3.98) - 2.00 (1.50,2.501 
DekouV(nen)°9 36 14.10(4.13) 184 12.00(3.50) 2.10 10.67,3.53) 
Reye6. EngelA 119 12.50(2.20) 249 10.30(3.90) - 2.20 (1.57,2.831 
w2,5 43 13.48(7.00) 154 10.85(3.79) 2.63 10.45,4.811 
Christensen 0ti'N' 8 12.90(5.30) 31 10.20(5.20) 2.70 (-1.40,6.801 
MkleadyR117 81 12.20(2.07) 352 9.30)1.02) - 2.90 12.44,3.361 
HusladS10 37 11.50(6.20) 204 8.60(2.91) 2.90 10.86,4.941 
YooJH 16 12.30(1.40) 42 9.10(1.00) - 3.20 12.45,3.951 
Pessar0A130 20 12.70)2.70) 28 9.30(1.60) 3.40 12.08,4.721 
Puln C W31 42 12.50(6.70) 42 8.80(2.40) 3.70 11.83,5.57) 
Joe SH w32 76 13.40(5.231 135 9.70(5.80) 3.70 12.17,5.231 
Lityriski P133 20 16.20(5.80) 20 12.10(2.50) 4.10 (1.33,6.871 
deBree AW34 206 17.10)3.59) 983 12.90(3.98) - 4.20 13.65,4.75) 
CVT a35 27 15.10(6.00) 39 10.50(3.30) 4.60 12.11,7.091 
1zcaino W36 12 16.61)11.63) 25 9.33(2.55) ---0 7.28 10.62,13.941 
D'A11gdo Aw37 39 18.10(14.10) 45 10.10(2.70) 0 8.00 13.51,12.491 
ZQtouiJ WN 6 19.90(10.30) 26 11.40(2.90) 8.50 10.42,16.581 
GeametiD WN 39 15.60(12.70) 65 6.60(1.90) ---0 9.00 14.99,13.011 
Ye dong2 ' 5 21.64(6.19) 21 11.50(4.26) 0 10.14 14.42,15.861 
VerelaM. W41 22 19.70(35.41) 49 8.40(13.71) 11.30 I-3.80,26.401 
tAJotedmean (95%CI) 1887 7252 . -. 93 (1.38,2.471 
Test for overd effect P<1.1111 
10 S0S 10 
Decreased levels klaeased levels 
'; The total number of subjects without known cardiovascular disease included in the meta-analysis was 
15,635 (TT: 1887, CT: 6496 and CC: 7252). 
From the variables evaluated in a meta-regression analysis, the only major source of 
heterogeneity detected was the mean level of serum folate. The WMD in plasma Hcy levels 
comparing the TT and CC genotypes was 0.048 µmol/L less for each increase in mean serum 
folate of 1 nmol/L, p=0.035. In studies conducted in North America the WMD in Hcy concentration 
(0.57 . tmol/L) was considerably lower than in studies conducted in Europe (2.04 µmol/L) or other 
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continents (2.97 µmol/L; Table 2.1). Conversely, the weighted mean serum folate concentration 
was higher in North American (25.3 nmol/L; 95%C1: 7.3,43.3) than European studies (13.6 
nmol/L; 95%Cl: 11.4,15.6) and studies conducted in other continents (15.3 nmol/L; 95%Cl: 9.0, 
21.6). No other sources of heterogeneity by age (p=0.94), ethnic background (Caucasians vs 
Non-Caucasians) (p=0.62), smoking (p=0.41) or gender (p=0.57) were observed in a meta- 
regression analysis of studies in which these variables were reported. WMDs in Hcy 
concentrations by genotype, according to the mean age of the sample evaluated, geographical 
location, and ethnic background are shown in Table 2.1. 
Table 2.1. Weighted mean difference in plasma homocysteine according to the MTHFR/C677T 
genotype (TT vs. CC) among subjects without cardiovascular disease. 
Groups Number of subjects 
(studies) 
WMD' in µmol/L 
(95%Cl) 
P-value 
All studies 9139 (43) 1.93 (1.38,2.47) <0.001 
Caucasians 6948 (32) 1.96 (1.41,2.51) <0.001 
Non-Caucasians 2191 (11) 1.83 (0.58,3.09) 0.004 
Mean age > 40 8575 (36) 1.96 (1.46,2.47) <0.001 
Mean age < 40 564 (7) 1.66 (0.00,3.31) 0.05 
Europe alone 7031 (26) 2.04 (1.45,2.64) <0.001 
North America alone 1027 (8) 0.57 (-0.28,1.42) 0.19 
Other continents alone 1081 (9) 2.97 (1.72,4.22) <0.001 
European & North-American, 7742 (29) 1.84 (1.29,2.39) <0.001 
subjects >40 years old 
Caucasians, > 40 6747 (29) 1.95 (1.39,2.51) <0.001 
`; WMD: Weighted mean difference, 
The distribution of the WMD in relation to its standard deviation in the funnel plot was symmetric, 
and the Egger test was non-significant (p=0.72) providing no positive evidence for small-study 
bias. A visual assessment of a graph of the individual study WMDs showed that none of the 
studies had an undue influence on the overall WMD. 
Among subjects with CVD, homozygous for the T allele, Hcy levels were 4.35 µmol/L (95%Cl: 
3.22,5.49; p<0.001) w2'w4, w7, w11, w16, w21, w26, w27, w29, w32, w37, w39-w55 higher than subjects homozygous for 
the C allele. A meta-regression analysis indicated that the greater difference in Hcy by genotype 
among people with CVD was partially explained by lower serum folate (the crude 13-coefficient for 
disease status was 3.04, falling to 2.73 after adjustment for serum folate). When the data from the 
previous groups were combined with data from studies that evaluated individuals with and without 
CVD without distinction, the WMD for homozygotes for T allele against homozygotes for the C 
allele was 3.10 µmol/L (95%Cl: 2.54,3.65; p<0.001). w'-w8' 
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2.4.2 Odds ratio estimated from non-genetic observational studies and the mean 
difference in homocysteine by the MTHFR/C677T polymorphism 
According to a previous meta-analysis of prospective studies, [37] a plasma Hcy concentration 
higher by 5 µmol/L corresponds to an OR for stroke of 1.59 (95%Cl: 1.29,1.96). An increase in 
Hcy concentration of 1.93 µmol/L (95%Cl: 1.38,2.47) in healthy TT-genotype subjects, would 
therefore result in an expected OR for stroke of 1.20 (95%Cl: 1.10,1.31) compared with individual 
homozygous for the C allele, if the association between Hcy and risk of stroke follows a log-linear 
relationship (Table 2.2), and is free from confounding and reverse causality bias. Expected ORs 
for stroke derived from differences in Hcy by genotype in all subjects without CVD, and also 
separately by ethnic background, geographical location and mean age are summarised in Table 
2.2. 
Table 2.2. Evaluation of consistency between odds ratios (ORs) derived by extrapolation from 
non-genetic observational studies with those derived from meta-analysis of genetic studies. All 
ORs are based on comparisons of TT vs. CC genotypes. 
Expected OR for Genetic ORT P-value 
stroke $ (95%Cl) for comparisons 
(95%Cl) 
Main comparison 
All studies 1.20 1.26 0.29 
(1.10,1.31) (1.14,1.40) 
Secondary comparisons 
Studies with mean age 1.20 1.26 0.30 
>40 years (1.10,1.30) (1.14,1.40) 
Europe & North America 1.17 1.21 0.37 
alone (1.09,1.27) (1.02,1.43) 
Caucasians alone 1.20 1.19 0.39 
(1.10,1.31) (1.02,1.39) 
$ ORs were calculated using data from subjects without cardiovascular disease. Mean expected odds ratios 
were calculated using the formula: expected OR= 1.59 raised to the power of d/5, where d=WMD in 
homocysteine by genotype, using the assumption that a5 µmol/L increase in homocysteine is associated 
with an OR for stroke of 1.59 [37]. t; ORs obtained from the genetic meta-analysis of association studies of 
MTHFR/C677T and stroke. ¶; P-value for the comparison using an interaction test (see methods) 1; The 
weighted mean age for cases and controls were 58 and 53 years old respectively. 
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2.4.3 MTHFR/C677T polymorphism and stroke 
Of the 49 potentially relevant studies identified in the primary search, 30 met the selection 
criteria . 
w40, w47 W53 w59, w7I, wI05-WI28 From the 19 articles excluded for the purpose of the main 
comparison, three were published in non-English journals, W129-w131 two reported the outcome silent 
brain infarction , 
"''32, W'33 and five were published only as abstracts . 
w134-"''38 Though excluded from 
the main comparison, these studies were used in a sensitivity analysis. Of the remaining nine 
publications excluded, five studies encompassed some duplication, W6Z'W139 M42 and four did not 
report the genotype frequency and the relevant information could not be obtained from the 
authors, w103, w143-w145 Of the 30 studies (6324 cases and 7604 controls) included, 19 were in 
Caucasians subjects, w53, w59, w71, w105, w107, w111-w116, wl19-w122, w124, w125, w127, w128 10 involved Asian 
subjectsw40, w47, wI06, wI08-w1 10, w117, w118, w123, w126 and one study included both Caucasian and subjects of 
Afro-Caribbean origin. w119 
The summary OR, under a fixed effect model, indicated that individuals with the TT-genotype 
compared to subjects homozygous for the C allele had an OR for stroke of 1.26 (95%Cl: 1.14, 
1.40; p<0.001)(Figure 2.2). w43w47, w53. w59, w71w105-w128 Significant heterogeneity among the results of 
individual studies was observed (PHet=0.034). A sensitivity analysis revealed that the study by 
Morita H. et al, 47 was mainly responsible for the heterogeneity. After excluding this study, the 
heterogeneity was no longer significant (p=0.32), but the estimate of the overall effect changed 
very little and remained significant (OR: 1.20 [95%Cl: 1.08,1.341; p=0.0006). Likewise, a random 
effect model that takes into account the intra and inter-study variability resulted in a similar overall 
estimate (OR: 1.26 [95%Cl: 1.07,1.471; p =0.004). A meta-regression analysis showed that ethnic 
background (Caucasians vs. non-Caucasians; p=0.23), the presence of risk factors such as age 
(p=0.38), gender (p=0.46), hypertension (p=0.15), smoking (p=0.43) and diabetes (p=0.10) were 
not significant sources of heterogeneity in a group of 20 studies with information on all these 
variables. w47. w53. w59, w105, w10B, w109, w111. w116 w117. wl 18 w119, w120. w121, w122, w123, w124, w125, w126, w127 
The distribution of the OR in relation to its standard deviation in the funnel plot was symmetric, 
and the Egger test was non-significant (p=0.32) providing no positive evidence of small-study 
bias. No individual study had an undue influence on the summary OR. A sensitivity analysis 
revealed a robust association between the MTHFR/C677T polymorphism and stroke (Figure 2.3). 
No significant changes in the summary OR were detected after adding studies published in non- 
English language, w'29 "'131 in abstract form, W134_WI38 and those using the outcome silent brain 
infarction. "r132, "''33 Similarly, no differences in the summary OR were observed when the analysis 
was restricted according to ethnic background (Caucasians or non-Caucasians) or to studies in 
which the outcome was solely ischaemic stroke (Figure 2.3). Data from five studies (611 cases 
and 2405 controls)` lOGw10wl1l, w18, w129 where information was available on the association of the 
MTHFR/C677T polymorphism and haemorrhagic stroke (TT vs. CC), yielded a summary OR of 
1.16 (95%CI: 0.90,1.50; p=0.25), under a fixed effect model. 
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Figure 2.2. Odds ratio of stroke in subjects with the TT-genotype in comparison with subjects 
homozygous for the C allele of the MTHFR/C677T polymorphism. 
Study 
Stroke 
TTICC+TT) 
Control 
TT$(CC+TT) 
TT vs CC 
Odds to 
(95%Cl) 
Odds Pitp 
(95°4C1) 
GrossmannR 1105 9/52 26/95 0.56 [0.24,1.301 
Mclkoy SP W71 1/40 2/52 0.64 (0.06,7.33] 
data y 1106 11/42 19/54 0.65 [0.27,1.59] 
Reuner KH '1107 7/44 23/108 0.70 (0.28,1.771 
Markus HS W3 37/199 22/98 0.79 (0.44,1.43) 
Bang G w108 15/55 16/53 0.87 (0.38,2.001 
YooJH w109 12/53 26/103 0.87 (0.40,1.891 
Zheng YZ WH 13/73 15177 0.90 (0.39,2.041 
Eike(b00m W 25/127 23/107 0.90 (0.47,1.691 
Sal* N wlll 23/148 16/97 0.93 (0.46,1.87) 
KostulasK1112 13/76 13/76 1.00 (0.43,2.33] 
LopaciukSW113 12/63 26/143 1.06 10.50,2.261 
LalouschekW wlla 11/49 10/49 1.13 (0.43,2.97] 
DoStetenoVwt15 17/45 35/100 1.13 (0.54, Z. 341 
SZONokiZ W116 114/529 89/475 1.19 10.87,1.621 
Notsu Y 11117 29/96 31/117 1.20 [0.66,2.19] 
LiZ 1118 423/957 398/1008 1.21 (1.01,1.451 
Voelsch9(Caucasians)wü9 17/64 14/62 1.24 10.55,2.80] 
Margag(ione4w120 50/103 196/523 -+- 1.57 (1.03,2.411 
Pezzin(Aw121 27/67 23/77 1.58 10.79,3.161 
Hermon ßw122 27/101 19! 105 1.65 [0.85,3.21] 
Ch0IBo wl 36/98 25/98 1.70 10.92,3.13] 
B'0124 11/60 3/27 1.80 (0.46,7.05] 
Pezzirw A 110 4/13 4122 2.00 10.40,9.911 
Yr@Wng ZI'* 8/23 5/26 2.24 [0.61,8.211 
MY wIU 14/37 24/116 -- F- 2.33 11.05,5.20] 
MortaHW47 55/135 33/186 3.19 11.92,5.301 
Press RD 1127 
w119 
9/65 1/29 4.50 (0.54,37.31) 
VoelschB(B(ecks) 4/26 2/63 5.55 (0.95,32.43( 
TopcE wlZ8 7/32 1165 T 17.92 [2.10,153.181 
Total (95%C() 3472 4211 $ 1.26 (1.14,1.401 
Test for overd effect P1,1111 
01 0.2 0.5 125 10 
Protective Risk 
The total number of stroke cases was 6324 (TT: 1041, CT: 2852 and CC: 2431) and the total number of 
controls was 7604 (TT : 1140, CT: 3 393 and CC: 3071). 
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Figure 2.3. Sensitivity analysis of the MTHFR/C677T polymorphism and stroke association. 
Summary odds ratio of stroke for TT subjects compared to CC subjects by publication type, stroke 
classification or type, and ethnic group 
MTHFRJC677T 
Odds ratio 
TT us CC 
Group of studies 95% Cl 
OR 
(95%Cl) 
All stroke -f- 1.26 [1.13, 1.401 
All stroke+Abstracts -IF- 1.23 [1.11, 1.361 
All stroke+ no English pub. --f- 1.33 11-20, 1.471 
All stroke+ Silent brain infarction -f-- 1.29 11-17, 1.421 
All stroke only in Caucasians 1.19 [ 1.0z, 1.391 
All stroke only in non Caucasians -+-- 1.32 11.1-S, 1-5z) 
Only Ischemic stroke -i-- 1.27 [1.14, 1-411 
0.5 0.7 1 1.5 2 
Decrease risk Increase risk 
2.4.4 Consistency between the odds ratio estimated from non-genetic and genetic 
studies 
OR estimates for TT homozygous subjects in comparison with CC genotype subjects, based on 
the WMD in Hcy by genotype together with the risk observed in non-genetic observational studies 
were, mathematically, very similar to those observed in the genetic meta-analysis (Table 2.2). The 
P value, for interaction, for the main comparison of the study, the non-genetic and genetic OR for 
stroke in TT vs. CC subjects, derived from all the studies was 0.29. Therefore, there was no 
evidence of a significant difference between the OR estimated from the increment in the Hey 
levels by genotype (MTHFRIC677T) and that observed from the genetic meta-analysis. Moreover, 
no significant differences between estimated ORs were observed when similar comparisons were 
conducted among more homogenous groups defined by geographical location, ethnic background 
and mean age (Table 2.2). In all the comparisons, the expected ORs were within the 95%Cl of 
the corresponding observed OR obtained from the genetic association studies. 
2.5 Discussion 
The main finding of these meta-analyses was that the OR for stroke conferred by the MTHFR-TT 
genotype (1.26 [95%CI: 1.14,1.401) was similar to that estimated by extrapolation from non- 
genetic observational studies and from the difference in the Hcy levels generated by the 
"'47 polymorphism (1.20 [95%Cl: 1.10,1.311). Indeed after exclusion of the study of Morita et al., 
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which was responsible for much of the heterogeneity in the genotype-stroke analysis, the 
summary OR for the MTHFR-TT genotype was 1.20 (95%Cl: 1.08,1.34), identical to the 
predicted effect of the polymorphism estimated from the studies of Hcy level and stroke risk. 
Since the genotype-Hcy and genotype-disease associations should both be unbiased and non- 
confounded, these results imply that the relationship between Hcy and stroke seen in prospective 
non-genetic observational studies is not subject to substantial residual confounding or reverse 
causality bias, and provides evidence for a causal role for Hcy in stroke pathogenesis. 
My first meta-analysis examining the association between Hey and MTHFR genotype, involving 
more than 31,000 subjects allowed us to refine the size estimate of the effect of the 
MTHFR/C677T polymorphism on plasma Hey concentration, and to explore sources of 
heterogeneity. The absolute difference in Hey conferred by the genotype though consistent in 
direction was greater in subjects with established atherosclerosis (4.35 µmol/L) than in individuals 
who were healthy at the time of measurement (1.93 µmol/L). Similar findings were obtained in a 
recent individual-patient data meta-analysis. [46] Therefore, my data suggests the presence of an 
additional effect of disease status on the MTHFR-Hcy association, partially explained by lower 
serum folate levels in subjects with disease. I therefore used estimates from healthy subjects 
when calculating the predicted OR for stroke among TT subjects. When making estimates of the 
genotype-intermediate phenotype association, for the Mendelian randomisation approach the 
potential modifier effect of disease status should be evaluated. [60,61] 
The second genetic meta-analysis (MTHFR/C677T and stroke), which included -14,000 
individuals, allowed us to obtain a precise estimate of the effect of MTHFR genotype on stroke 
risk. Subjects homozygous for the T allele had an OR for stroke of 1.26 (95%Cl: 1.14,1.40) 
compared with subjects homozygous for the C allele. This difference in risk is similar to that 
estimated from the difference in Hcy levels by genotype in healthy individuals, (OR: 1.20 [95%Cl: 
1.10,1.311). Moreover, when the comparison was restricted to Caucasian individuals or to studies 
conducted in Europe or North America, within a comparable age range as the population included 
in the meta-analysis of prospective studies of Hey and stroke risk, 1371 similar results were 
obtained. 
Clinical studies have shown that supplementation with B-vitamins (folic acid, B-6 and B-12), 
decreases Hey levels by an average of 3 µmol/L. [49] If Hey is causally associated with an 
increased risk of stroke, as this and other studies suggest, [461 then nutritional interventions to 
lower Hey might be expected to produce a relative risk reduction in the incidence of stroke of 
about 23%. [381 A number of randomised clinical trials of the effects of lowering Hey with B 
vitamins (folic acid, B-6 and B-12) on cardiovascular outcomes have been conducted and other 
are still ongoing and their results are placed in the context of an updated analyses of genetic 
studies in the Chapter 3. Despite evidence for causality, from this and other similar analyses, 
such randomized intervention trials of Hey lowering are important firstly because of several 
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potential limitations of the type of study I have conducted, secondly to establish precisely the 
magnitude of the treatment effect, and lastly to ascertain whether there are any unexpected 
harms (e. g. colorectal cancer) from such therapies. 
Despite the consistent association demonstrated between the MTHFR/C677T polymorphism, Hcy 
and stroke risk, the size of the effect is modest in comparison to orthodox cardiovascular risk 
factors and does not necessarily provide a rational basis for screening for the MTHFR/C677T 
polymorphism or for the measurement of Hcy in isolation, in the prediction of stroke. Whether 
either of these measurements would add useful predictive information to more established risk 
prediction tools (e. g. Framingham risk equation) will require further evaluation. 
The interpretation of the analysis must be made in the context of the limitations of the available 
data. In the meta-analysis of the MTHFR variant and Hcy levels, significant heterogeneity was 
observed (PHet<0.001). This is perhaps not surprising since the effect of the mutation could be 
modified by environmental factors such as folate levels, as detected in my meta-regression 
analysis. This is supported by the smaller effect of the MTHFR/C677T polymorphism on the Hcy 
in studies conducted in North America, in which the mean levels of serum folate were higher, 
presumably as a result of folic acid fortification of cereals, and flour initiated in 1996 and fully 
established by 1998. However, larger data-sets using individual-patient data will be required for a 
more precise quantification of this potential gene-environment interaction. For this reason, only 
the WMDs derived from a random effect model were used in the current analysis. 
Publication bias is an unlikely explanation of the observed association between the MTHFR 
polymorphism and Hcy, and between this variant and stroke risk, as indicated by the results 
obtained from the funnel plots and the Eggers tests. Although confounding is less likely in 
analyses of an association of a genotype with disease, some imbalance in the distribution of 
cardiovascular risk factors by MTHFR genotype cannot be totally excluded. However, previous 
studies that evaluated the effect of the MTHFR variant on CHD suggested that systematic 
confounding from other cardiovascular risk factors (e. g. age, gender, hypertension, diabetes, 
obesity, or alcohol intake) is of little relevance. [46,62] 
The Mendelian randomisation approach is a potentially useful tool to evaluate the nature of the 
observed associations between putative risk factors and disease. This approach overcomes some 
limitations of observational studies. [22-24] However, this approach has its own theoretical 
limitations, which were mentioned previously in Chapter 1, section 1.3 in this document. Despite 
evidence for causality, from this and other similar analyses, randomised intervention trials of Hcy 
lowering are important firstly because of several potential limitations of the type of study I have 
conducted, secondly to establish precisely the magnitude of the treatment effect, and lastly to 
ascertain whether there are any unexpected harm from such therapies. [63] However, the data 
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obtained from this study and previous analyses of the same type, provide a source of optimism 
that such therapies will be beneficial. 
In conclusion, synthesis of the genetic evidence to December2003 on MTHFR-Hcy levels-Stroke 
indicated a considerable consistency in the risk of stroke observed for subjects carrying the 
MTHFR variant with that suggested from observational studies. Nonetheless, there were two 
important limitations, publication bias and the presence of an effect modification of the MTHFR- 
Hcy-Stroke association by folate levels that unfortunately could not be analysed in a detailed 
manner due to limited number of evidence for such analyses. In order to address these limitations 
in detail the work obtained in Chapter 3 was initiated. 
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Chapter 3 Homocysteine and stroke: Gene-environment interaction 
In Chapter 2, I synthesised the published genetic evidence to December 2003 on the 
MTHFR/C677 variant-Hey and stroke. Although the results were promising, there were important 
limitations that were not adequately addressed. Firstly, a possible overestimation of a genetic 
effect due to small-study bias, and secondly, the presence of effect modification on the MTHFR- 
Hcy-Stroke association by folic acid intake suggested by the results from Chapter 2. These are 
now addressed in detail in the present Chapter. In addition, I also contextualized the genetic 
evidence with that from that of clinical trials in stroke using Hcy-lowering therapies. 
3.1 Homocysteine and stroke: gene-environment interaction and implications for 
clinical trials of folic acid 
Evidence from prospective cohort studies have estimated that a reduction of 3 µmoVL in serum 
homocysteine, after a mean follow-up of 7.3 years, is associated with decreased risk of CHD by 
18% and stroke by 24%. [37,38] Nonetheless, residual confounding and reverse causation, as 
discussed in Chapter 2, are still possible explanations for these estimations. [40,41 ] 
A genetic approach that overcomes reverse causality and minimises residual confounding has 
been used previously to judge the possible causal role of Hey in stroke and CHD. [37,46] In 
Chapter 2, I described the results of the Mendelian randomisation experiment of Hey in stroke. In 
those analyses, I utilised published genetic association studies on the MTHFR/C677T variant 
(rs1801133) that serves as an unconfounded proxy for Hey level. Although the results from those 
literature-based meta-analyses provided some support for a causal role of Hey in stroke, there are 
several limitations that currently limit definitive conclusions to be drawn. First, since my Mendelian 
randomisation experiment was based on published studies, there is scope for small-study bias. 
This has been suggested as an explanation for the association of MTHR1C677T in CHD. [64] 
Indeed, in my previous meta-analysis of genetic studies on stroke only two studies included more 
than 400 cases. 
Second, my analysis on stroke (Chapter 2, section 2.4) as well as data from other studies, [65] 
suggests that the effect of MTHFR/C677T variant on the Hey concentrations could be modified by 
the prevailing intake of folic acid. In individuals with high levels of folic acid the effect of 
MTHFR/C677T variant on Hey levels will be lower compared to individuals with low levels of folic 
acid. If this is the case, and also taking into consideration that mandatory policies of folic acid 
fortification of cereals and flour has been established in several countries, [661 it would affect not 
only the interpretation of genetic studies on MTHFRIC677T and stroke, but also the results from 
emerging and ongoing randomised clinical trials of Hcy-lowering interventions. [671 
In order to further evaluate the potential limitations of findings on stroke and Hey presented in 
Chapter 2 in a reliable manner, I have updated the previous literature-based meta-analyses to 
40 
January 2008, and also assembled a network of genetic studies on stroke that now includes both 
large studies and unpublished studies to provide a much larger aggregate sample size and to 
help overcome small-study bias. Moreover in this update analysis I have also been able to 
investigate, in more detail, the potential modifying effect of folic acid consumption. The results 
from this updated meta-analysis has further been contextualised with a pooled analyses of 
published randomised clinical trials evaluating the effect of Hcy-lowering interventions (B- 
vitamins) on cardiovascular end-points, specifically stroke, to assess the concordance between 
the findings of genetic and interventional studies. 
3.2 Establishment of a large scale collaboration to evaluate the effect of MTHFR/C677T 
polymorphism in homocysteine and stroke 
Relying exclusively on literature-based meta-analyses for the investigation of a gene-environment 
interaction in stroke may have problems. Meta-analyses using "only published data" are prone not 
only to small-study bias, but also to missing data of relevance to the investigation of gene- 
environment interaction (e. g. levels of Hey and folate). In addition, there is also the scope for 
reporting bias, mainly from prospective cohort studies that obtain information on multiple incident 
disease outcomes. Such studies may have obtained information on incident stroke and have 
typed the MTHFR/C677T for other reasons may not have reported the association due to the 
relative small number of strokes per-study that poses an obstacle to publication. For these 
reasons, I supplemented information from published studies with unpublished genetic data 
obtained by assembling a large collaborative network of investigators allowed me to obtain 
information on the MTHFR/C677T effect on stroke, as well as on Hey and folic acid 
concentrations for a more precise estimation of genetic effect sizes, while minimising the scope 
for reporting and publication bias. The collaborative group for the genetic analysis was assembled 
by direct contact with principal investigators of any study that had previously reported at least one 
genetic finding in stroke (for case-control studies) or in cardiovascular disease (for cohorts) in a 
peer reviewed journal, and using a database I have developed and maintained for this and other 
studies [68,69,70]. This approach allowed me to amalgamate a total of 109 genetic studies 
evaluating the effect of the MTHFR gene on stroke including a total of 92,944 individuals (18,533 
stroke events and 74,411 controls) covering the main geographic regions around the world. This 
database is valuable not only because it contains three times more information than my previous 
analyses reported in Chapter 2, but also because it provides information on the MTHFR effect on 
Hey and stroke risk in regions with very different prevailing levels of folic acid consumption, and 
with different policies on the folic acid fortification of cereals and flour. 
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3.3 Methods 
3.3.1 Search strategy genetic studies 
Two electronic databases (MEDLINE and EMBASE) were searched up to January 2008 by Mr 
Paul Newcombe and I, for all studies on the association between the MTHFR/C677T 
polymorphism and stroke. I used the text words, which were also MeSH terms, "polymorphism", 
"mutation", "genotype", "genetic", "gene(s)", "allele(s)" in combination with "stroke", 
"cerebrovascular disorder/disease", "cerebral ischemia", "hemorrhagic stroke", "(silent) brain 
infarction". Literature searches were limited to "human". All languages were included. Mr Paul 
Newcombe and I searched for any additional studies in the references of all identified 
publications, including previous relevant meta-analyses. This sensitivity search strategy allowed 
me to identify comprehensively published genetic studies in stroke. These were then contacted an 
invited to participate in the collaboration. 
3.3.2 Search strategy for randomised trials 
I conducted a literature search in MEDLINE up to August 2008 to search for randomised clinical 
trials using homocysteine-lowering interventions that evaluated cardiovascular end-points. The 
MesH terms utilised were "cardiovascular disease", "coronary heart disease", "coronary stenosis", 
"myocardial infarction", "cerebrovascular accident", "stroke", and "randomised controlled trial", 
"clinical trial", and "folic acid". I also searched in previous published meta-analyses addressing 
this question. [67,71] 
3.3.3 Selection criteria 
3.3.3.1 MTHFR polymorphism and homocysteine level 
For inclusion, studies had to have an analytical design (case-control, cohort or cross-sectional) 
and examine the association between Hey levels and the MTHFR/C677T polymorphism. Studies 
were included only if they were published as full-length articles or letters in peer-reviewed 
journals. For duplicate publications the smaller dataset was excluded. 
3.3.3.2 MTHFR polymorphism and stroke risk 
For inclusion, studies had to have an analytical design (case-control, cohort, or cross-sectional), 
and had to examine the associations between ischaemic or haemorrhagic stroke, or silent brain 
infarction and the presence of the MTHFR polymorphism. All languages were included. For 
duplicate publications the smaller dataset was excluded. In all searches, when relevant 
information was not reported or there was doubt about duplicate publications, Mr Paul Newcombe 
and I contacted the authors to obtain the required information. In addition, principal investigators 
from any genetic study that has published in a peer-reviewed journal was also invited to 
participate in this collaboration by providing genotype counts by case-control status, according to 
different stroke sub-types as well as Hey and folic acid levels by genotype. 
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3.3.3.3 Randomised clinical trials of homocysteine lowering interventions in stroke 
Studies had to be randomised, and parallel in design in adults, and examine the effect folic acid 
supplementation (with or without additional vitamin B supplementation) on stroke. Studies had to 
have a minimum follow up of 12 months. Only studies published as full-length papers or letters in 
peer-reviewed journals in English Language were included. 
3.3.4 Data Extraction 
For the genetic studies, the following variables were extracted: country and year in which the 
study was conducted, study design, proportion of males, mean age of participants, frequency of 
genotypes and alleles by case control status, Hcy and folate concentrations, stroke sub-type, 
language of publication, and ethnic background were extracted and entered into a database by 
myself and Mr Paul Newcombe. Results were compared and disagreements resolved by 
consensus. Authors from a total of 72 new identified studies were contacted (on at least three 
occasions) to obtain data on MTHFR/C677T genotype, Hcy and folate concentrations (to avoid 
reporting bias) by case-control status, including stroke sub-type, as well as to obtain any relevant 
missing data or when other clarifications of the published information were deemed necessary. A 
positive reply was obtained and information provided by authors of 28 studies. 
For the randomised trials the following variables were extracted: year of conduction of the trial, 
geographic region in which the trial was conducted, type of blinding, number of participants in 
each arm, number of stroke events in each arm, the diagnostic criteria used for the stroke 
outcome, dose of folic acid in the intervention group, type of intervention used in the control arm, 
mean duration of the trial, and baseline and post-intervention levels of Hcy in each arm. 
3.3.5 Statistical Analysis 
Statistical analysis was conducted following the guidelines from the HuGENet published in the 
HuGE Review Handbook for meta-analysis of genetic association studies. [72] 
3.3.5.1 Homocysteine levels and MTHFR polymorphism 
I used meta-analytic techniques, using random effect models, to obtain the weighted mean 
difference (WMD) in plasma/serum level of Hcy according to the MTHFR/C677T genotype (CC: 
homozygous common allele; CT: heterozygous and TT: homozygous rare allele). Individuals 
homozygous for the C allele were used as the reference group. The estimate of WMD was 
restricted to analyses made in individuals without clinical evidence of CVD (ischaemic heart 
disease, stroke, or venous thrombosis). In order to explore the modifying effect of folic acid levels 
on the MTHFR/C677T-Hcy association two strategies were utilized both incorporating meta- 
regression. First, I used the information on the geographical location and date on which the 
genetic study was conducted to generate geographical regions to serve as proxies of the folate 
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supplementation status. For this classification, I considered whether policies for folic acid 
fortification had been initiated and the date of implementation. The categorization was developed 
by Dr. Robert Clarke from University of Oxford, a collaborator in the analyses described in this 
Chapter. Categories were sorted according to the level of folic supplementation from the lowest to 
the highest as follows. (1) Asia: in addition to Asians countries (e. g. China, India, Korea, Thailand, 
Mongolia) this category also included countries from North and sub-Saharan Africa. (2) Europe- 
low: including studies from Scandinavia or Netherlands conducted at any time, and European 
countries (including Turkey and Russia) conducted prior to folic acid fortification of cereal and 
flour initiated 1995. (3) Europe moderate: including European countries (including Turkey and 
Russia) in 1995 or thereafter (except Scandinavia and Netherlands). (4) America & Australia & 
New Zealand low-moderate (pre-fortification): which included studies from North-America 
Australia and New Zealand prior to 1995, and studies from Central and South America conducted 
at any time. (5) America & Australia & New Zealand high (post-fortification): which included 
studies from North-America Australia and New Zealand conducted in 1995 and thereafter. For a 
total of 24 Studies (of 96) on which information was unavailable from the publication, or previous 
publications from the same study, or after contacting study authors on the timing of the study, the 
submission/publication date was used as the year the study was conducted. The second broad 
approach was possible in a sub-set of 34 studies with information on folic acid level. For these, a 
meta-regression analysis of the differences in Hcy by MTHFR genotype against the folic acid 
concentrations was conducted. Previous analyses were then repeated only in studies with sample 
size equal or greater than 500 individuals in order to explore the influence of small-study bias. 
3.3.5.2 MTHFR and Stroke 
I conducted a second meta-analysis of published and unpublished genetic studies on stroke to 
obtain a per-genotype summary OR and their 95%CI (using random effect models) for all strokes 
types combined, using individuals homozygous for the C-allele as the reference group. This 
outcome referred to as "main stroke comparison" was selected in order to increase comparability 
with the results from prospective cohort studies and randomised clinical trials. This main stroke 
comparison included studies reporting: (i) only ischaemic stroke, (ii) only haemorrhagic stroke, (iii) 
both (ischaemic and haemorrhagic by separate) stroke types, or (iv) only unclassified stroke from 
studies in which neuroimaging tools were not available to classify the event as haemorrhagic or 
ischaemic. For studies reporting ischaemic and/or haemorrhagic stroke, the diagnosis was done 
by neuroimaging (MRI or CT). For this meta-analysis, I assumed equivalence between risk ratio 
and OR. As described in section 3.3.5.1, I utilised the geographical categories (or region of folate 
supplementation) to explore whether the MTHFR/C677T effect on stroke is modified according to 
the concentrations of folic acid. Previous analyses were then restricted only to studies with ? 400 
stroke events, to evaluate the potential influence of small-study bias. 
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3.3.5.3 Randomised clinical trials of homocysteine lowering medications in Stroke 
Finally, I conducted a third meta-analysis of randomised controlled trials that compared the effect 
of folic acid supplementation (with or without additional B vitamins) on stroke outcomes in trials 
that used placebo, or low dose-folic acid, or usual care in the comparator arm. The trial arm 
containing folic acid (with or without additional B vitamins) was assigned as the experimental 
group. For the stroke outcome (incidence of stroke) a pooled relative risk and 95%Cl was 
calculated using the method of DerSimonian & Laird. When data was available from the 
publication, I also calculate the mean difference in the change of Hcy between randomised 
groups (&-experimental arm minus A-comparator). 
In all meta-analyses, the DerSimonian and Laird Q test was used to evaluate the degree of 
heterogeneity between studies, and the l2 measure was used to describe the proportion of total 
variation in study estimates that is due to heterogeneity. [72] Funnel plot and the Egger regression 
test were conducted to evaluate the presence of small-study bias. [72] For all previous analyses a 
random effect model was used, in order to allow for any heterogeneity across studies. 
3.4 Results 
3.4.1 Homocysteine and MTHFR/C677T polymorphism 
A total of 96 datasets (from 79 studies) including a total of 58,644 individuals met our selection 
criteria S1-s79 From the 96 datasets, a total of 66 datasets including 52,332 subjects without 
evidence of CVD were utilised for the analyses, which is more than three times the information 
included in the analyses in Chapter 2. The additional 30 datasets (of 96) evaluating individuals 
with CVD were excluded. Among subjects without CVD, the WMD in plasma Hey between 
subjects homozygous for the T allele compared with individuals homozygotes for the C allele was 
2.15 . tmol/L (95%Cl: 1.74,2.55). The l2 measure was 84.1%. For subjects heterozygous the 
mean difference in Hey levels was of 0.42 µmol/L (95%Cl: 0.29,0.55) compared with subjects 
with the CC-genotype. The ;2 was equal to 50.6%. 
The MTHFR/C677T effect on Hey was highly dependent of the geographical region in which the 
study was conducted. There was a clear trend for subjects homozygous for the T-allele when 
compared with individuals homozygous for the C-allele, to have higher levels of Hey in regions 
with no supplementation of folic acid (Asia). The effect was smaller in the studies conducted in 
geographical regions with policies for folic acid fortification (Americas-Australia-New Zealand), for 
details see section (i) Figure 3.1. The X2 value for heterogeneity between sub-groups of 
geographical locations was equal to 157.06 (p< 0.0001) for the TT vs. CC comparison. When the 
analyses were limited to large studies (>_ 500 individuals), similar results were obtained, see 
section (i) Figure 3.1. The patterns were similar when heterozygous subjects were compared with 
subjects homozygous for the C-allele, though the magnitude of the genetic effect was smaller 
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(see section (ii) of Figure 3.1). The X2 for heterogeneity between geographical regions was 9.19 
(p= 0.057) for the CT vs. CC comparison. 
Figure 3.1. Homocysteine differences in subjects without cardiovascular disease by 
MTHFR/C677T genotype according to regions of supplementation. Upper panel includes all 
studies and bottom panel includes only studies with more than 500 individuals. 
section (i) MTHFR TT vs. CC section (ii) MTHFR CT vs. CC 
Geographical No of subjects Mean difference Geographical No of subjects Mean difference 
Region TT CC (96% Cl) Region CT CC (95°/ Cl) 
All studies All Studies 
Asia 1081 2398 'ý- 3 29 (2 37,420) Asia 2916 2398 0.86 (048,1.23) 
Europe Low 984 5243 2.44 (1 65,3.23) Europe Low 4629 5243 -ý 0 33 (0.08,0.59) 
Europe Moderate 992 3720 2.05 (1.49,2.60) Europe Moderate 3399 3700 0.33 (0.09,0.57) 
Am-Aus-N Zeal 261 518 1.52 (0.68,2.35) Am-Aus-N Zeal 529 518 0.22 (-026,0.70) 
Low-moderate Low-moderate 
Am-Aus-N Zeal 2859 11569 0.13 (-0.85,111) Am-Aus-N Zeal 11234 11569 032 (0 12,0.51) 
High High 
Large studies Large Studies 
Asia 690 1321 3 77 (2 75,4 78) Asia 1741 1321 0.38 (0.07.0.69) 
Europe Low 908 4796 'ý- 3.06 (2.18,3.95) Europe Low 4274 4796 0.47 (0 28,0.66) 
Europe Moderate 203 1185 ' 2.06 (1.16,2.96) Europe Moderate 804 1165 0.38 (0 06,0.70) 
Am-Aus-N Zeal 
i 
2773 11229 1 40 (1 16,1.64) Am-Aus-N Zeal 10966 11229 0.30 (0 18,0.42) 
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A meta-regression analysis of the differences in Hcy by genotype (TT vs. CC) against the 
geographical location, coded in ascending order of the levels of folic acid supplementation (Asia= 
1; Europe-low= 2; Europe-moderate= 3; America-Australia-New Zealand low-mod= 4 and 
America-Australia-New Zealand high= 5) showed a reduction in the effect of genotype on Hcy 
levels. For a1 category-increase in geographical location, the genetic effect on Hcy levels was 
reduced by 0.66 µmol/L (p< 0.0001). In order to explore the possible effect of small-study bias, 
the previous mete-regression was then restricted only to large-studies (? 500 individuals) and the 
pattern was similar (beta-coefficient for a1 category-increase= -0.59 µmol/L; p= 0.02). In a subset 
of 34 studies with information on folic acid, a meta-regression analysis indicated that for every 
increase of 1 ng/mL in folic acid concentration, the mean difference in Hcy levels for TT-subjects 
vs. CC-subjects decreased by 0.18 µmol/L, p= 0.03. 
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The P value for the Egger regression asymmetry test (including all 66 studies regardless of the 
geographical location) was 0.06 for TT vs. CC comparison, and 0.13 for the CT vs. CC 
comparison. 
3.4.2 MTHFR/C677T Polymorphism and Stroke 
A total of 134 datasets from 109 studies including 18,533 stroke events and 74,411 controls met 
our selection criteria and were included in the meta-analysis for our main stroke 
comparison. ýo, Sa7, s5s, s5s-iss. ss5, sss, ssa-575, S77, S7s-s1 67 Of these, 95 datasets (16,735 cases and 69440 
controls) provided information for ischaemic stroke as outcome, 18 datasets (1344 cases and 
19,623 controls) to hemorrhagic stroke, and 21 datasets (5375 cases and 23,776 controls) 
provided data on total stroke. Total stroke included studies that reported both hemorrhagic and 
ischaemic stroke, or those that only reported unclassified stroke (neuroimaging tools were not 
available to classify the event as ischaemic or hemmorhagic). Of the later group a total of 14 
studies came from individuals of European ancestry. 
The summary OR for the main stroke comparison was 1.40 (95%Cl: 1.27,1.54), for subjects 
homozygous for T-allele compared to individuals homozygous for the C-allele. The 12 measure for 
heterogeneity was 46.9%. The OR for heterozygous subjects was 1.17 (95%CI: 1.09,1.24), and 
the 12 measure was equal to 45.8%. When analyses were restricted only to large studies (? 400 
stroke events) the OR was 1.12 (95%Cl: 0.99,1.27) for TT-individuals and 1.06 (95%Cl: 0.99, 
1.14) for CT individuals compared to subjects homozygous for the C-allele. Analyses based on 
different stroke sub-types are shown in Figure 3.2. No heterogeneity for the effect estimates was 
observed according to the stroke sub-types in either of the genotype comparison. The P value for 
heterogeneity was equal to 0.17 for the TT vs. CC comparison and 0.85 for CT vs. CC 
comparison. Nonetheless, the power to detect heterogeneity according to stroke sub-types is 
limited due to reduce number of certain stroke types, especially hemorrhagic. 
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Figure 3.2. Odds ratio of the MTHFR/C677T variant on different stroke sub-types. Left panel 
compares individuals homozygous for T-allele with CC-subjects. Right panel compared 
heterozygous with CC-subjects. 
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When studies were categorized by geographical region according to the folate supplementation, 
important differences were observed in the magnitude of the genotypic risks. In Asia, region 
associated with lower population levels of folic acid, [46,73] and also a region in which the 
MTHFR/C677T variant exhibited the biggest effect on Hcy levels (Figure 3.1), showed the highest 
increase in risk of stroke, summary OR of 1.66 (95%Cl: 1.42,1.94) for the TT vs. CC genotype 
comparison(Figure 3.3). By comparison, in regions such as Europe low and moderate with 
intermediate levels of folic acid and smaller differences in Hey levels by MTHFR genotype (Figure 
3.1), the magnitude of the association between stroke and MTHFR genotype were null or lower; 
summary OR for Europe low of 1.04 (95%Cl: 0.90,1.20) and Europe moderate of 1.32 (95%Cl: 
1.12,1.54). Regions in which there are policies for folate fortification (America, Australia, and New 
Zealand post-fortification) the point estimate is smaller (OR of 1.16), however the confidence 
intervals are still wide, ranging from 0.76 to 1.77 (Figure 3.3). The X2 value for heterogeneity 
among geographical regions was equal to 16.77 (p= 0.002) for the TT vs. CC comparison. 
Similar differences in the genotypic risks, although of lower magnitude were also observed for 
heterozygous individuals compared with subjects homozygous for the C-allele (Figure 3.3). The 
OR for Asian studies was 1.34 (95%: 1.19,1.49), for Europe-moderate was 1.15 (95%: 1.05, 
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MTHFR MTHFR 
TT vs. CC CT vs. CC 
1.27), while non-significant associations were observed for studies conducted in America, 
Australia or New Zealand before or after the implementation of folic acid fortification policies 
(Figure 3.3). The X2 value for heterogeneity among geographical regions was equal to 24.98 (p< 
0.0001). 
Figure 3.3. Odds ratio of the MTHFR/C677T variant on stroke (main comparison) stratified by 
region of supplementation. Left panel compares individuals homozygous for T-allele with CC- 
subjects. Right panel compared heterozygous with CC-subjects. 
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When the MTHFR/C677T effect on stroke by geographical region was restricted to large studies 
(>_ 400 stroke events) a similar pattern of associations was also observed in both genotype 
comparisons. The summary OR of stroke for studies in Asia was 1.28 (95%Cl: 1.11,1.48) for the 
TT vs. CC comparison and, 1.19 (95%CI: 1.04,1.36) for the CT vs. CC comparison. In contrast, 
studies in Europe low or moderate no increase in the risk of stroke was observed for the 
MTHFR/C677T variant. Unfortunately no large studies have been conducted (or those were not 
identified by our extensive search strategy) in some geographical regions, such as America, 
Australia or New Zealand (Figure 3.4). 
After including all studies regardless of geographical region by folate supplementation policy, the 
P value for the Egger regression asymmetry test was < 0.001. However, this asymmetry could be 
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due to differences in the genotypic effect by geographical location (and therefore by folate levels) 
as suggested in Figure 3.1 & Figure 3.3. Therefore, I obtained the Egger test for each 
geographical region, the P values were as follow: Asia= 0.002, Europe-low= 0.75, Europe- 
moderate= 0.04, Am-Aus-NZ low/mod= 0.05 and Am-Aus-NZ high= 0.6. These analyses suggest 
that the genetic risks may have been overestimated in smaller studies, and that a less biased 
genetic estimate was obtained from large studies (bottom panel of Figure 3.1 and Figure 3.4). 
Figure 3.4. Odds ratio of stroke (main comparison) by region of supplementation restricted to 
large studies (>_ 400 stroke events). Left panel compares individuals homozygous for T-allele with 
CC-subjects. Right panel compared heterozygous with CC-subjects. 
Region of No TT vs CC 
Odds ratio 
supplementation Cases (95% Cl) 
Asia 
LiZ 1823 1.21 (1.01,1.45) 
Li CM 454 1 77 (0 95,3.29) 
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Kostulas K 600 1 1 0.92 (0 71,1 18) 
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3.4.3 Genetic studies of MTHFR/C677T-stroke in the context of randomised trials of Hcy 
lowering interventions. 
A total of 10 randomised trials of Hcy-lowering interventions including 25,379 individuals, (1015 
stroke events) met our selection criteria. [74,75,76,77,78,79,80,81,82,83] The main study 
characteristics are described in Table 3.1. None of the RCTs was stopped prematurely and, with 
the exception of two small trials including only 681 individuals (Liem et al, and Righetti et 
al), [74,75] all trials were double blind. Nine out of ten trials, providing 95 percent of the stroke 
outcomes, have been conducted outside Asia, i. e. in Europe, America, and Australia. 
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All individuals included in the trials had a previous history of CHD, stroke or renal disease. In all 
trials, except the VISP trial [76] that evaluated only ischaemic stroke, the stroke outcome 
evaluated was composed of both fatal and non-fatal ischaemic, or hemorrhagic events. The 
weighted mean follow was 5.3 years. After pooling data from ten trials the summary relative risk 
for stroke in subjects randomised to active treatment was 0.87 (95%Cl: 0.77,0.99) and was 
associated with a mean reduction in Hcy levels of 2.47 µmol/L in favour of the folic acid arm (with 
or without B-vitamins), see Figure 3.5. A meta-regression analysis of the log of the relative risk for 
stroke against the mean difference in Hcy achieved by the intervention was not significant (b- 
coefficient= 0.06, p= 0.16). 
Figure 3.5. Pooled relative risk of stroke from randomised clinical trials of Hcy-lowering 
interventions in the context of genetic studies of the MTFHR/C677T variant on stroke. 
Study design Difference in Stroke 
Hcy (µmol/L) events 
Genetic studies MTHFR-Stroke (CC vs. TT genotype) 
All genetic studies -2 15 18533 
Genetic studies Asian -329 7608 -l-- 
Genetic studies non Asian -1.8 10925 4 
RCTs using Hcy-lowering interventions (mainly from non Asian regions) 
Toole 18 300 
Liem -2.6 20 
HOPE-2 -3.2 258 
Wrone -3.6 27 
Bonaa -3.4 98 
Zoungas -47 26 
Righetti -15.1 14 
Mark N. R_ 57 - 
Ebbing -28 67 
Albert -2 27 148 
Overall RCTs -2.47 1015 
Relative risk 
(95% Cl) 
071(064,078) 
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1 00 (0 80,1 30) 
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0.95 (0.68,1 32) 
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0.55 (0 19,1 62) 
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1 14 (0 82.1 57) 
0.87 (0.77,0.99) 
0.4 0.8 12 
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When the results of randomised trials were compared with the effect of allocation to the naturally 
randomised MTHFR/C677T variant as proxy for an Hcy-lowering intervention, a similar degree of 
reduction in the risk of stroke was observed especially when trials were compared with genetic 
studies conducted in the same geographical region in which trials have been conducted, i. e. non- 
Asians. The relative risk reduction observed in trials of 13% (95%Cl: 1% to 23%) was within the 
range predicted by genetic studies of 20% (95%CI: 10% to 29%) (Figure 3.5). The random error 
in the effect estimate from genetic studies was considerably smaller than that observed for 
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randomised trials. Indeed, genetic studies from a comparable geographical region (i. e. in Europe 
America and Australia) included up to ten times more stroke events than randomised trials (Figure 
3.5). 
3.5 Discussion 
In order to investigate the possible modifying effect of folate consumption on the Hcy-stroke 
association, that may affect the interpretation of a possible causal role for Hcy in stroke, I 
conducted a systematic evaluation of two randomised sources of evidence, genetic studies and 
clinical trials. 
A systematic evaluation of the evidence from (published and unpublished) genetic studies 
showed that the effect of the MTHFR/C677T variant on Hcy and stroke was modified by 
geographical setting of the study which, in turn corresponded to the policy on folate fortification in 
that region. Genetic studies conducted in Asia uncovered the largest genetic effect on Hcy (3.29 
µmol/L; for TT vs. CC comparison). In contrast, for the same genotype comparison, in regions in 
which policies for folic acid fortification have been implemented, [661 the gene effect on Hcy was 
substantially lower (0.13 . tmol/L), while in regions such as Europe the effect was intermediate 
(2.05 µmol/L). A similar pattern, although lower in magnitude, was also observed for subjects 
heterozygous for the MTHFR/C677T variant. Importantly, the modification of the MTHFR/C677T- 
Hcy association by the region of supplementation of folate was unaffected when the evidence was 
restricted to large studies, reducing the possibility of small-study bias as an explanation for the 
differences observed (Bottom panel of Figure 3.1). The interpretation that geographical setting is 
acting as a proxy for folate consumption and that this modifies the genetic effect is supported from 
the meta-regression analyses that indicated that the difference in Hcy levels by MTHFR genotype 
is reduced as the concentrations of folic acid increase. However, the number of studies with 
information on folic acid levels that were included in the meta-regression analyses was 
substantially lower, 34 out of 66 datasets. 
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When evaluating the effect of the MTHFR/C677T variant on risk of stroke, a similar modification of 
the genotypic risk by the region of supplementation of folate was also observed, which mirrored 
the MTHFR-Hcy association. Studies in Asia had the largest genotypic risk on stroke, studies in 
Europe an intermediate effect, and studies in America, Australia or New Zealand showed the 
lowest or null effect stroke. However, the amount of evidence from the America, Australia or New 
Zealand is considerably smaller, up to 17 times fewer cases when compared to studies in Asia 
and Europe (Figure 3.3). This pattern was not only evident for TT homozygous when compared 
with subjects homozygous for the C-allele, but also for subjects heterozygous for the 
MTHFR/C677T variant. As for the MTHFR-Hcy association, the findings of an effect modification 
on the MTHFR-stroke associations by region of folate supplementation remained largely 
unaltered when the analyses were restricted to large studies, diminishing the possibility of small- 
study bias as an explanation (Figure 3.4). Although the modifying effect on MTHFR-Stroke 
association by geographical location could be due to differences in the levels of folate 
consumption, a detailed investigation of this possibility was hampered due to lack of studies with 
all the necessary information. 
Despite synthesis of the genetic evidence suggested an increase risk of stroke associated with 
the MTHFR/C677T variant (used as unconfounded proxy of Hcy), it does not necessarily follow 
that reducing Hcy levels will reverse the risk of stroke in adult life. Such evidence, if feasible, 
should be derived from randomised clinical trials using an intervention that specifically reduces 
the levels of Hcy, such as folic acid. 
A pooled analysis of 10 trials published up to August 2008 using folic acid interventions with 
information on stroke (including 1015 events) indicated that after a mean follow up of 5.3 years 
and an average reduction in Hcy levels of 2.47 µmol/L, the risk of stroke was reduced by 13% 
(95%Cl: 1% to 23%). However, I was unable to investigate whether the reduction in the risk of 
stroke associated with Hcy-lowering interventions in trials is modified by the region of folate 
supplementation (and ideally by levels of folic acid) in a similar manner to that conducted for 
genetic studies. The reasons for this are that the large majority of trials were based in Europe, 
North-America and Australia and also, because only aggregate data were obtained for the meta- 
analyses of clinical trials. 
However, it is important to highlight a few important differences between the evidence obtained 
from randomised clinical trials and genetic studies. First, the majority of trial evidence comes from 
settings where policies for folic acid fortification had already been implemented. [66,84] By 
contrast, the large majority of the genetic evidence judged by the number of stroke events is 
derived from unfortified regions (17,593 out of 18,533 stroke events). Second, despite the level of 
reduction in Hcy concentrations being largely comparable across the two levels of evidence (2.47 
µmol/L for clinical trials and 1.8 . imol/L for genetic studies), the length of follow up is considerable 
different. Only three trials including 463 stroke events had five or more years of follow 
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up, [77,81,821 and for all trials randomisation to the intervention occurred in adult life, mean-age 
range from 54 to 69 years old. In contrast genetic studies can be conceived as life-time natural 
randomised trials since randomisation to the allele variants (used as instrument for Hcy levels) 
occurred at time of gamete formation. Third, the number of stroke events in published trials is 
substantially lower than that included in my genetic analyses (1015 events in trials vs. 10925 
events in genetic studies of similar geographical location). All these reasons explain why evidence 
on trials is still not-definitive, but also why the expected reductions derived from genetic studies 
are perhaps greater than those observed in trials conducted to date, for detailed discussion see 
section 8.5 in Chapter 8. 
Despite, all these differences a considerable concordance between randomised trials and genetic 
studies was observed, utilising the evidence available to August 2008. Genetic studies conducted 
outside Asia (as the trials) showed that individuals homozygous for the C-allele that carried lower 
levels of Hcy by 1.8 µmol/L compared with TT individuals, also had a reduced risk of stroke by 
20% (95%Cl: 10% to 29%). Reduction that is similar to that observed in clinical trials, 13% 
(95%Cl: 1% to 23%; see Figure 3.5]). However, as observed from the analyses restricted to large 
genetic studies, it is entirely possible that the expected reduction for trials conducted outside Asia 
to be null or a much lower benefit of around 8%, compared with the current point estimate of 13%. 
If adequately powered genetic studies of the MTHFR/C677T variant on stroke can be envisaged 
as a type of randomised evidence of the expected benefit that could be achieved by long term 
reductions in Hcy levels, the genetic analyses presented in this Chapter suggest that the relative 
risk reduction should be greater in Asian populations compared to populations of European 
descent (Asian: 40% [95%Cl: 30% to 49%] vs. Non Asian: 20% [95%Cl: 10% to 29%]). In 
addition, since the event rates of stroke are higher in Asian countries compared to those from 
European descent populations, [85] and also considering that Asian countries account for a large 
proportion of the worldwide population (and therefore of stroke events) the public health impact 
benefit could be of great importance. [85] 
Although the analyses I present here suggest that reducing Hcy may reverse the risk of stroke, 
there is still considerable controversy whether these findings also apply to CHD. There is the 
possibility that Hcy is indeed causally associated to both stroke and CHD, but that the magnitude 
of the association, as reported from observational studies, is greater for stroke than for CHD. A 
similar situation is seen for systolic blood pressure which has a stronger association with stroke 
than CHID. If this is case, the genetic signal to be detected by studies evaluating the 
MTHFR/C677T variant on CHD would also be smaller. Along with the fact that the majority of 
large CHID-genetic studies are being conducted in individuals of European descent, this could 
partially explain why a clear genetic signal for MTHFR has not yet been detected for CHD. 164] 
Also, if this is correct the expected benefit from randomised trials in CHD would be smaller, 
suggesting existing trials may be underpowered for CHD. 
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The analyses I presented in this Chapter have to be considered within the context of their 
strengths and limitations. The establishment of a large genetic collaboration including a 
considerable amount of previously unpublished information of relevance to the gene environment 
interaction (folic acid and Hcy in genetic association studies of stroke), have diminished the 
possibility of publication and reporting bias. The large sample size included in both genetic meta- 
anlaysis (58,644 for MTHFR-Hcy and 92,944 for MTHFR-Stroke) increased the ability to detect 
differences according to regional policies on folate supplementation as well as by the level of folic 
acid from individual studies. Finally, I also contextualized the genetic findings with a systematic 
evaluation of findings from published trial using Hcy-lowering interventions (i. e. I compared the 
observed effect on stroke from genetic studies with the observed effect size from trials) rather 
than focusing solely on statistical tests in the genetic associations. 
In conclusion, the concordance of findings on the genetic effects of MTHFR on Hcy levels and the 
genetic association with stroke risk argues in favour of the existence of a gene-environment 
interaction. This has important repercussions for the interpretation of emerging results of clinical 
trials using Hcy-lowering interventions, which to date seem to suggest that the high risk of stroke 
conferred by high Hcy levels is reversible. 
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Chapter 4 C-reactive protein and myocardial infarction 
In Chapters 2 and 3, I utilised a Mendelian randomisation approach to evaluate the potential 
causal role of Hcy in stroke. For this, I took advantage of the large amount of available evidence 
on a well known gene variant (MTHFR/C677T) that was used as a proxy for an indirect biomarker, 
Hcy. The Mendelian randomisation approach described in this Chapter has two differences 
compared with the previous Chapters. First, this is the result of a prospective collaboration of 
genetic studies in which de novo genotyping of a single (the most promising at the time) CRP- 
variant was utilised. Second, in contrast the MTHFR/C677T-Hcy-Stroke experiment, due to the 
particularity that the genetic-variant used as proxy lies in the gene (CRI') that codifies for the 
biomarker of interest (plasma CRP), it allows me to obtain empirical evidence on a different type 
of Mendelelian randomisation experiment. Further details about the different uses of Mendelian 
randomisation are discussed in Chapter 8. 
4.1 C-reactive protein and coronary events in observational studies 
Prospective studies indicate a robust association, in healthy individuals, between levels of the 
acute phase reactant CRP and later coronary events, [86-88] and it has been proposed that 
measurement of CRP may be a useful adjunct to coronary risk assessment and, perhaps, 
causally involved in atheroslerosis. [11] However, CRP concentrations are associated with 
smoking status, blood pressure, abdominal obesity, diabetes, physical activity, and other products 
of the inflammatory response, and are also higher in individuals with clinical CVD. [89-92] Despite 
statistical adjustment, this association may therefore be subject to residual confounding or bias 
due to reverse causation. 
A randomised controlled clinical trial of a selective intervention to reduce CRP would provide an 
unbiased insight into the nature of the association. Unfortunately, no such selective intervention 
currently exists for use in humans. Although inhibitors of HMG-CoA reductase (statins) and 
glitazones reduce CRP, [93,94] they also have major effects on lipid profile and glucose 
metabolism. An alternative approach to control for confounding and reverse causality is to identify 
a common polymorphism in the CRP gene reliably associated with differences in circulating CRP 
concentration. Due to second Mendel's law, if CRP actually increases the risk of coronary events, 
then carriage of an allele that exposes individuals to a long term elevation in CRP should confer 
an increased risk of coronary events proportional to the difference in CRP attributable to the 
allele. This relation should be largely unconfounded and free of reverse causality bias. [22,23] 
Therefore, if non-genetic observational studies were unbiased, the increase in risk estimated from 
these studies should be consistent with the increase in risk conferred by carriage of the allele. 
CRP concentration is a heritable trait, [95,961 and in three small studies I and others have found 
that homozygosity for the rarer T allele of a +1 444C>T polymorphism (rsl 130864) in the 3' 
untranslated region of the CRP gene was associated with higher basal and/or stimulated CRP 
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concentrations. [97,981 In order to test whether the increase in risk of coronary events in 
individuals homozygous for this polymorphism (rsl 130864) is close to that predicted under the 
assumption that the CRP-coronary event association from previous non-genetic studies is 
unbiased, a large number of European descent men were genotyped de novo. 
This approach, of conducting new genotyping within the framework of a prospective collaboration 
of studies, contrasts with that approach I conducted for Chapters 2 and 3, for which a genetic 
variant that modify the concentration of the biomarker of interest had been widely studied for 
several years and allowed me to conduct, in the first instance, a synthesis of the available 
evidence. 
4.2 Methods 
4.2.1 Study populations 
After obtaining ethical approvals, genotyping for the CRP polymorphism and measurement of 
plasma CRP concentration were conducted in samples obtained from a number of cross-sectional 
or prospective studies, or randomised controlled trials summarized in Table 4.1. [99-1041 
From the Second Northwick Park Heart Study (NPHS-2)[99] genotyping was conducted in 2676 
Caucasian men of whom 103 developed a non-fatal MI after a median follow-up of 10.6 years. 
In a nested case-control genetic study from the West of Scotland Coronary Prevention trial 
(WOSCOPS), [100] which randomised 6595 male participants, initially free from clinically evident 
cardiovascular disease to either pravastatin or a placebo, 348 incident non-fatal Mls were 
identified and defined as cases and were matched by age and smoking status with 1103 controls 
drawn from the remainder of the cohort. 
In the Lower Extremity Arterial Disease Event Reduction (LEADER) trial [101] a randomised 
controlled trial of bezafibrate in men with lower extremity arterial disease, a total of 647 Caucasian 
men in the active treatment and 419 in the placebo arm were included. There were 43 incident 
non-fatal MIs during follow-up and these subjects were defined as cases. 
The Hypercoagulability and Impaired Fibrinolytic function MECHanisms predisposing to MI 
(HIFMECH)[1021 study was a European multicentre case-control study of MI. For the present 
study a total of 491 cases and 517 controls were available for genotyping. 
The cross-sectional "Army-study" recruited Caucasian men from the Army Training Regiment, 
(Bassingbourn, UK) to evaluate the relationship between genetic factors and inflammatory 
response to exercise. DNA was extracted from 219 individuals for CRP genotyping and the 
measurement of CRP plasma concentration. [98] 
The UCL DiAbetes and Cardiovascular disease Study (UDACS) study[1031 is a cross sectional 
case-control study to evaluate risk factors for coronary heart disease in subjects with diabetes 
mellitus. For the current study only Caucasian males (n=348) without coronary heart disease were 
included and contributed to the first analysis. 
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The Electron Beam Computerised Tomography (EBCT)[104] study was designed to compare 
coronary artery calcification and coronary risk factors in Caucasian Type-1 diabetic patients and 
non-diabetic participants. Controls were a random sample of the general population (94 men and 
107 women), stratified to have a similar age and gender distribution to the patients with diabetes. 
For the present study the male controls were included (n=72) and contributed to the first analysis. 
To test the association of +1444C>T genotype with CRP concentration, male subjects without 
clinically evident cardiovascular disease from six studies with available DNA and plasma samples 
were studied; Table 4.1. A second analysis was conducted to evaluate the association between 
genotype and risk of MI in male subjects from four studies; Table 4.1. 
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4.2.2 Data collection 
Data on demographical variables, cardiovascular risk factors and plasma CRP were obtained from 
the original studies. Subjects were classified using unified definitions of hypertension, 
hypercholesterolemia, type-2 diabetes mellitus and obesity from the guidelines on primary prevention 
of the American Heart Association. [5] For the studies relating genotype and coronary 
events, [99,100,101,102] non-fatal MI according to WHO critena, [105] was considered the primary 
outcome, as this end-point had been uniformly used across all studies. Analysis of genotype and 
CRP were limited to male subjects to preserve consistency with available studies of genotype and 
coronary events, which were all conducted in men. 
4.2.3 Laboratory analysis 
All studies included in the present report used high sensitivity assays to measure plasma CRP 
concentrations. Plasma CRP concentrations for the NPHS-2 (717 subjects) and LEADER studies 
were measured by use of commercial assays (R&D Systems). Inter-assay and intra-assay 
coefficients of variations were 6.2% and 1.9% respectively, with a detection limit of 0.1 mg/L. For an 
additional 2221 subjects from the NPHS-2 study an Enzyme Immunoassay (Kordia Life Sciences) 
was used to measure CRP concentrations. For the EBCT and HIFMECH studies CRP was measured 
with a highly sensitive in-house enzyme-linked immunosorbent assay with rabbit anti-human CRP 
(Dako, Copenhagen, Denmark) as a catching and tagging antibody with inter and intra-assay 
coefficients of variations of 4.7 and 3.8% and a limit of detection of 0.15mg/L. For the WOSCOPS 
study a validated in-house assay was used with a lower limit of detection of 0.1 mg/L. The intra-assay 
and inter-assay coefficients of variation were 1.9% and 6.2%, respectively. In the Army-study, plasma 
CRP was measured on a BN Prospec (Dade Behring, Milton Keynes, UK). Inter-assay and intra- 
assay coefficients of variation were <4% and <2% respectively with a detection limit of 0.2 mg/L. In 
the UDACS study, CRP was measured using a highly sensitive ELISA assay (Dako A/S, Glostrup, 
Denmark). Inter-assay and intra-assay coefficients of variation were 8% and 10% respectively with a 
detection limit of 0.26 mg/L. 
4.2.4 C-reactive protein genotyping 
The CRP/+1444C>T single nucleotide polymorphism (SNP; rs1130864) was genotyped by PCR and 
RFLP analysis using primer pairs described previously, [98] and the restriction enzymes Sdul or 
Bsp12861 which cleave the 181bp PCR product into 23bp and 158bp fragments only in the presence 
of the common C allele. All DNA analysis was performed by staff unaware of the clinical status of the 
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subjects. Except the WOSCOPS study (genotyping conducted by members of the laboratory of Dr 
Naveed Sattar), all genotyping was conducted by Dr Tina Shah at the Centre for Cardiovascular 
Genetics and Centre for Clinical Pharmacology, Department of Medicine, UCL. 
4.2.5 Statistical Analysis 
4.2.5.1 Genotype and CRP concentration 
To quantify the effect of the CRP gene polymorphism on CRP concentration, a total of 4659 men from 
six studies were genotyped; Table 4.1. I calculated the within-study mean difference in CRP 
concentration between individuals homozygous for the T allele and carriers of the C allele and then 
weighted each mean by the inverse of its variance to obtain an overall WMD. In the calculation of the 
WMD, I limited the analysis to subjects without known coronary or peripheral artery disease at the 
time of blood sampling in order to avoid the potential for established disease to modify the size of the 
genotype-CRP association. However, an analysis including all subjects was also conducted. 
Therefore, for prospective studies, baseline CRP data were used from all available subjects without 
clinically evident atherosclerosis. For case-control studies, genotype-CRP associations were 
analysed solely using control subjects. Because of its skewed distribution, CRP values were log- 
transformed, using the natural log-scale before the analysis. I calculated the absolute geometric- 
WMD in CRP concentration by CRP genotype, using the following formula: geometric WMD= 
[(relative difference in CRP concentration between TT homozygotes and C-allele carriers x mean 
CRP concentration in C-allele carriers) - mean CRP concentration in C-allele carriers]. In addition, to 
test whether the association between the CRP/+1444C>T polymorphism and CRP concentration 
could be confounded by other risk factors, I compared the distribution of cardiovascular risk factors in 
groups defined by CRP genotype. Random and fixed effect models were used for these analyses. 
4.2.5.2 Genotype and non fatal myocardial infarction 
To examine the effect of CRP genotype on risk of non-fatal MI, a total of 6201 men from four studies 
were genotyped; Table 4.1. The adjusted ORs and 95%CI for subjects homozygous for the T allele 
compared with carriers of the C allele were calculated from each study. In addition, for the two 
intervention trials [100,1011 the potential interaction of the genotype-MI association with the active 
therapy was also evaluated. I then pooled the within-study ORs to obtain a summary adjusted-OR 
and 95%Cl for non-fatal MI, under both fixed and random effect models. Fixed effect summary-ORs 
were calculated using the inverse variance-weighted method, [1061 and the DerSimonian and Laird Q 
test was used to evaluate the degree of heterogeneity between studies. [55] 
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4.2.5.3 Consistency between the odds ratios from genetic and from non-genetic observational 
studies 
I estimated the expected OR for non-fatal MI, corresponding to the WMD in CRP between TT 
subjects and C allele carriers, based on data from prior non-genetic observational studies that 
examined the CRP-coronary event association. To do this I used information from the most recent 
meta-analysis of observational studies of CRP and coronary events, as well as data from the 
Reykjavik Heart Study. The first estimate, based on an OR of 1.58 (95%Cl: 1.48,1.68), for the top vs. 
bottom tertiles of the CRP distribution, came from the recent meta-analysis of 22 prospective studies 
including 7068 cases with different degrees of adjustment for traditional cardiovascular risk factors 
across the studies included and no adjustment for regression dilution bias. [107] The second estimate 
was based on an maximum-adjusted OR of 1.45 (95%Cl: 1.26,1.68) between top and bottom tertiles 
of the CRP distribution reported in the Reykjavik Heart Study, [107] the largest prospective 
observational study of CRP which contributed 2459 cases to the meta-analysis and also undertook a 
comprehensive adjustment for potential confounders (age, sex, period of recruitment, smoking, 
systolic blood pressure, total cholesterol level, triglyceride levels, body mass index, forced expiratory 
volume in one second, diabetes, and socio-economic status). The third estimate from Reykjavik Heart 
Study, [107] was based on an OR of 1.92 (95%Cl: 1.68,2.18) for top vs. bottom tertile of CRP, based 
on a more limited degree of adjustment (age, sex and period of recruitment). The final estimate also 
from Reykjavik study was based on the adjusted standard 10-year follow-up risk of 1.84 (95%Cl: 
1.49,2.28) for top vs. bottom tertile of CRP. [107] 
For these estimates I assumed that the usual mean difference in CRP between the individuals in the 
top and bottom tertiles was 1.4mg/L, [90] and that the CRP-coronary event relationship was log-linear. 
The expected OR for TT homozygous subjects with reference to C allele carriers was calculated 
using the formula: expected OR= OR-non genetic studies(wMD/' 4) The 95%Cl for the expected OR for 
TT homozygous subjects with reference to C allele carriers was obtained by simulation, as described 
in Chapter 2. Briefly, one million replications of the expected OR were obtained using the WMD in 
CRP by genotype and the OR from non-genetic observational studies with their corresponding 
standard errors, therefore the uncertainties surrounding the two associations, genotype-intermediate 
phenotype and intermediate phenotype-disease risk were take into account. [58] The values for the 
2.5 and 97.5 percentiles of the simulated distribution were used as limits of the 95% confidence 
interval for the expected OR. [58] This expected OR was compared with the observed summary-OR 
obtained from the genetic studies, by means of an interaction test, as described in Chapter 2. [59] 
Data were analysed using the Review Manager software (version 4.2) from the Cochrane 
Collaboration 2003 and Stata 8.2. 
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4.3 Results 
4.3.1 Allele and genotype frequencies 
The allele and genotype frequencies of the +1444C>T polymorphism were in Hardy-Weinberg 
equilibrium for all studies included in the present report, apart from a marginal distortion in the NPHS- 
2 study (Table 4.2). The frequencies of the rare allele in disease-free subjects from all studies were 
very similar (range: 26% to 33%). 
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Table 4.2 Allele and genotype frequencies of CRP/+1444C>T polymorphism in the studies evaluated. 
Study Controls 
(number) 
P value for H -W 
equilibrium 
Cases 
(number) 
P value for H-W 
equilibrium 
NPHS-2 
+1444CC 1261 0.03 57 0.48 
+1444CT 1047 41 
+1444TT 265 5 
T-allele frequency 0.30 0.24 
WOSCOPS 
+1444CC 511 0.88 175 0.17 
+1444CT 481 136 
+1444TT 111 37 
T-allele frequency 0.32 0.30 
LEADER 
+1444CC 514 0.27 21 0.31 
+1444CT 412 16 
+1444TT 97 6 
T-allele frequency 0.29 0.32 
HIFMECH 
+1444CC 254 0.27 246 0.28 
+1444CT 224 196 
+1444TT 39 49 
T-allele frequency 0.29 0.30 
Army 
+1444CC 122 0.42 - 
+1444CT 92 - 
+1444TT 13 - 
T-allele frequency 0.26 - 
UDACS 
+1444CC 167 0.12 - 
+1444CT 139 - 
+1444TT 42 - 
T-allele frequency 0.32 - 
EBCT 
+1444CC 39 0.85 - 
+1444CT 29 - 
+1444TT 6 - 
T-allele frequency 0.28 
Not applicable. 
4.3.2 CRPI+1444C>T polymorphism and CRP concentrations 
Using data from 4659 men from six studies, the weighted mean CRP concentration in C-allele 
carriers without known cardiovascular disease was 2.01 mg/L (95%Cl: 1.94,2.07). Under a fixed 
effect model, the geometric-weighted mean difference in CRP concentration between individuals 
homozygous for the T allele compared with carriers of C allele was 0.68 mg/L (95%Cl: 0.31,1.10). 
There was no significant between-study heterogeneity (P value for heterogeneity [PHet]= 0.47; Figure 
4.1. When alternative models of the effect of genotype on CRP were evaluated, only the (TT) vs. (CC) 
comparison was significant (WMD= 0.78 mg/L [0.41,1.20]; p<0.0001), while heterozygosity (CT vs. 
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CC) was not (WMD= 0.06 [-0.24,0.44]; p=0.66). When subjects with coronary or peripheral 
atherosclerosis at the time of blood sampling were included in this analysis (n= 5658), 
the WMD 
between individuals homozygous for the T allele compared with carriers of C was very similar (0.74 
mg/L [95%CI: 0.37,1.10], p<0.0001). 
Figure 4.1 Mean log-CRP and mean difference in log-CRP (mg/L) by study among subjects without 
known cardiovascular disease. 
Study N 
TT 
Log. mean(SD) H 
CT+CC 
Log-mean(SO) 
Ti as (CT+CC) 
Drfference in log-CRP value Difference in log-CRP value 
(95%CI) (96%C) 
WOSCOPS1 99 2.64(1.07) 919 0.62)1. )7' 0.02 (-0.20,0.241 
WOSCOPSfi 35 1.00(0.87) 281 0.89(1.05) 0.11 1-0.20,0.421 
230 1.08(1.01) 1991 0.88)1.31) - 0.20 10.06,0.341 
UD CS 42 3.58 (0.78) 306 0.30 )0. B5 0.28 (0.03,0.531 
EIREH 37 0.69(1.18) 428 0.34(0.941 0.35 1-0.04,0.741 
EBCT 6 0.26(0.93) 66 -0.22(1.381 0.48 1-0.31,1.271 
Army 13 0.04(1.32) 206 -0.60(1.06' 0.64 1-0.09,1.371 
Totý(95%0) 462 4197 0.19 (0.09,0.291 
Relative 3tterence$1.21 [1.09,1.341 
test for overal effect; 0: 0,0001 Geometry Vvi'O" 0.68 mg!! [C. 31,1.01 
"1 . 0. ý 0 0.5 1 
Lower CRP Aes Higher CRP values 
*; Data for control subjects. t; Data for subjects with non-fatal MI. $; Relative difference was obtained by antilog 
of the difference in log-CRP values. **; Geometric WMD= [(relative difference in CRP concentration between TT 
homozygotes and C-allele carriers x mean-CRP concentrarion in C-allele carriers) - mean-CRP concentrarion in 
C-allele carriers]. 
To evaluate potential confounding of the genotype-CRP association, I quantified the association 
between TT genotype and age, systolic and diastolic blood pressure, body mass index, current 
smoking, glucose, alcohol intake, fibrinogen, triglyceride, total and HDL cholesterol. No significant 
difference was observed for any of these risk factors, with the exception of a slightly higher body 
mass index among TT subjects (mean difference=0.34 kg/m2; p=0.02; Table 4.3). In view of the 
multiple comparisons made, however, this significance level is not particularly extreme. Moreover, 
this apparent association was not significant when subjects with and without CHD were considered 
together, and it is likely, but not yet certain, to reflect the play of chance. 
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Table 4.3 Cardiovascular risk factor distribution according to the CRP/+1444C>T polymorphism. 
Comparisons are made between TT homozygotes and C-allele carriers. 
Variable Subjects 
(studies) 
Weighted mean 
difference 
[TT minus C-carriers] 
(95%CI) 
P value 
Age (years) 6358(7) 0.17 (-0.19,0.52) 0.35 
Systolic blood pressure (mmHg) 6356 (7) -0.31 (-1.78,1.16) 0.68 
Diastolic blood pressure (mmHg) 6356 (7) -0.70 (-1.56,0.16) 0.11 
Body mass index (kg/mz) 6359 (7) 0.34 (0.06,0.62) 0.02 
Total cholesterol (mmol/L) 6115 (6) -0.01 (-0.08,0.06) 0.87 
HDL-cholesterol (mmol/L) 4714 (5) -0.01 (-0.04,0.01) 0.32 
Triglyceride (mmol/L) 6041 (5) -0.03 (-0.11,0.06) 0.51 
Fibrinogen (g/L) 5656 (4) 0.03 (-0.02,0.08) 0.20 
Glucose (mmol/L) 1913 (3) -0.01 (-0.13,0.12) 0.90 
Alcohol intake (U/week) 4549(4) 0.01 (-1.38,1.39) 0.99 
Current smoking' 6132 (6) 1.00 (0.84,1.20) 0.98 
C-reactive protein (mg/L) 4659 (6) 0.68 (0.31,1.10) 0.0001 
*; For this variable instead of the WMD, the value reported is the weighted odds ratio. 
4.3.3 Odds ratio estimated from observational studies and the expected mean difference in 
plasma CRP 
Expected ORs for non-fatal MI among TT homozygotes compared to C allele carriers based on a 
between-genotype WMD difference in CRP of 0.68 mg/L (95%Cl: 0.31,1.10) were 1.37 (95% Cl: 
1.14,1.68), 1.20 (95% Cl: 1.07,1.38), 1.34 (95%Cl: 1.12,1.67) and 1.25 (95% Cl: 1.09,1.43) based 
respectively on the Reykjavik Heart Study minimally and maximally adjusted models, Reykjavik study 
10-year estimate, and on the meta-analysis of studies to 2004. [107] 
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4.3.4 Odds ratio of non-fatal myocardial infarction for the CRP/+1444C>T polymorphism 
Data from four new studies involving 985 subjects with non-fatal MI and 5216 control subjects were 
pooled to obtain a summary adjusted OR. After combining the studies under a fixed effect model, 
subjects homozygous for the T allele compared with C allele carriers, had no significant increase in 
the risk of non-fatal MI (summary adjusted-OR= 1.01 [95%Cl: 0.74,1.38]; p=0.95). No significant 
inter-study heterogeneity was observed (PHet=0.14); Figure 4.2. When the risk of non-fatal MI 
conferred by homozygosity for the T allele was restricted to prospective genetic studies, there was 
still no significant association with non-fatal MI (OR=0.98 [95%Cl: 0.70,1.38]; p=0.93). No significant 
increase in risk was observed in the individual studies, and there was no significant interaction 
between treatment and genotype-outcome association in the two clinical trials involved in this 
analysis: for LEADER, p=0.53 and WOSCOPS, p=0.44. 
Figure 4.2 Adjusted odds ratio for non-fatal MI among subjects with the +1444TT-genotype in 
comparison with carriers of the +1444C allele. 
Study Cases Controls 
TT vs (CC+CT) 
Adjusted 
Odds ratio 
95% CI 
Odds ratio 
95% CI 
HIFMECH 491 517 1.14 [0.5s, 2.35] 
LEADER 43 1023 1.48 (0.57,3.811 
NPHSII 103 2573 ý- 0.33 [0.12,0.911 
WpsC0P5 348 1103 1.08 10.73,1.601 
Total (95% CI) 985 5216 1.01 1 0.74,1.381 
Test for heterogenety: P=0.14 
Test for overal effect: P=0.96 
01 0.2 0.5 125 10 
Decreased risk Increased risk 
'; A multivariate logistic regression model was used to adjust the OR from each study by age, total-cholesterol, 
alcohol intake, body mass index, hypertension, diabetes, and smoking. 
4.3.5 Consistency between the odds ratios estimated from the mean difference in CRP level 
and the odds ratio from the genetic study 
The estimate of the observed OR from the genetic study (1.01 [95%CI: 0.74,1.38]) was 
mathematically smaller than the expected OR (1.37 [95%Cl: 1.14,1.68] or 1.34 [95%Cl: 1.12,1.67]), 
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calculated using data from the minimally adjusted estimate or the 10-year estimate from Reykjavik 
Heart Study. It was, however, closer to estimates based on data from the maximally adjusted model 
of the large Reykjavik Heart Study (1.20 [95%Cl: 1.07,1.381) and to an estimate based on an 
updated meta-analysis of studies to 2004 (1.25 [95%Cl: 1.09,1.431; Figure 4.3). The P value for 
interaction for the comparisons of the minimum and maximally adjusted estimates from Reykjavik 
study, and from an updated meta-analysis of studies to 2004 with the observed genetic estimate is 
outlined in Figure 4.3. 
Figure 4.3 Comparison of expected and observed odds ratios for non-fatal MI for individuals 
homozygous for the CRP +1444C>T polymorphism. 
Study 
Odds ratio 
Number of CHI) cases (95% Cl) 
P-value for comparison with 
Genetic study 
Reykjavik study mir»mw acjustmerd 2459 -ý 1.37 [1.14 -1.68] 0.10 
Reykjavik study full adjustment 2459 f 1.20 (1.07-1.381 0.24 
Meta-analysis 2004 7068 f 1.25 (1.09 -1.431 0.18 
Presert genetic study 985 1.0110 74 -1.381 
0.5 0.7 1 1.5 2 
Decreased risk Increased risk 
Expected ORs were calculated assuming a log-linear association between CRP and non-fatal MI, and that a 
1.4mg/L difference in CRP corresponds to an OR for coronary events of 1.92 (95%CI: 1.68-2.18) and 1.45 
(95%Cl: 1.25-1.68) based on the minimum and fully adjusted models from Reykjavik Heart study published in 
2004 and 1.58 (95%Cl: 1.48-1.68) based on an updated meta-analysis published in 2004, (Data derived from 
references No 90 and 107 respectively). 
4.4 Discussion 
Using pooled data from 4659 individuals, I found that men homozygous for the T allele of the 
+1444C>T polymorphism of the human CRP gene had a circulating CRP concentration 0.68 mg/L 
(95%Cl: 0.31,1.10) higher than carriers of the C-allele, confirming the results of earlier smaller 
studies. [97,98] CRP genotype therefore contributes to the variation in CRP concentration observed in 
the population. 
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It was estimated that this difference in CRP of 0.68 mg/L (95%Cl: 0.31,1.10) would confer an OR for 
non-fatal MI of 1.25 (95% Cl: 1.09,1.43) or 1.20 (95% Cl: 1.07,1.38) using data from a meta-analysis 
of prospective cohort studies published in 2004, [107] and from the maximally-adjusted model of the 
Reykjavik Heart Study[1071 respectively, assuming the observational associations have been 
unbiased. However, despite possessing a genotype that would have exposed them to a long-term 
elevation in CRP concentration, for men with the TT genotype, the point estimate of the OR for non- 
fatal MI was 1.01 (95% Cl 0.74,1.38). This finding is important since, in contrast to the reported 
association between CRP and coronary events in previous studies, the association between CRP 
genotype and events should not be subject to reverse causality bias, regression dilution bias or to 
confounding by other cardiovascular risk factors related to CRP, though some doubt about a marginal 
effect of the genotype on body mass index remains to be evaluated. This is supported by the data in 
Table 4.3, which indicate that traditional cardiovascular risk factors and some inflammatory markers, 
that are known to be associated with CRP, were not associated with +1444C>T genotype. 
The estimate of risk derived from the genetic association studies of CRP reported here should not be 
biased, but it is currently much less precise than the estimates obtained from classical observational 
epidemiology. It is likely that for this reason an interaction test, which has low power, did not provide 
formal evidence for heterogeneity between genetic and non-genetic ORs at the 5% level of 
significance (Figure 4.3). 
It is clear, however, from visual inspection of the Forest plot, that the genetic risk estimate is closer to 
more recent estimates of the CRP-coronary event association reported in an updated meta-analysis 
of observational studies published in 2004, [107] and in the maximally-adjusted model of the large 
Reykjavik Heart Study cohort. [107] Thus, recent results from prospective observational studies in 
which the random error has been reduced substantially by considering more studies in a meta- 
analysis, and in which more extensive statistical adjustment has been conducted, as exemplified in 
the Reykjavik Heart Study, indicate that the association of the CRP with coronary heart disease risk 
has decreased substantially in comparison to earlier estimates. The strong potential for confounding 
in observational studies of the measured phenotype (CRP), and the utility of genotype as a proxy for 
CRP was also illustrated by a recent study [108] in which a range of covariates that exhibited strong 
correlations with CRP were distributed evenly among 3500 British women separated according to 
genotypes for a CRP/1059G>C (rs1800947) polymorphism that is in LD with the variant reported 
here. [109] 
Although a null association was identified between CRP genotype and coronary events in this study 
the width of the confidence limits is such that our observation could be compatible with a modest but 
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potentially important causal link. It is estimated that about 20,000 CHD cases and a similar number of 
controls will be required to confirm or refute an small but important causal effect, although even larger 
numbers will be needed for more detailed analyses. [1 101 However, evidence from different sources 
indicate that, if anything, the discrepancy observed between the genetic and non-genetic-ORs is likely 
to be greater. First, the observational estimate of the CRP-coronary event association [1071 on which 
I based the non-genetic OR, did not adjust for regression dilution bias and so may have been 
underestimated. On the contrary this bias is unlikely to affect the genetic esfimate. [22,231 Second, 
emerging evidence supporting the current null genetic estimate comes from three genetic studies in 
European descent individuals, with an additional 1858 cases and 1347 controls, [111,112,1131 where 
carriers of the C allele of the 1059G>C variant (in LD with the +1444/C>T variant) did not have an 
increased risk of cardiovascular events despite having a CRP concentration that was 0.3-0.6 mg/L 
higher than GG homozygous subjects. Moreover, recent data from two other genetic studies in 
European descent individuals found no association of the +1444/C>T variant with cardiovascular 
events despite a similar effect of this variant on CRP concentration. [111,1141 
An additional approach in future Mendelian randomisation studies is to genotype several SNPs at the 
CRP locus to generate all common haplotypes, and to ensure inclusion of SNPs with demonstrated 
functionality from in vitro studies in such analyses. 
In conclusion, European descent individuals men with a genotype that would have exposed them to a 
long-term elevation in CRP concentration (0.68 mg/L [95%Cl: 0.31,1.10]) were not at increased risk 
of non-fatal MI (OR: 1.01; 95% Cl: 0.74,1.38), though the confidence limits currently encompass 
substantial uncertainty. Taking this into account, it is at the very least likely that unbiased and non- 
confounded estimates of the effect of CRP on coronary events are smaller than earlier studies 
estimated, a finding that is in agreement with the latest evidence derived from prospective 
observational studies and also with more refined and carefully conducted mechanistic studies. [115] If 
our null point estimate of the genetic effect is stable with the addition of further studies, it might lead 
to the re-evaluation of CRP both as a risk marker and as a potential therapeutic target. 
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Chapter 5 C-reactive protein and cardiovascular disease: A tagging-haplotype 
approach for Mendelian randomisation 
In Chapter 4, I described the proof of principles of a Mendelian randomisation experiment in CRP 
and coronary events, using a single-variant approach. In this Chapter, I expanded the results from 
my previous Chapter in two ways. Firstly, I used a tagging-haplotype that captures most of the 
genetic variation in individuals of European ancestry, and secondly I increased the number of 
cardiovascular outcomes to be evaluated by a genetic approach. 
5.1 CRP as a therapeutic target in cardiovascular disease 
Multiple observational studies have reported consistent associations of CRP with presence or 
progression of asymptomatic atherosclerosis in coronary, carotid, peripheral vascular beds, as 
well as with the development of incident diabetes and stroke. [115] Although these observations 
support the view that inflammation plays a critical role in atherogenesis and in the development of 
some cardiovascular disorders (e. g. diabetes), it is uncertain whether CRP (an inflammatory 
biomarker) itself is causally linked with the progression of atherosclerosis or with cardiovascular 
events. [115] If CRP is causally involved in cardiovascular disease, it would legitimise to CRP as a 
valid therapeutic target. Indeed, interventions that specifically modify CRP are being developed 
for clinical testing. [116] 
However associations of CRP with indices of atherosclerosis, diabetes, and stroke could equally 
be explained by confounding or reverse causation as described in Chapter 4. In addition, 
controlling of confounding through statistical models requires a judgement about the causal 
pathway. For example, if high blood pressure or diabetes were to mediate rather than confound 
the CRP-cardiovascular event association, as some studies suggest [117,118], adjustment for 
these factors would underestimate the true causal association. Likewise, many emerging 
biomarkers (e. g. fibrinogen, interleukin-6, vonWillebrand Factor, E-selectin, ICAM-1 and VCAM) 
exhibit associations both with CRP and with risk of cardiovascular disease, but it remains unclear 
whether they lie on the CRP causal pathway. [115] Although some experimental studies and 
animal models have suggested CRP as a pro-inflammatory and pro-thrombotic molecule (that 
may explain the association with those biomarkers), these studies are also affected by important 
sources of bias that limit their findings. [115] All these make it difficult to assess the independent 
effect of CRP in observational studies. 
An alternative approach to confirm (or refute) the causal effect of CRP on (i) other emerging risk 
factors, (ii) surrogate end-points and (iii) cardiovascular events is to identify common genetic 
variants in the CRP gene that are reliably associated with differences in concentrations of CRP, 
its cognate protein . [68,1191 If the purported effects of plasma CRP on emerging risk factors, end- 
points or clinical events are real, a tagging-SNP approach within the CRP gene that captures 
most of genetic variation with in the CRP gene should exhibit an effect on those different 
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outcomes in a manner proportional to its effect on the levels CRP. This genetic strategy (or 
Mendelian randomisation), minimises confounding, and abolishes reverse causation due to the 
particular properties of genetic variants described in Chapter 1. [120] 
In Chapter 4, I described the proof of principle of how to conduct a Mendelian randomisation 
experiment for CRP by using a single CRP gene-variant (rsl 130864). Since then multiple genetic 
studies have shown that a range of different CRP-genetic variants are all associated with CRP 
concentrations, [68] but their effects on surrogate end-point and cardiovascular disorders have 
been conflicting . 
[108.119,121,122,123,1241 Recently, the Cardiovascular Health Study reported 
on consistent associations of tagging (t) single nucleotide polymorphisms (SNPs) in the CRP 
gene with CRP level in both European descent and African-American individuals. Associations of 
some but not all CRP genotypes were seen with an increase in risk of cardiovascular mortality, 
but not with index of sub-clinical atherosclerosis (carotid intima media thickness). Interestingly, no 
CRP genotypes was associated with non-fatal myocardial infarction or with stroke. [125] The 
results were interpreted as indicating a possible causal role of CRP in fatal but not non-fatal 
cardiovascular events through a process that does not involve enhancement of atherosclerosis. 
Although the associations of genotype with CRP concentration in the Cardiovascular Health study 
appear robustly consistent with other studies, there is the possibility that with the relatively small 
number of clinical events, and the multiple comparisons made, by ethnic group, by genotype and 
by clinical end-point that associations with fatal disease outcome arose by chance. These 
associations therefore require replication, particularly because several prior studies did not 
observe associations of CRP genotypes with cardiovascular risk factors such as hypertension 
(see Table 4.3, Chapter 4), diabetes or cardiovascular events despite their consistent association 
with CRP level. [108,119,121,122,123,124] 
Using data from two population-based studies of European descent individuals in the UK, the 
Edinburgh Artery study and Northwick Park Heart Study-2, I evaluated the effect of the CRP 
tagging SNPs on established and emerging cardiovascular risk factors, index of the progression 
of atherosclerosis in the lower extremity (ankle brachial pressure index) and incident 
cardiovascular events. Conducting the analyses in two independent data sets allowed me to 
check the consistency of the associations evaluated. 
5.2 Methods 
5.2.1 Study design 
5.2.1.1 NPHS-2 
This study was previously described in Chapter 4. NPHS-2 is a prospective study of 3,012 healthy 
men of European descent (age range at recruitment 50 to 64 years), with enrolment commencing 
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in 1989. [99] Nine general practices participated in the study. The study was approved by the local 
institutional review committee and all subjects provided written informed consent. None of the 
participants had a clinical history of unstable angina, myocardial infarction (MI; including silent 
infarction), coronary surgery, other cardiovascular diseases, aspirin or anticoagulant use, or 
malignant disease (except skin cancer other than melanoma) at the time of recruitment. 
Demographic information was obtained at baseline by means of a structured questionnaire. 
Patients still alive were recalled annually for measurement of blood pressure and certain other 
circulating factors as reported previously. The cardiovascular endpoints examined were fatal CHD 
events, non-fatal MI (based on World Health Organisation criteria), coronary artery surgery, and 
silent MI on follow-up ECG (Minnesota criteria), and these are referred to collectively as CHD 
events. Cerebrovascular events (fatal and non-fatal) were defined using the ICD9 codes 430.0, 
431.0,434.9, and 436.0. Incident diabetes was defined by practice note search for physician 
diagnosed and treated Type 2 diabetes mellitus according to current national guidelines. 
5.2.1.2 Edinburgh Artery Study 
The Edinburgh Artery Study (EAS) is a prospective study of 1592 European descent individuals 
(809 men and 783 women) aged 55 to 74 years enrolled in 1988. Individuals recruited were 
randomly selected from 11 general practices serving a range of socioeconomic and geographic 
areas throughout the city of Edinburgh. Details of the study recruitment, and examination process 
have been described elsewhere. [1261 Ethics committee approval was given for this study, and 
informed consent was obtained from each subject. Participants completed a self-administered 
questionnaire at baseline and at 5 and 12 years of follow-up that included demographical and 
lifestyle variables, the WHO angina and intermittent claudication questionnaires. Individuals were 
also invited for a clinical examination at baseline and at 5 and 12 years after enrolment. Ankle 
systolic pressures were measured first in the right leg and then in the left leg at the posterior tibial 
artery using standard methods previously described. [1261 Ankle-brachial index (ABI) was 
calculated by dividing the ankle systolic pressure by the brachial systolic pressure. The lower of 
the two indices was used in the analysis as indicative of worse disease. Reproducibility of the ABI 
and its quality control measures have been described previously. [126] Throughout the follow-up, 
fatal and non-fatal cardiovascular events were recorded and defined with criteria adapted from the 
American Heart Association. Subjects who developed major CHD during the follow up years were 
those who had experienced an event of fatal/ non-fatal MI or who had a coronary artery bypass or 
coronary angioplasty. Cerebrovascular events (includes fatal and non-fatal events) were defined 
according to that used by the American Heart Association. To identify all deaths occurring in the 
cohort, each participant's record was flagged at the UK National Health Service Central Registry. 
If a post-mortem examination was not performed, causes of death were verified by consulting 
hospital or general practitioner records. Diabetes at baseline was defined using recall of doctors' 
diagnosis and WHO 1999 criteria (fasting glucose >7 mmol/L or 2-h glucose >11.1 mmol/L) 
applied to data collected during the oral glucose tolerance test. At baseline, 277 subjects had a 
history of Ml, stroke, angina or intermittent claudication and were excluded from further analysis. 
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5.2.2 Measurement of CRP concentrations 
In NPHS-2, CRP was measured using commercial high-sensitivity assays (R&D Systems or 
Kordia Life Sciences). Inter-assay and intra-assay coefficients of variation were <6.2% and <1.9% 
respectively, with a detection limit of 0.1 mg/L. Of 2,738 men with CRP measures, 1,541 were 
from samples obtained at baseline, 724 from samples obtained at year 1,341 at year 2,100 at 
year 3,27 at year 4, and 5 at year 5. Descriptions of the measurement of other biomarkers have 
been reported previously. [99] Baseline CRP in Edinburgh Artery Study was measured 
immunologically using a high-sensitive assay (BN ProSpec nephelometer [Dade Behring]). Intra- 
assay and inter-assay variability coefficient were 4.7% and 8.3% respectively. Technical details 
and quality control for other biomarkers included have been described elsewhere. [126] 
5.2.3 Genotyping of single nucleotide polymorphisms in the CRP gene 
Polymorphisms in the human CRP gene (OMIM: C-reactive protein, pentraxin related; 1q21-q23) 
were identified by reference to public-domain databases of human sequence variation. This 
information was combined with previous polymorphism screen of the CRP gene conducted at the 
Centre for Clinical Pharmacology in UCL by Dr Tina Shah, to generate a consensus map of 
polymorphic sites (Figure 5.1). 
Figure 5.1 Summary map of all reported SNPs in the CRP gene. Figure adapted from Figure 2 
manuscript of CRP CHD Genetics collaboration. Eur J Epidemiol 2008; 23: 531-40. Authors/Writing 
committee: J Danesh, A Hingorani, F Wensley, JP Casas, L Smeeth. 
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Using validated genotype data (minor allele frequency > 5%) from individuals of European 
descent from the NHLBI PGA database (http: //pga. mbt. washington. edu/), and the human 
HapMap database (http: //www. hapmap. orgi), and based on the pattern of linkage disequilibrium 
across the CRP gene, Dr Tina Shah (Centre for Clinical Pharmacology, Department of Medicine, 
UCL) selected a set of tSNPs capable of capturing maximum haplotype diversity among 
individuals of European descent using the programme Tag IT 
(http: //popqen. biol. ucl. ac. uk/software. htmi Figure 5.2. 
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In NPHS-2, DNA was extracted for 2,775 men, and genotyping data was available from 2,676. 
Genotyping for db SNP rs1130864 (+1444C>T) was by PCR and RFLP as described in Chapter 
4, but genotyping was repeated in 200 subjects using a 5'nuclease assay (Taqman) with an inter- 
assay agreement rate of >_99%. The dbSNP rs1205 (+2302G>A) and dbSNP rs3093077 
(+4899T>G) were also determined by a 5'-nuclease assay (TaqMan). Primers and probe sets 
were designed and manufactured using Applied Biosystems `Assay-by-Design' custom service. In 
Edinburgh Artery Study, DNA was extracted for 913 individuals, and genotyping data was 
available from 908 subjects for three CRP tSNPs (three tagging). 
Genotyping for db SNP rs1130864 (+1444C>T), dbSNP rs1205 (+2302G>A) and dbSNP 
rs3093077 (+4899T>G) was determined by a 5'-nuclease assay (TaqMan). Genotyping for both 
studies was conducted at the Dept. Medicine at UCL by Dr Tina Shah (for NPHS-2) and members 
of Dr Helen Ireland's group (for EAS). In both studies, positive and negative control samples were 
included on each assay plate for quality control, and cases and controls were distributed over all 
study plates, minimising the risk of differential mistyping by case control status. Genotyping was 
conducted in a blind fashion to the case-control status. 
5.2.4 Statistical analysis 
Data were analyzed with the use of the SPSS version 12.0 software package for EAS study (by 
Dr lonna Tsoulaki) and Stata 9.0 in NPHS-2 study (by Ms Jackie Cooper) following a pre- 
specified analysis plan I developed. Log-transformations using the natural log-scale were 
conducted for data not normally distributed and for these variables means are geometric and 
standard deviations approximate. Throughout all analyses, a two-sided probability value <0.05 
was taken to denote statistical significance. I then pooled the results from EAS and NPHS-2 by 
random effect models, using the inverse variance method. [106] 
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Figure 5.2 Identification of (t)SNPs that capture haplotype diversity at the CRP locus among 
individuals of European ancestry. Panel (a): Ten common SNPs with minor allele frequency 
greater than 5% lie on 4 major haplotypes. Panel (b): Strong LD between markers of the same 
colour allows typing of a single marker from each group without loss of information on variation. 
Panel (c): typing of 3 markers (+1444, +2302 and +4899) allows reconstruction of the four 
common haplotypes. Figure adapted from Figure 3 manuscript of CRP CHD Genetics 
collaboration. Eur J Epidemiol 2008; 23: 531-40. Authors/Writing committee: J Danesh, A 
Hingorani, F Wensley, JP Casas, L Smeeth. 
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5.2.4.1 CRP, cardio-metabolic traits, sub-clinical atherosclerosis and cardiovascular 
events 
Associations between plasma CRP concentrations and incident cardiovascular outcomes 
(hypertension diabetes, CHD and stroke) were assessed using Cox proportional hazards 
regression. Hazard ratios and 95%Cl were obtained for the top versus the bottom tertile of the 
CRP distribution. A progressive adjustment for potential confounders were conducted as follows: 
for CHD and stroke the model-1 includes age, gender and practice (for NPHS-2 only); model-2: 
previous model plus smoking, diabetes, body mass index, systolic blood pressure, LDL- 
cholesterol, HDL-cholesterol and physical activity (for EAS only). Model-3 includes previous 
variables plus fibrinogen. 
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Statistical models conducted to explore the CRP effect on diabetes were: model-1 that includes 
age and gender and practice (only for NPHS-2); model-2: previous model-1 plus body mass 
index, triglycerides and physical activity (only for EAS). Model-3 includes previous model-2 plus 
fibrinogen. 
When evaluating associations of plasma CRP levels with cardiovascular risk factors, the 
biomarker/complex trait (in a standardised scale) was regressed (using normal error regression) 
on the CRP tertile, while for categorical variables (which were converted into binary outcomes) a 
logistic regression model was used. In both regression models the effect of CRP tertile was 
estimated as a linear trend. Beta-coefficients represent the number of standard deviations 
increase in the continuous variable for a unit increase in CRP tertile, while for categorical 
variables; they represent the odds ratio for a unit increase in the CRP tertile. 
5.2.4.2 CRP haplotype cardio-metabolic traits, sub-clinical atherosclerosis and 
cardiovascular events 
Only haplotype analyses are included in the present report. All other analyses using individual 
SNPs of the CRP gene were also generated but not reported here. For each genetic variant, 
deviation of genotype frequencies from Hardy-Weinberg equilibrium was assessed using chi- 
squared tests. Inference of haplotype (using db SNPs: rs1130864, rsl 205 and rs3093077) were 
performed using a maximum likelihood model based on the stochastic-EM algorithm implemented 
in the THESIAS program (http: //www. genecanvass. orq). THESIAS allows the simultaneous 
estimation of haplotype frequencies and of their associated effects on the phenotype of interest. 
Haplotypes with frequency of less than 5% were excluded. 
In order to evaluate the effect of the CRP haplotypes on CRP levels, and on other cardiovascular 
risk factors, for continuous variables, the standardised biomarker/complex trait was regressed on 
the CRP-haplotype, while for categorical variables a logistic regression model was used. As for 
the plasma CRP analyses, for the CRP gene a linear effect was assumed. Beta-coefficients 
represent the number of standard deviations increase in the outcome/biomarker for a unit 
increase in haplotype, while for categorical variables they represent the odds ratio for a unit 
increase in haplotype. 
Hazard ratios and 95%Cl, adjusted for age, gender and practice (for NPHS-2 only) were obtained 
to measure the strength of the association between the CRP-haplotypes with incident 
cardiovascular outcomes: CHD, stroke and diabetes. For the haplotype trend the effect 
represents the change from two copies of one haplotype to two copies of the next. For all genetic 
analyses, the CRP-haplotype associated with lowest CRP value (direct intermediate phenotype) 
was considered the reference group. 
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5.3 Results 
5.3.1 Plasma CRP, cardiovascular events and cardiovascular traits 
As reported in many previous prospective studies, higher CRP concentrations were associated 
with an increased risk of CHD events in both studies (403 CHD events: 178 in EAS and 225 in 
NPHS-2). A pooled HR of 2.08 (95%Cl: 1.63,2.67) for individuals in the top tertile of CRP 
distribution compared to the bottom tertile was observed for the statistical model with less 
adjustment (model-1). Similarly, high baseline CRP levels were associated with a hazard ratio of 
2.21 (95%Cl: 1.47,3.33) for stroke (172 stroke events: 124 in EAS and 48 in NPHS-11) and 2.46 
(95%Cl: 1.68,3.60) for type-2 diabetes mellitus (model-1 in Figure 5.3). However, for all three 
cardiovascular events, an important reduction in the magnitude of the effect was observed as the 
statistical models included additional potential confounders. For CHD the hazard ratio for the top 
tertile was reduced by a 70% from 2.08 (95%Cl: 1.63,2.67) to 1.32 (95%Cl: 0.98,1.76); for stroke 
by 36 percent from 2.21 (95%Cl: 1.47,3.33) to 1.77 (95%Cl: 1.12,2.81) and for diabetes by 35 
percent from 1.99 (95%Cl: 1.68,3.60) to 1.64 (95%Cl: 1.07,2.51) (model-3 in Figure 5.3). A 
positive association of CRP was also observed for ABI. Individuals in the top tertile of the CRP 
distribution had on average lower values of ABI at baseline (-0.06 [95%Cl: -0.08, -0.031) and were 
also associated with a decrease in ABI after 12 years of follow up of -0.05 (95%Cl: -0.07, -0.02). 
This indicates a faster progression of sub-clinical atherosclerosis in subjects with high values of 
CRP. 
However, high levels of CRP were also associated with several established risk factors (Figure 
5.5). Individuals with higher CRP concentrations had higher than average values of blood 
pressure, proatherogenic lipid fractions, body mass index, fasting glucose, and higher prevalence 
of smoking. CRP was also inversely associated with HDL-cholesterol, apolipoprotein-Al, and 
lower levels of physical activity. In addition a substantial number of emerging biomarkers which 
have also been associated with high risk of CHD, were also associated with CRP levels such as: 
fibrinogen, interleukin-6, Lp-PLA2, triglycerides, D-dimer, E-selectin, ICAM-1, vonWilebrand 
factor, tissue plasminogen activator, and Factor VII (Figure 5.5). However, these emerging 
biomarkers (with the exception of fibrinogen) were not included in any of the statistical models 
that evaluate an independent effect of CRP on cardiovascular events, due to the uncertainty of 
whether these biomarkers are real confounders or by contrast actually lie on the causal pathway 
of CRP and cardiovascular events. If they lay on the causal pathway, adjustment for these risk 
factors will partially or totally remove the causal effect of CRP. This illustrates the great potential 
for residual confounding, and difficulties in statistical adjustment to evaluate the independent 
effect of CRP in the multiple cardiovascular outcomes associated. 
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Figure 5.3 Hazard ratios of CHD (upper panel), stroke (middle panel) and diabetes mellitus (lower 
panel) for concentrations of CRP according to different statistical models. 
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5.3.2 CRP haplotype and CRP levels 
In subjects of European descent, several combinations of three tagging SNPs were equally 
capable of capturing the 4 most common CRP haplotypes, accounting for 94 percent of all 
chromosomes (Figure 5.2). Of these SNPs, the combination rs1130864, rs1205 and rs3093077 
were typed in EAS and NPHS-2. Genotype frequencies conformed to Hardy-Weinberg equilibrium 
for all SNPs. The four most common haplotypes inferred from the 3 tSNPs (C1444T / G2302A / 
T4899G: CAT; CGT; TGT and CGG) were concordant with those generated from typing 9 SNPs 
with minor allele frequency >5% in the NHLBI PGA Seattle SNPs resource. Haplotype 
frequencies in the EAS were: CAT: 0.33, CGT: 0.31, TGT: 0.29 and CGG: 0.07 from a total of 908 
individuals, while for the NPHS-2 the frequencies were CAT: 0.33, CGT: 0.31, TGT: 0.30 and 
CGG: 0.05 from a total of 2161 individuals. 
A substantial difference in the CRP levels according to the four CRP-tagging-haplotypes inferred 
from the individuals SNPs was observed (Figure 5.4). Using the CAT haplotype as the reference 
group a gradual increase in the CRP levels was observed with relative differences in CRP levels 
of 9.4%, 25.8% and 41.9% for the CGT, TGT and CGG haplotypes respectively. Differences in 
haplotypes are per 2-copies of each CRP haplotype (see section (i) of Figure 5.4. ). Differences in 
the standard deviation of log-CRP levels per 2-copies of each haplotype are also described in 
Figure 5.4. 
5.3.3 CRP haplotype, cardio-metabolic traits and progression of atherosclerosis 
While plasma CRP itself was strongly associated with a range of established risk factors and 
biomarkers for CHID, including some biomarkers, such as 1L6 or fibrinogen that were strongly 
associated with plasma levels of CRP, none of the inferred haplotypes, exhibited an association 
with any of these cardiovascular traits (section (ii) of Figure 5.5). No effect of the CRP haplotypes 
on the progression of atherosclerosis (indicated by the ABI) was observed (section (ii), Figure 5.5) 
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Figure 5.4. Effect of the CRP-haplotypes on CRP levels. i) Weighted mean difference, and ii) 
Standardised mean difference. Haplotype CAT is used as reference group. 
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5.3.4 CRP haplotype and cardiovascular events 
Though CRP tagging-haplotypes exhibited a clear association with CRP concentration of up to a 
41.9% relative difference for the extreme haplotype (CGG vs. CAT-reference), no increase in risk 
of CHD was observed for each haplotype and neither for a trend-effect for CRP-haplotype, HR of 
0.95 (95%Cl: 0.84,1.07) (Figure 5.6). A similar scenario was observed for stroke (HR of 1.00 
[95%Cl: 0.85,1.17]) and type-2 diabetes mellitus (HR of 0.99 [95%Cl: 0.86,1.14]), see Figure 
5.6. 
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Figure 5.5 Standardised mean difference on cardiovascular traits according to concentrations of 
CRP (per-tertile increase) and by CRP haplotype (per-haplotype increase). 
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5.4 Discussion 
Using data from two population-based cohorts, a CRP tagging-haplotype approach was not able 
to detect an increase in the risk of cardiovascular events for which consistent associations for 
plasma CRP have been reported. However, a substantial and clear effect of the CRP tagging 
haplotypes on CRP concentration was observed. No associations were observed between CRP 
tagging-haplotypes and progression of the ABI (surrogate end-point of peripheral and generalized 
atherosclerosis) or with any of the multiple emerging biomarkers that were associated with 
plasma CRP. 
84 
Figure 5.6 Hazard ratio of cardiovascular event according to the C-reactive protein tag- 
haplotypes. a) CHD; b) Stroke; c) Type-2 Diabetes Mellitus; and d) Trend-effect for CRP- 
haploytpe for the CHD, stroke and diabetes. 
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Since a genetic strategy, using tagging SNP approach that covers most of the genetic variation of 
the CRP locus, and the usual observational approach are prone to different sources of bias, the 
overall lack of consistency of these two strategies, across all the cardiovascular outcomes, 
between the genetic and the observational approach might at this stage indicate: i) that the 
plasma CRP effects observed in observational studies is perhaps an overestimation due to the 
presence of multiple biases (residual confounding and reverse causation), or ii) that association of 
plasma CRP reflect a true causal association, but that a gene-based approach, which overcomes 
some biases, is still largely underpowered to detect a small but important causal effect of CRP in 
cardiovascular disorders, if considering that such an effect will be concordant with the effect of the 
CRP gene on the plasma CRP. 
85 
The lack of consistency between a genetic approach and the usual observational strategy was 
also observed for progression of the ankle-brachial index, as well as for all the emerging 
biomarkers, cardiovascular traits or behaviours with which plasma CRP has been consistently 
associated (Figure 5.5). The only exception to this was the presence of a clear effect of the CRP 
tagging-haplotypes on its cognate protein (Figure 5.4). This provides empirical evidence for the 
theoretical principle of Mendelian randomisation, of random allocation of genetic variants and 
therefore independence from the effect of any other characteristic. [22,23] The discrepancy 
between the effect of plasma CRP and CRP tagging-haplotypes (on the association with 
emerging biomarkers, suggests that perhaps those biomarkers (e. g. fibrinogen, IL-6, ICAM-1) 
exhibit an association with CRP because of a common link, rather than a causal effect of CRP on 
these markers. An important interpretation is that these biomarkers will be confounding the 
directly observed CRP-cardiovascular event association rather than explaining it. Further details 
of the use of genetic-variants to disentangle networks among blood proteins are described in 
Chapter 7. 
Results from the current Chapter, should also be interpreted in the context of the available 
evidence from the literature on genetic association studies on the CRP gene. The three CRP tag- 
SNPs used here have been consistently and robustly associated with differences in the CRP 
levels as indicated by a recent systematic review of genetic studies evaluating the effect of any 
CRP genetic variant on the CRP concentrations. A per-allele effect on CRP concentrations that 
ranged from -0.35 mg/L for the rs1205 variant up to 0.48 mg/L for the rs4899 variant (Figure 
5.7). [68] 
Despite the consistent association of CRP-gene variants with CRP level, genetic studies that 
have investigated the effect on cardiovascular outcomes have often observed a null effect on 
indices of atherosclerosis (carotid intima media thickness), [121 ] CHID [122,123] and 
cardiovascular disorders such as type-2 diabetes mellitus, 11241 high blood pressure, [108] or 
clustering of cardiovascular risk factors, [1191 known as metabolic syndrome for which a positive 
association of plasma CRP have been reported. [1271 
In conclusion, men of European ancestry with CGG haplotype of the CRP gene that exposed 
them to a 42% higher level of CRP compared with individuals with CAT haplotype, did not exhibit 
(i) an increased risk of any cardiovascular event (CHD, stroke or diabetes), or (ii) a difference in 
the progression of atherosclerosis (index by changes in the ABI) or (iii) a difference in the levels of 
other biomarkers. These are in clear contrast to what is observed for CRP itself. 
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Figure 5.7 Summary effects of eight CRP genetic-variants on CRP concentrations derived from 
published studies in European descent individuals. Highlighted in grey the 3 tag-SNPs used in 
NPHS-2 and EAS. Figure adapted from Figure 4 manuscript of Verzilli C, Shah T, Casas JP et al. 
Am J Hum Genet 2008; 82: 859-72. 
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Results from Chapter and Chapter 4, together with the available evidence indicates a clear effect 
of CRP variants on CRP levels but not on cardiovascular events, [122,123] suggesting that the 
plasma CRP-cardiovascular event association is due to residual confounding and or reverse 
causation, which are unavoidable limitations of observational studies. Nonetheless, before 
refuting a small but important causal effect of CRP on cardiovascular diseases, larger Mendelian 
randomisation experiments are needed before CRP is removed from the list of potential 
therapeutic targets for CHD prevention. The undergoing effort of the CCGC collaboration, which 
will include over 30,000 CHD events and 110,000 controls, using individual patient data will 
provide a unique opportunity to judge a possible causal role of CRP in CHD. [110] 
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Chapter 6 Lp-PLA2 and CHD 
In Chapters 2 to 5, I utilised the Mendelian randomisation approach to investigate a potential 
causal role of biomarkers (Hey and CRP) in cardiovascular disease (Stroke and CHD). In this 
Chapter, I describe an extension of the Mendelian randomisation paradigm, that capitalise on 
genetic studies being a type of natural randomised trial, which could help to increase or reduce 
confidence in therapeutic targets under evaluation. 
6.1 Lp-PLA2 as an emerging risk factor for CHD 
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor 
acetylhydrolase, is a member of a family of intracellular and secretory phospholipase enzymes 
that hydrolyze the sn-2 ester bond of phospholipids of cell membranes and lipoproteins to 
generate lysophospholipids and fatty acids. [128] Lp-PLA2 is mainly produced in macrophages 
and activated platelets, and when released into circulation it is transported mainly on LDL- 
cholesterol particles with a smaller proportion on HDL-cholesterol. [128] It has been suggested 
that Lp-PLA2 could exert either pro-atherogenic effects because the products 
(lysophosphatidyicholine and oxidized fatty acids) it releases from the hydrolysis of oxidized LDL 
are thought to have a deleterious effect on the artery wall, or protective anti-atherogenic if, in 
hydrolyzing platelet-activating factor, it reduces inflammation and the thrombotic tendency of the 
blood. [1281 
6.2 Lp-PLA2 levels and risk of CHD: evidence from observational studies 
Evidence from several prospective cohort studies (including studies from the general population 
and from individuals with established CHD) have reported a consistent association of Lp-PLA2 
levels (either mass or activity) with an increase in the risk of CHD. Results from 14 prospective 
studies published by September 2006 were synthesised in a literature-based meta-analysis that 
showed an increase in risk of 1.21 (95%CI: 1.11,1.32) for a1 standard deviation increase in the 
Lp-PLA2 mass or activity, with a similar magnitude of effect observed among studies including 
mainly healthy individuals compared with studies of subjects with evidence of established 
CHD. [129] In addition, the strength of the Lp-PLA2-CHD association was of a similar size for 
studies measuring mass, compared with those measuring activity, of the Lp-PLA2 enzyme. [129] 
Nonetheless, and as described previously for the CRP and Hcy, (see Chapters 2 and 4) the 
increase in risk of CHD associated with high levels of Lp-PLA2 reported in prospective cohorts 
could be entirely or largely explained by the multiple associations of Lp-PLA2 levels with other 
established as well as emerging risk factors for CHD, a phenomenon known as confounding 
(described in section 1.2 Chapter 1). Concentrations of Lp-PLA2 activity or mass have been 
associated with several established as well as emerging risk factors for CHID. Individuals with 
higher levels of Lp-PLA2 tend to be older, to have higher levels of total-cholesterol, LDL 
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cholesterol, triglycerides, apolipoprotein-B, blood pressure, body mass index, interleukin-6, CRP 
and fibrinogen. Likewise, individuals with higher than average levels of Lp-PLA2 exhibit lower 
levels of protective risk factors such as HDL-cholesterol and alcohol consumption. [130] These 
multiple associations of Lp-PLA2 means that despite statistical adjustments conducted by 
individual studies, residual confounding could still explain some or all of the observed association 
with CHD. In consequence, despite the encouraging evidence from observational studies, it is not 
sufficient to establish an unequivocally causal role of Lp-PLA2 in CHD. 
6.3 Randomised evidence to elucidate the causal role of Lp-PLA2 on CHD 
An approach that eliminates bias present in observational studies and therefore provides the 
strongest evidence on a causal role of Lp-PLA2, is to randomly allocate individuals to 
interventions that modify Lp-PLA2 activity in a selective manner. One possibility is to conduct a 
randomised clinical trial of a selective intervention such as the new drug "darapladib", a selective 
Lp-PLA2 inhibitor (formerly SB-480848). [131,132] 
Recently two small, mechanistic, placebo-controlled randomised trials of darapladib were 
conducted providing the first indication of the effects of inhibiting the Lp-PLA2 enzyme. [131,132] 
The first trial, a dose-finding trial including 964 individuals treated for 81 days, provided 
suggestive evidence of a dose-dependent reduction of Lp-PLA2 activity of 43%, 55%, and 66% 
for darapladib doses of 40,80 and 160 mg daily respectively. No clear effect on lipid particles 
(LDL, HDL or triglycerides) was observed, indicating the lipid-independent or specificity of the 
intervention. [131] In the same trial, inhibition of Lp-PLA2 with darapladib had no effect on several 
biomarkers (P-selectin, CD40 ligand, urinary 11-dehydrothromboxane 62) measured as proxies of 
platelet activation. The second trial (330 individuals with 12 months follow up) evaluated the effect 
of 160 mg daily of darapladib on human atherosclerotic plaque measured using intravascular 
coronary ultrasound. There was no effect on the plaque deformability, the primary outcome, or on 
the total atheroma volume, even though the drug decreased the Lp-PLA2 activity by 59%. 
However, the intervention decreased the necrotic core volume of the plaque, a secondary 
outcome, by -5.2 mm (p=0.012) compared to the placebo group. [132] 
The efficacy profile of the Lp-PLA2 inhibitor has been sufficient to encourage further large and 
long term randomised trials evaluating hard clinical end-points. However, it seems reasonable to 
increase the confidence in the validity (efficacy and safety) of the drug target before proceeding 
into such costly trials and therefore minimize the risk of exposing individuals to an intervention 
with harmful effects. This is of great importance, considering the recent series of unexpected 
harmful effects of several new agents in recent phase-III trials in CVD, such as the case of the 
CETP-inhibitor torcetrabip and the dual- proliferator-activated receptors agonist 
muraglitazar. [1 33,134] 
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An approach that could help to increase or reduce the confidence in Lp-PLA2 as a valid drug 
target sufficient to inform on the decision to pursue or abandon LpPLA2 as a target that does not 
require the exposure of individuals to a drug, would be to investigate the effect on cardiovascular 
traits and CHD risk of randomly allocated variants within the Lp-PLA2 gene (known as PLA2G7) 
that modify levels of its cognate protein (Lp-PLA2) measured by activity or mass. This would 
generate a "tike-with-like" comparison between the drug (darapladib: LP-PLA2 inhibitor) and the 
gene (PLA2G7: gene product Lp-PLA2). In both trials and genetic studies there is a random 
allocation procedure involved, in the case of the drug by trial randomisation procedures and in the 
case of the allelic-variant the natural randomisation resulting from Mendel's 2nd law, see Figure 
6.1. 
This extension of the Mendelian randomisation paradigm is complementary to that previously 
described in Chapters 2 to 5, in which Mendelian randomisation was used to provide unbiased 
evidence of causation of emerging biomarkers on cardiovascular disease. This new use of 
Mendelian randomisation capitalizes on genetic studies being a type of natural randomised trial 
(Figure 6.1). [1201 
As genetic effects are smaller than the effects of potent drugs, the establishment of a robust 
natural randomised trial requires the investigation of several thousands of cases as well as 
individuals with a wide range of phenotypic data. 
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Figure 6.1. Parallel between randomised clinical trials and genetic studies addressing the same 
molecule target (e. g. Lp-PLA2 enzyme). 
Drug Intervention 
Randomised clinical trial 
Sample 
Genetics 
Natural randomisation 
Drug Randomisation 
17 
Population 
PLA2G7 Genotype Randomisation 
Darapladib Placebo Genotype as Genotype AA 
Lp-PLA2 activity Lp-PLA2 activity Lp-PLA2 Lp-PLA2 activity 
Lower unchanged activity Lower unchanged 
CV event CV event CV event CV event 
rate lower rate higher rate lower rate higher 
6.4 Genetic evidence on the regulation of Lp-PLA2 activity 
Lp-PLA2 activity is a highly heritable trait, with up to 62% of the plasma variation attributed to 
heritable factors. [1351 It is almost certainly likely that this degree of heritability is accounted for by 
several genes acting together to regulate the Lp-PLA2 activity, as well as by shared, non-genetic 
familial factors (e. g. shared environment). However, of all the genes that influence LpPLA2 
activity, it is cis-variants in the PLA2G7 gene itself that encodes Lp-PLA2 (from now on referred to 
as a pQTG: protein quantitative trait gene) that provides the most specific instrument with which 
to model the pharmacological effect of LP-PLA2 inhibition by darapladib. The use of SNPs from 
other genes would lack specificity and therefore their findings would not be of help in assessing 
Lp-PLA2 as a drug-target (For more details see Chapter 7). The PLA2G7 gene is organized into 
12 exons spanning at least 45 kb of DNA sequence, and is located on chromosome 6p21.2-p12. 
The search for variants within the PLA2G7 gene that determine differences in the Lp-PLA2 mass 
or activity has been complex and slow. In 1996, Stafforini D, et al. showed that a point mutation 
in exon 9, aG -* T substitution, resulting in a Val -> Phe transversion at position 279 of the 
mature protein (V279F) was responsible for the inherited deficiency in Lp-PLA2 activity present 
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in around 4% of the Japanese population. [136] More recently this mutation has also been 
reported in other populations (e. g. Turkish, Azerbaijan) but is almost absent in European descent 
populations. [128] Earlier attempts to evaluate genetic variants within PLA2G7 in European 
populations have often focused on single variants. Of these, one of the most widely studied has 
been the genetic rs1051931 known as Val379AIa located at exon 11. In some previous reports 
this SNP was associated with differences in the Lp-PLA2 activity, but with contradictory reports of 
its effects on CHD risk. However, individual studies have been underpowered to detect plausible 
genotypic effects. [137,138] Therefore, a thorough SNP selection process joined with large sample 
sizes is desirable in order to investigate Lp-PLA2 as a drug target. 
6.5 Rationale for the establishment of the prospective Lp-PLA2 genetics collaboration 
In order to overcome the previous limitations, a group of investigators led by Prof. Philippa 
Talmud at the Centre for Cardiovascular Genetics at UCL, joined efforts to establish a prospective 
group of 11 genetic studies compromising 20,898 individuals of European ancestry including up to 
8412 CHD cases, with the aim of utilising a genetic approach to evaluate the validity of the Lp- 
PLA2 as drug-target. As a first step, members of Prof Talmud's group, conscious of the genetic 
architecture (LD) of the PLA2G7 gene, have identified the 12 common tagging-SNPs across the 
PLA2G7 gene (r2 >_ 0.8 and MAF >_ 0.04). (Figure 6.2) These 12 SNPs were evaluated in the 
NPHS-2 study to determine their effects on Lp-PLA2 activity levels in order to identify the most 
appropriate genetic tools to be evaluated in a large scale collaboration with cardiovascular events 
as an outcome and in addition to evaluate the effect of the gene variants on continuous traits 
relevant to CHD risk. A second source of SNPs selection was derived from a comprehensive 
screening on the PLA2G7 gene, aimed to select tagging SNP (r2? 0.7 and MAF >_ 0.05) in both 
European descent and African-American populations living in the United Stated. [139] 
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Figure 6.2. Genetic architecture of the PLA2G7 gene in subjects of European ancestry 
participating in NPHS-2 study. Displayed the 12 tagging SNPs (placed according to their genetic 
location) from PLA2G7 gene typed in NPHS-2. Depicted is the LD plot visualised using the 
program Haploview. R2 values among the tSNPs are displayed in the cells. Highlighted by a 
rectangle are the five tSNPs selected from NPHS-2 and typed in the genetic collaboration. In 
addition, two tSNPs rs1805018 and rs9381475 were selected from the publication by Sutton et 
aI. [139] 
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6.6 Methods 
6.6.1 Study population 
After obtaining ethical approval from respective studies, genotyping for the PLA2G7 
polymorphisms and measurement of the Lp-PLA2 activity were conducted in samples obtained 
from a number of cross-sectional, case-only, case-control, or prospective studies summarised in 
Table 6.1. 
From a total of 3012 participants from the Second Northwick Park Heart Study (NPHS-2; 
described in Chapters 4 and 5) [99] recruited between 1989-1994, genotyping was conducted in 
2706 men of whom 229 developed an incident coronary event after 12 years of follow up. CHID 
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events include non-fatal MI, CHD deaths, revascularization procedures or a silent MI after the 5th 
phase of follow up. 
The European Prospective Investigation into Cancer and Nutrition study, Norfolk-UK component 
(EPIC-Norfolk)[1401 recruited between 1993 and 1997 a total of 25,663 men and women of 
European descent. For the current analyses, a nested case-control design based on participants 
free of cardiovascular disease at baseline was utilised and includes a total of 2159 incident CHD 
cases and 2159 controls with DNA available after mean follow up of 12 years. CHD cases were 
defined as subjects with ischaemic heart disease mentioned anywhere on their death certificate 
(i. e. not just as an underlying cause), or ischaemic heart disease on their ENCORE database for 
(East Norfolk Health Authority) hospital discharge occurring after their health check. Ischaemic 
heart disease is defined as ICD9 410-414 or ICD10 120-125. All hospital admissions are coded 
using ICD10, whereas death certificates are a mixture of ICD9 and ICD10. 
From 10308 individuals originally included in the Whitehall-2 study [141] during 1985-1988, DNA 
was available for 5664 individuals, and a total of 457 CHD events were included for this analysis. 
CHD event was defined as having a non-fatal MI (MONICA criteria), or a CHD death. 
The jypercoagulability and Impaired Fibrinolytic function MECHanisms predisposing to MI 
(HIFMECH)[138] study was a European multicentre case-control study of MI. For the present 
study a total of 527 cases (fatal and non-fatal events) and 566 controls were available for 
genotyping. 
From the 1592 men and women originally recruited in Edinburgh Artery Study (EAS)[126] during 
1987, a total of 913 had DNA available for genotyping. After a mean follow up of 12.8 years, 117 
CHD events had accrued. CHD outcome comprised non-fatal MI, CHD death and 
revascularization procedures. 
The AtheroGene[1371 case-control study recruited a total of 1318 individuals (between 1996 
and 2000) with coronary artery disease defined as a diameter stenosis >_ 30% in at least one 
major coronary artery and a total of 485 healthy individuals. For the present analysis a total of 
1304 cases and 468 controls with DNA available were included. All participants were Germans 
and inhabitants from the geographical region in which the recruitment was conducted. 
The Southampton Atherosclerosis Study (SAS)[142] compromised a total of 1300 subjects 
recruited during 1999 to 2001, with coronary artery disease defined as a stenosis >_ 50% of the 
diameter in at least one major epicardial coronary artery. For these analyses a total of 1164 
individuals with DNA available were included. 
The Ludwigshafen Risk and Cardiovascular Health Study (LURIC)[143] included 3148 European 
descent individuals hospitalised for coronary angiography between 1997 and 2000. A case of 
coronary artery disease was defined as a subject with coronary stenosis >_ 20% in at least 1 of 15 
coronary segments according to the American Heart Association. A control was a subject without 
angiographic evidence of coronary stenosis. 
A total of 731 controls and 2581 cases with DNA available were included in this report. The 
Cyprus study [144] (still in recruitment phase) is a prospective cohort aiming to include 2000 
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individuals aged 40 or more. To date 767 subjects have been recruited and of which 739 
individuals with DNA available have been included in this analysis. 
The UCL DiAbetes and Cardiovascular disease Study (UDACS)[103] is a cross sectional case- 
control study to evaluate risk factors for coronary heart disease in subjects with diabetes mellitus. 
For the current study only European descent individuals (n=424) without coronary heart disease 
were included. 
The THROMBOgenic Factors and Recurrent Coronary Events (THROMBO) study [1451 involved 
a total of 766 patients who had survived a myocardial infarction, of whom 529 individuals with 
DNA available were included in this analysis. Blood markers (including Lp-PLA2 activity) included 
in the THROMBO study and presented here were determined 2 months after the index MI. For the 
current analyses only the baseline information was utilised, since coronary events were recurrent 
instead of incident events. 
Figure 6.3. Linkage disequilibrium map of the seven PLA2G7 tagging-SNPs included in the Lp- 
PLA2 genetic collaboration. Highlighted with a black rectangle-box is the rs1051931 (A379V). 
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6.6.2 Data collection 
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Following a pre-determined analysis plan generated by myself, information was obtained on Lp- 
PLA2 activity levels, cardiovascular risk factors, PLA2G7 variants and cardiovascular events from 
the 11 participating studies within the collaboration. The analysis plan included unified definitions 
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for coding of all relevant variables utilised in the analysis. For a sub-set of pre-defined variables 
(Lp-PLA2 activity, CRP, and triglycerides) natural-logarithmic transformations were used and 
these variables were always analysed in the log-scale. For the different multivariate models 
utilised to obtain risk of CHD, these included the same group of covariates across all the studies. I 
used the established definitions within each study for cardiovascular events. However, studies 
were then divided in two categories; those using CHD as an outcome (EPIC-Norfolk, NPHS-2, 
Whitehall-2, EAS, Cyprus, HIFMECH) and those using coronary artery disease as an outcome 
(Southampton Atherosclerosis, AtheroGene and LURIC). All the analyses were limited to 
individuals self-identified as being of European descent. 
6.6.3 Laboratory analysis 
In order to decrease any source of inter-study variability Lp-PLA2 activity in AtheroGene, EPIC- 
Norfolk, NPHS-2, UDACS, and Cyprus was determined in a single laboratory and investigator (Dr 
Ewa Ninio at INSERM U525, Paris), who assayed Lp-PLA2 activity using a radiometric assay as 
reported previously [146,147] For the THROMBO study, plasma Lp-PLA2 activity was determined 
by a commercial colorimetric assay (Cayman Chemical Co. ) with 2-thio-PAF as substrate and 
following the manufacturer's directions. [145] For the LURIC study, LpPLA2 activity was measured 
by use of the Azwell Auto PAF-AH reagent set (Azwell). [148] A mean intra-assay coefficient of 
variation of 4.0% was observed for the NPHS-2 samples tested, and a mean inter-assay 
coefficient of variation of 25%. 
96 
cö 
d 
0ö 
Oy0 
U) 
(n (D 0) ö an NN 0 V) O 0 
Ay Ot 
>. z } Z 
Ü 
' RU 
R N 
cÖ O 
O C) N ýM 0 
43) 
J cV cfl 
Z 04 
> - Lo a 
w aý 
Co 
cO L c 
Loac C °Z 3 
y o co U ` - ° O N c v 
Ul f0 3 
0 
"O U 
0V 7 
fn 
Ü (6 
(n 
) 
Ca 0 Xjc 
O 
ND (0 N a) 
V OONmR QO OO "a y 
y 
-p -c 
O ý0 
Da- to 
NE2 
r= 
co N 
m OL 
p 
'O 
H _ OUD co c 'O 
ä LL -M L 
c 3a)IE: °'ýa L _ 0 U) e `' V 
ý 
U) va 
V) W 3 (3) 
3 
M O V1) c ý 35 vD - X (D ZQ c N, -(, ) ° cu -6 o d (U R OL O, C 70 70 ß C 
a) N 0). 
`' 
Q 0) 
.0WN o: CL C C U 
'ý C 
(p a"O ýa-+ 
Z 0 L- 
)" C$ 
' ' 
U 
) -p U 
. )L N C 
Cy 
NÜ 
cý aC 
C Ü 
N 
CO 
_ O 
Vi 
p C 
- U (9 
C 
MO a) 0- p N a) Ec 70 E5 co C 
R n- 3cvýn ° mN t:: 70ý3ý (I C: C)->1 o C: (L) (n ö 
0) >, vm 
ý ) C` caa c ED > v 
CN c C t. C - iri co _ :3 ä (0 
(0 
cäm >' 
0)(D ) +' i/i °O° 
M 
E Eoü E ° v; Nc 
V) Q° a Qcoo a Q U' M °Dý °ö U v) U -o UQ 
OL 
I- ^ 
r- O 
co CO 
rr 
ö° 
LUcO 
ti 
M ti M 
N co 
IT (Y) 0Op0) N 
`- 
N 
C)) 0 q 
O cn (n N- U) 
N 
0) 0 LO 00 L L 
r- 'IT 
O O 
CY) 
N-V O1-- 
114" 
N- 
OI, - 
cC9 NCO 
Ov- 
00 O 
"' 0jON 
ý 
V- Cl) 
O p~ )0) 
n co 
1 0)0) 
U) (A N 
0 C) 
N 
Q 
Iý O 
M. -- CO 0)O 
(0 (0 M- 
(0'- 0 O) 
O 
(3)O 
Lf) 
( 
O 
C) O (00 Ö LO _ C) N U') LO 
_ Lr) C) O 
r -N c- ý 
CD O 00 
V) cn 
C C p 
0) 
_ 
O +` C C 
dO co u NÜ 
p LO 
m O 
L U - pC 
° vl 
.C 
7 
C° > 
Ü 
(n 
C 
OU 
a) U 
C 
>. 
{- '-' 
}. 
C aý o m O a). 0 c N 
:3 
N n Eý^ >.. 
- 
p 
U 
ý a) -0 c na) " ö oY 
d ? 
0 ni 
O° Y 
Cl) n 
o >1 U) Y? Oc ft- a a w nz u) p ý? Z) m ýG U ä 
Z 
Ü) z U 
w 0 2 U 0 Z Ü LL _ 
w = 
r 
rn 
0 
I- cu 
c 
c 
0 
U 
w 
as 
e9 
0ö w 
dU 
ap a) 
ý= a v, 
v 
a)0 o 
- 
(n .. wem' rnýn c 
Ch 
Z 
>- O 
Ný >- CC) 
t9 > 
E, O 
M ä ý z U) 00 H c v }° Z } 0 
U) 
o 
MN 
.ý 
7 
jA rC 
NO 
C .TU >> > NNO 
:_ 
N rn ) 
'6 OU 
_ (3 .U 
L t N 
C13 
U O ö O Ü 0 O cu 
C 
a) 
w OOU 
X 
NO '0 mLM 
0) 
(0 O 
O E" N +C - 2) LI 
yY 
U yÖNC p) Ln 0 of 
U N 
C ýUUN N 3i M0 'o .= 
ßC N` 
OO 
UI CO 
0 
73 p 
' 
-2p N 
' U 
Gl 
ýp O 
N Z3 E 
l9 () 
LLI 
>J 
'O f9 C 
> 
=p O 
p 
N t U) 
X"gym >a_%m U -C: - 
E "-m - C x- N C 
" 
O O to uý C p) N 
p 
OÜ 
ý 
Oa 
(U 
N 
.O 7 I Oö O Np D ýp 
3OL 
U ý- 
L 
ýA N 
CN ÜU 
(0 N 
U) CC 
y 
OLC 
Co 
UO 
C M OL 
N 4) 3m ý`, 
" O- OU 
L N 
UO 
N >> f0 f0 
EL 
0O 0o 4J 0 
(N(N 
Q Q 
N 
L v- N U N> E ` Uw F- N cn F- i- Z _ 7c Z (O 
L 
N 
y a >s 
Y 
73 L 
y0 
pd 
L ,C 
lD 
- 
(0 
U t] 
CN i> 
C 
f0 
N 
ýp >ý 
0 70 
NOL 
0 Oa L) 
- (ho 
3U ýý ön Eö C14 7t - 
C 
(n 
NO 3 
0)- C 
ONO 
NC2 LO a) V) 
0 U 
cm 
E c C `O 2OOE CU ZC 
> 
a) -D 
OdC7 O p) 
CT 
E (u E (9 NÜi 
(( 0 Qm 
L) Va 
O 
"' U) a a) 
C Np 
w+ +' 7- 1] 
Ü (n DN 
COL 
7Y 
` 
m cO 
(6 U 
NC 
CC 
p YO '1 O N> 
O 
M 
N a 
oC 
CO 
C 
O 
N "ý pý "ý C CGUO 
1) 
,6 (0 
C 
to NU '+ 
c- (n - 
) 0) 
Ul N 
.p 
0 C (0 
ýp t 
CC U c0 'a c0 
OLC O 
U 
.=UM 
L =N Q D OU f0 COC UU cD O- 
ÖU 
7 
C 
` 
0 mN U . m 1 < cU QI + 
r- OD Lo 
M 
ý 
M 
rr 
0 04 N 00 
IT d 
C) 
C O 1- O CO 
:a 
'c 
Il- IT 
CO . -- 
1ý q- 
t0 CO C) O ' 
> 0)m 
U ) 
0 0)N 00 
C ch (j) . (n U d 
Q) 
N 
0 
(3) C) (3) 6M) O(0 
ý C7 
O 
Q LUO 
0 00 
ý 
O 
LOC)0 LO LO 
0) 0) 
LO 
V% (n 
Oa00 Ö 
r r 
Ö 
r 
Ö 
C 
N r -C 
N 
O 
C (L) 
p 'D 
ö 
Q V NN NL 
V 
`- , Q) 
O 
U 
.- 
(D 
0 
O -U 
.0 
7J 
y , C 1. 
C p 
(p 
> 
U 
: C 
O f6 
CC r > C 
V: E N 
ä 
0 
ÜO 
- 
UO N 4) 
(D Ü 3j ý Ü Ü ää 
d 
0,0 CV 
dý 
Eu) 0 0 
Z 
ä 0 0 
(n of D U) < W 
OD rn 
6.6.4 Genotyping of single nucleotide polymorphisms in the PLA2G7 gene 
Following previous identification of tag-SNPs in the PLA2G7 gene (i. e. a subset of all SNPs in the 
gene that captures information on untyped SNPs because of LD) by Prof Talmud's group (Figure 
6.2), plus recent findings published by Sutton et al. [139] on PLA2G7 variants, a total of seven 
PLA2G7 variants were finally selected based on their effects on Lp-PLA2 activity or CHD risk, 
while considering their LD structure to avoid the inclusion of SNPs in strong LD (Figure 6.3). See 
Table 6.2 for the list of included variants. 
Table 6.2 Description of coding of PLA2G7 variants included in the analysis. 
rs_number Common Rare Homozygous common Heterozygous Homozygous 
allele allele allele (reference group) rare allele 
coded =1 coded =2 coded=3 
rs974670 CT CC CT TT 
rs1805017 G A GG GA AA 
rs9381475 C T GG GA AA 
rs10948300 A T AA AT TT 
rs2216465 GC GG GC CC 
rs1421378 AG AA AG GG 
rsl051931 GA GG GA AA 
(A379V) 
For all the studies (except HIFMECH) the genotyping for the A379V (rsl051931) was done using 
Taqman assays by design. For HIFMECH study, genotyping was determined using an allele- 
specific polymerase chain reaction (PCR), using one sense primer (5'-AGG GAG ACA TAG ATT 
CAA CTG-3') and one anti-sense primer (5'-CGT TTT GTA AGA ATG CTA ATG AA-3'). Use of 
these primers introduces a Pstl site in the A379 allele in all subjects excluding rare homozygotes. 
The size of the undigested fragment is 69 base-pair (bp). After restriction, Pstl generates 
fragment sizes of 49/20 bp in common homozygotes, 69/49/20 bp in heterozygotes and 69 bp in 
rare homozygotes. Restriction enzyme digestion was performed in a volume of 13 pl containing 5 
pI of the PCR product and the buffer recommended by the manufacturer (Promega Inc. ) for 240 
min at 37 °C. Fragments were resolved using Microtitre Array Diagonal Gel Electrophoresis on 
ethidium-bromide stained 7.5% polyacrylamide gels. One heterozygote individual, as confirmed 
by sequencing and one negative control were included in each PCR run. All rare homozygote 
samples were re-amplified and re-digested to confirm genotype. All other additional SNPs 
(rs974670, rs1805017, rs9381475, rsl0948300, rs2216465 and rs1421378) were genotyped 
using Taqman assays by design. With the exception of EPIC-Norfolk and LURIC studies, whose 
genotyping was done using local laboratory facilities available to the investigators, all genotyping 
was conducted by members of Philippa Talmud's group at the Centre for Cardiovascular Genetics 
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at UCL. All genotyping was performed by investigators unaware of subject status and confirmed 
by a second viewer. 
6.6.5 Statistical analysis 
Following the pre-specified analysis the following variables were log-transformed using the natural 
log-scale: triglycerides, and CRP. All other variables were analysed in their original scale. 
Throughout all analyses, a two-sided probability value <0.05 was taken to denote statistical 
significance. Results across studies were pooled by random model effects, using the inverse 
variance method. 
6.6.5.1 Lp-PLA2 activity, cardiovascular traits and risk of CHD 
For this section, only data from the NPSH-2 and EPIC-Norfolk prospective studies was used as 
they were the only prospective studies with coronary events and levels of Lp-PLA2 activity. 
To evaluate the associations between levels of Lp-PLA2 activity with cardiovascular traits, 
quartiles of log-Lp-PLA2 activity were generated, and the unadjusted means with their respective 
standard deviations were obtained for the following cardiovascular traits: age (years), body mass 
index (kg/m), systolic blood pressure (mm Hg), total-cholesterol (mmol/L), LDL cholesterol 
(mmol/L), HDL-cholesterol (mmol/L), log-triglycerides (mmol/L), log-CRP (mg/dL) and alcohol 
consumption (unitstweek). Then, using the bottom quartile (Q1) as the reference category, the 
mean difference for each quartile was obtained and results were pooled across studies using 
random model effects. For these associations, only individuals without known CHD at the time of 
measuring the Lp-PLA2 activity were included, to reduce inflation of the effect size possible in 
individuals with established disease. 
The association between Lp-PLA2 activity and incident CHD was assessed using Cox 
proportional hazards regression. Hazard ratios (HR) and 95%Cl were obtained for each quartile, 
using the bottom quartile as the reference group. Hazard ratios and their 95%Cl for each quartile 
were then pooled across the two studies to obtain a summary effect for each quartile. A 
progressive adjustment for potential confounders was conducted as follows: model-1 included 
age (continuous), gender and practice (for NPHS-2) and enrolment date (for EPIC); model-2: 
adjusted for variables in previous model plus body mass index (continuous), smoking (current or 
ex vs. never), diabetes (yes vs. no), systolic blood pressure (continuous), CRP (continuous), 
fibrinogen (continuous), alcohol (continuous as: units/week). Model 3: adjusted for variables in 
model-2 plus: total-cholesterol (continuous), triglycerides (continuous) apo-Al (continuous), apo-B 
(continuous). If apo-Al was not available, HDL-cholesterol (continuous) was used. Similarly, if 
apo-B was not available LDL-cholesterol (continuous) was used. For details of CHD outcome 
definitions see section 6.6.1 from this Chapter. 
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6.6.5.2 PLA2G7 gene variants and Lp-PLA2 activity levels 
For this section, data from 11 studies were included. Coding of the genotypes for each of the 
PLA2G7 variants was conducted as described in Table 6.2. For all the analyses, individuals 
homozygous for the common allele served as the reference group. For associations of PLA2G7 
variants with Lp-PLA2 levels and cardiovascular traits only individuals without known CHID were 
included. Levels of LpPLA2 activity were log-transformed and all analyses were conducted using 
log-transformed values. 
To evaluate the effect of the different PLA2G7 variants on levels of Lp-PLA2 activity, 6081 
individuals without clinically evident cardiovascular disease from 7 studies with available DNA and 
Lp-PLA2 activity levels were studied; see Table 6.1. The unadjusted mean value of the log-LP- 
PLA2 activity with its respective standard deviation was obtained for each genotype from the 
seven PLA2G7 variants. Mean differences in log-Lp-PLA2 (log-ratio) for each genotype were 
obtained and results were pooled across studies using random model effects. 
6.6.5.3 PLA2G7 gene variants and cardiovascular traits 
From the previous analyses, the gene-variant exhibiting the largest effect on Lp-PLA2 activity was 
then used as proxy of the likely effect on cardiovascular traits to be observed when using an Lp- 
PLA2 inhibitor in a clinical trial. The effect of the gene variant on cardiovascular traits is expected 
to be proportional to the magnitude of the effect that the gene-variant exhibits on the Lp-PLA2 
activity levels. For this analysis, unadjusted mean values of cardiovascular traits with their 
respective standard deviations were obtained for each genotype. Mean differences in the 
cardiovascular traits for each genotype were calculated and then data were pooled across studies 
using random effect models. For cohort studies with repeated measures of some continuous 
traits, the baseline or first available measure (in the case of missing data) was utilised. 
Cardiovascular traits included here are those evaluated in the observational component, in order 
to allow a more like-with-like comparison. 
6.6.5.4 PLA2G7 gene variants and risk of CHD 
To evaluate the effect of the PLA2G7 variants on the risk of CHID, a total of 8 studies including 
19,506 individuals were included. For each gene-variant, using individual homozygous for the 
common allele as the reference group, a measure of association was obtained for each genotype 
comparison. Specifically, the log-odds ratios and their standard errors for case-control studies and 
log-hazard ratios with their standard errors for cohort studies were obtained for each genotype 
comparison from each gene-variant analysed. All measures of effect were adjusted by age 
(continuous), and gender. Enrolment date or practice centre was also included if relevant to each 
study. Assuming equivalence of log-odds ratio with log-hazard ratios, these measures of effect 
were then pooled across studies using random effect models and from now on these will be refer 
red to as the odds ratios. Initially, pooled OR were obtained separately according to the outcome 
reported; i. e. coronary artery disease (determined by coronary angiography) or CHD. If no 
evidence of heterogeneity was observed between the outcomes a summary OR was calculated. 
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6.7 Results 
6.7.1 Lp-PLA2 activity, cardiovascular traits and risk of CHD 
Using data from the NPHS-2 and EPIC-Norfolk cohort studies, it was observed that healthy 
individuals with higher than average levels of Lp-PLA2 activity tend to be older, to have higher 
levels of established risk factors such as body mass index, blood pressure, total-cholesterol, LDL- 
cholesterol and triglycerides. Similar positive correlations were also observed for the emerging 
risk factors fibrinogen and CRP. Lp-PLA2 activity was also inversely correlated with HDL- 
cholesterol and alcohol consumption (for details see Figure 6.4). These multiple associations of 
Lp-PLA2 activity illustrate the great potential for confounding of the Lp-PLA2 activity-CHD 
association. 
Figure 6.4. Mean differences in cardiovascular traits by quartile of Lp-PLA2 activity. Subjects 
from the bottom quartile (Q1) were used as the reference group. 
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As indicated by previous observational studies, [129] high levels of Lp-PLA2 activity were 
associated with a higher risk of CHD. The large number of cases accrued in the NPHS-2 and 
EPIC-Norfolk cohorts (1229 CHD events) allowed me to explore the shape of the Lp-PLA2 
activity-CHD association, which appears to be continuous with no clear evidence of threshold 
effect across the quartiles of Lp-PLA2 activity (Figure 6.5). Individuals in the top quartile had a HR 
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of 1.49 (95%Cl: 1.23,1.81) compared with individuals from the bottom quartile in a minimally 
adjusted model (Model-1). However, as the level of adjustment increased the magnitude of the 
Lp-PLA2 activity-CHD association diminished to a HR of 1.06 (95%Cl: 0.84.1.34), see right panel 
Figure 6.5. 
Figure 6.5. Hazard ratio (HR) of CHD by quartiles of Lp-PLA2 activity. Left panel describe the 
shape of the association using the minimally adjusted model (model-1). Right panel describe the 
effect on the HR (for the top vs. bottom quartile comparison) of progressive levels of adjustment. 
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6.7.2 PLA2G7 gene variants, Lp-PLA2 activity and cardiovascular traits 
Figure 6.6 shows the mean difference in Lp-PLA2 activity (log-ratio) by genotype from each of the 
seven gene variants included. The most widely studied variant was the rsl 805017 including 6004 
individuals, while variant rs2216465 included 3383 individuals. Using individuals homozygous for 
the common allele as the reference group (G1), a significant increase in the levels of Lp-PLA2 
activity, in an additive fashion was observed for individuals carrying the rs1051931 variant. 
Individuals homozygous for the rare allele had a relative difference of 7%, and subjects 
heterozygous had a 3% relative difference compared with those homozygous for the common 
allele. A trend towards an inverse association, lower levels, especially for subjects homozygous of 
the rare allele was observed for the following gene-variants: rs1421378, rs1805017 and 
rs2216465. None of these variants exhibited a strong LD (rz <0.2) with the variant rs1051931. A 
null association with levels of Lp-PLA2 activity was observed for the variants rs974670, 
rs9381475 and rsl 0948300. For details see Figure 6.6. 
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Plasma values of Lp-PLA2 activity itself were strongly associated with a range of established risk 
factors and emerging biomarkers for CHD (see Figure 6.4). However, the gene variant rsl 051931 
selected as an unconfounded tool of the Lp-PLA2 activity (as well as a proxy of Lp-PLA2 inhibitor, 
darapladib) did not exhibit any systematic association with any of the cardiovascular traits 
evaluated, including some lipid fractions that had strong association with Lp-PLA2 activity (Figure 
6.7). 
Figure 6.6. Mean differences by genotype in the Lp-PLA2 activity levels according the PLA2G7 
variants evaluated. Data pooled from 7 studies including up to 6081 individuals without clinically 
evident cardiovascular disease. 
Mean difference (95%CI) in log-LpPLA2 activity by PLA2G7 variants 
[ GI: Homozygous common-allele; G2: Heterozygous; G3: Homozygous rare-allele I 
G1 
G2 
G3 
G1 
G2 
G3 
G1 
G2 
G3 
6.7.3 
rs974G70 
n= 3943 
r,. 
-03 002 06 Lower higher 
Reference 
0.00 (-0 01,0.03) 
001 (-005 007) 
12 
rs1061931 
n= 5711 
G1 f Reference 
G2 0.03 (0 01.0.05) 
G3 
0.07 (0.03,0.11) 
-. 03 0.02 . 06 12 
Lower higher 
rsl806017 rs2216466 
n=6004 n=3383 
Reference G1 
-0.01 (-003,001) G2 
-0,03(-0,05,000) G3 
-. 03 002 . 
06 
. 
12 -03 0.02 06 
Lower higher Lower higher 
rsl0948300 
n=3384 
Reference 
-0.01 (0.03,0.02) 
-0.02 (-0.14,0.10) 
-. 03 002 . 06 12 
Lower higher 
PLA2G7 gene variants and risk of CHD 
rs1421378 
n= 5050 
G1 
" Reference 
G2 -0.01 (-0.03,0,01) 
G3 -0.04 (-0.07, -0.01) 
- 03 0.02 06 . 
12 
Lower higher 
rs9381476 
n=5259 
Reference U1 Reference 
-0.00 (-003,002) G2 -0 01 (-0.03,0 01) 
-0.05 (-0.08, -0.01) G3 -0.02 (-0.08,0.04) 
__ rýrr 
12 -. 03 0.02 06 12 
Lover higher 
After pooling data from 8 studies with a variable number of CHID cases per-variant, ranging from 
1528 events for the rs974670 up to 8412 events for the rs1051931, no evidence of a clear 
association with CHD was observed for any of the seven variants evaluated (Figure 6.8). Indeed, 
the variant rs1051931 that was consistently associated with a small-to-moderate difference in the 
levels Lp-PLA2 activity and included more than 8000 cases did not show an increase in the risk of 
CHD (see Figure 6.8). Nonetheless, the effect of the rs1051931 variant on Lp-PLA2 activity was 
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small-to-moderate in magnitude, therefore it is possible that the expected effect on CHD risk 
could lie within the confidence intervals of the effect observed for each of the genotype 
comparisons. No heterogeneity according to the outcome evaluated (CHD vs. Coronary artery 
disease) was observed (Figure 6.9) 
Figure 6.7. Mean differences in cardiovascular traits by genotype according the PLA2G7 variants 
evaluated. Data pooled from up to 10 studies and 12,938 individuals without cardiovascular 
disease. 
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6.8 Discussion 
After including data from 1229 incident events an increase in risk of CHD was observed for 
individuals with high levels of Lp-PLA2 activity, as previously reported by several prospective 
studies. [129] The current analysis showed that the increase in risk seems to be present across all 
levels of Lp-PLA2 activity, without clear evidence of a threshold effect. However, the magnitude of 
the association diminished substantially as the number of cardiovascular risk factors adjusted for 
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increased, especially after the inclusion of lipid particles in the model (Figure 6.5). This finding, 
along with the multiple correlates observed for Lp-PLA2 activity (Figure 6.4) suggests that 
residual confounding is a potential explanation for the association observed. Alternatively, it is 
possible that some of the variables judged as confounders might mediate the effect of increased 
Lp-PLA2 activity on risk of CHD and if so, adjustment for such variables would be inappropriate, if 
the aim is to identify Lp-PLA2 activity as a causal factor in CHID. 
In order to try to minimise previous uncertainties about a causal role of the Lp-PLA2 on CHD, and 
also to accumulate more evidence on the validity and safety of the Lp-PLA2 molecule as a drug- 
target, a genetic approach was adopted using variants within the gene encoding Lp-PLA2 
(PLA2G7). A careful selection of PLA2G7 gene-variants was conducted to minimise the likelihood 
of a false-negative finding due to inadequate selection of genetic tools. This included the 
identification of common tag-SNPs for European descent individuals which were initially evaluated 
in the NPHS-2 study, and whose results were then complemented with published-evidence on the 
effects of PLA2G7 variants on Lp-PLA2 activity and disease risk. [139] These two sources of 
evidence served for the final selection of the seven variants utilised in the genetic component. Of 
the seven variants selected, four (rs1051931, rs1421378, rs1805017 and rs2216465) exhibited 
some differences in Lp-PLA2 activity by genotype (Figure 6.6). The magnitude of such 
associations was small to moderate. Indeed, the rsl051931 that exhibited the strongest effect had 
only a relative difference on the Lp-PLA2 activity levels of 7% and 3% for subjects homozygous 
for the rare allele and heterozygous individuals respectively (Figure 6.6). The other variants 
identified showed associations of similar or smaller magnitude to the one observed for the 
rs1051931 variant. 
In a second analysis, based on its effects on Lp-PLA2 activity, the rs1051931 variant was used as 
proxy of the Lp-PLA2 inhibitor darapadib to try to elucidate expected effects on cardiovascular 
traits and disease risk likely to be observed as a consequence of the Lp-PLA2 inhibition. When 
such analysis was conducted, no clear effect of the rs1051931 variant on any of the 
cardiovascular traits analysed was observed. These results are directionally concordant with the 
preliminary data from the two recent short-term and randomised trials in humans using the Lp- 
PLA2 inhibitor darapladib conducted to date. [131,1321 Despite reducing Lp-PLA2 activity, by 66% 
at 160 mg daily darapladib did not modify the concentrations of lipid particles (LDL, HDL or 
triglycerides). Similar findings have been recently observed in a pig model in which elevations in 
lipid concentrations and Lp-PLA2 activity were seen by rendering the pig diabetics. However, 
treatment with darapladib normalised Lp-PLA2 activity but had no effects on lipids. [1491 Finally, I 
evaluated the effect of the seven PLA2G7 variants on CHD risk, and despite that some 
comparisons included more than 8000 cases, no clear genetic signal could be detected for any of 
the genetic comparisons (Figure 6.8). 
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It is, however, important to take into consideration the limitations of the genetic approach adopted 
here. First, the use of a Mendelian randomisation strategy relies greatly on the ability (magnitude) 
of the gene-variants to serve as a proxy of the biomarker (Lp-PLA2 activity) or the drug (Lp-PLA2 
inhibitor). A dose of 160 mg daily of darapladib, the dose suggested as the most appropriate to be 
used in trials evaluating clinical events, exhibited a relative reduction of Lp-PLA2 activity of 59% 
after 12 months and 66% after 4 weeks. [131,1321 In contrast, the variant rs1051931 that exhibited 
the largest effect on Lp-PLA2 activity only showed a modest relative difference of 7%, albeit likely 
to be lifelong. Assuming the effect of Lp-PLA2 inhibitor on the Lp-PLA2 activity is linear and dose- 
dependent as suggested by the available evidence from trials, [ 131,132] this would suggest that 
the variant rs1051931 should be equivalent to a dose of around 17 mg of darapladib, almost ten 
times lower than the dose of darapladib intended to be used in trials evaluating clinical events. 
Although somewhat crude and simple, this calculation serves to illustrate that perhaps the lack of 
association observed with the gene-variants, especially with CHD risk, could be due to the limited 
ability of common variants within European descent individuals to behave as good proxies of both 
Lp-PLA2 levels and the Lp-PLA2 inhibitor. This restrained the power of the sample size included 
(8412 CHD cases) to detect a genetic signal on disease risk. Another alternative would be to use 
as a proxy the PLA2G7 null variant found in individuals of Japanese or Chinese ancestry. This 
loss-of-function V279F variant occurs at polymorphic frequencies, with heterozygote frequencies 
of 27% and 4% homozygotes and is inherited in an autosomal recessive manner. Enzyme activity 
is significantly impaired in heterozygotes and is completely abrogated in homozygotes [136,150] 
This mutation has been associated with a significantly greater incidence of nonfamilial 
hypertrophic cardiomyopathy, [151] while the results from a study of almost 4,000 Japanese 
concluded that the variant occurred at a much higher frequency in those suffering from a 
myocardial or cerebral infarct. [152] Thus the consequence of natural Lp-PLA2 inhibition is 
suggestive of a detrimental effect on cardiovascular outcome. 
In conclusion, I have shown a gradual increase in risk of CHD was observed across all the levels 
of Lp-PLA2 activity, though residual confounding may explain a considerable part of the 
association. A genetic approach using the Lp-PLA2 gene was limited by the inability of common 
variants in European descent to exhibit important differences on the Lp-PLA2 activity levels, 
limiting substantially the power of this nevertheless large collaboration. Future research on 
individuals of European ancestry should aim to investigate the existence of rare variants with 
greater effect on Lp-PLA2 activity and on cardiovascular risk, although this may require several 
tens of thousands of cases. This may be possible through the Lp-PLA2 Studies Consortium which 
is compiling information on 31 cohorts with nearly 75,000 participants. [153] 
107 
Figure 6.8 Relative odds of CHD associated with variants of the PLA2G7 gene. Data pooled from 
up to 8 studies including up to 8412 CHD cases. 
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Figure 6.9 Odds ratio (95%CI) of the rsl 051931 variant on the risk of CHD stratified by outcome. 
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Chapter 7 Integrating information on genotype and blood proteins to evaluate causal 
biological pathways in cardiovascular disease 
An article use findings from this chapter has been re-submitted to Human Molecular Genetics, the 
authors of this manuscript are Fotios Drenos, Philippa J. Talmud, Liam Smeeth, Jutta Palmen, 
Steve E. Humphries, Aroon D. Hingorani (Senior author) and myself. Manuscript number: HMG- 
2008-D-01203. R1 
In previous chapters, I have mentioned repeatedly that confounding is one of the main limitations 
to establish the causal role of a biomarker using observational studies. This is due to the wide 
range of associations that these biomarker often exhibit, especially with other biomarkers as well 
associated with CHD risk. Therefore, the distinction of causal of from non-causal associations 
among biomarkers is of great importance. This Chapter described a genetic approach that serve 
to dissect biological pathways with focus on blood proteins associated with CHD risk. 
7.1 Inter-correlated blood proteins and CHD 
Like many common disorders, CHD results from a complex interplay between environmental and 
genetic factors, complicating the identification of the causal factors, and therefore delaying the 
development of new treatments [154]. As far back as 1981 over 200 phenotypic traits had been 
shown to be altered in those with, or at higher future risk of CHID [155]. These phenotypic traits 
represent components of pathways or process (e. g. inflammation, coagulation) suggested to be 
implicated in CHD aetiology by other study designs. Those traits include mainly circulating blood 
markers such as (i) lipid particles (e. g. HDL-cholesterol, LDL-cholesterol, or triglycerides), (ii) 
metabolites (e. g. vitamin D, vitamin C, Hcy or folic acid, uric acid, glucose) and (iii) single blood 
proteins (e. g. CRP, Factor VII, or Lp-PLA2) of the previous three group of blood makers 
associated with CHD the focus of this chapter will be on a subset of single blood proteins. 
There are at least two major obstacles that limit the identification of causal relationships from 
observational associations of blood protein concentration and CHID alone. First, alterations in 
measured blood proteins may reflect the disease process rather than be the cause of it (reverse 
causation). In CHD, this can be a problem even if phenotypes are measured years ahead of 
clinical events because CHD has often an extremely long preclinical phase, with atheroma (the 
pathological substrate for CHD events) being present in a sub-clinical form from as early as the 
second decade of life. Second, alterations in blood proteins of interest may simply mark the 
presence of some other causal factor (confounding). [156] These two major obstacles to any non- 
randomised experiment (observational research) are discussed in detail in Chapter 1. 
The potential for confounding is large because many of the blood proteins associated with CHD 
risk are closely inter-correlated, with the phenotypic changes clustering among those at higher 
risk of disease. This makes it challenging both to ascertain the nature and direction of the 
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biological inter-relationships among blood proteins and to assess the independent effect of any 
blood protein on disease risk. A relevant example that illustrates this comes from the blood 
proteins CRP and fibrinogen. Both proteins are associated with high risk of CHID and there is 
strong correlation between them. [121 Currently, the evidence to decide whether these markers 
confound the associations of each other with CHD, or on the other hand, whether they lie on the 
same causal pathway is derived from non-randomised observations, (mainly laboratory research 
in animals, cell and tissues), which are prone to considerable amount of bias. However the issue 
is critical because in the first scenario adjustment would be legitimate (indeed necessary) where 
as in the second it would be inappropriate. [1571 This uncertainty introduces a large degree of 
subjectivity when deciding on the causal nature of an association between blood proteins and 
disease risk (Figure 7.1), and on the validity, or otherwise, of these markers as therapeutic targets. 
The ideal method to establish unequivocally a causal role in CHD for a particular blood protein of 
interest is through the use of an intervention that specifically modifies such blood protein in a 
randomised experiment. A similar approach has been conducted for the blood marker LDL- 
cholesterol that has proved to be causally involved on CHD, largely part by developing the HMG- 
CoA reductase inhibitor (statin) class of drugs that reduce blood levels of LDL-cholesterol, and 
testing their effects in randomised trials [158]. However, the cost and risk associated with the 
development of the many selective drugs needed to target the vast array of blood proteins 
implicated in CHD currently precludes a comprehensive and systematic approach to understand 
their causal relevance of all markers and limits translation of the basic science and 
epidemiological findings into new medications. 
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Figure 7.1. Difficulties in establishing causal pathways among correlated blood proteins and CHD 
risk using as an illustrative example the case CRP, and Fibrinogen (FIB) in CHD. 
Models derived from existing observational evidence 
a) Both blood proteins are associated with CHD 
CRP C HD FIB CHD 
b) Both blood proteins are highly correlated 
FIB FIB 
CRP ---------- CHD 
CRP ---------- CHD 
Potential Scenarios to explain the existing observational evlnence 
c) Scenario (i) Inappropriate to adjust in both scenarios, since they lay in the causal pathway 
CRP --lo, FIB -º CHD FIB --f CRP -º CHD 
d) Scenario (ii) Appropriate to adjust in both scenarios since they are not in the causal pathway 
FIBýýýý FIB"--`ý 
__ 
Causal '* Causal ý'' 
__r 
CHID Factor 
r' 
CHD Factor 
CRP -- CRP -' 
FIB FIB 
CRP ---------- CHD 
CRP ---------- CHD 
Many (if not all) of the blood proteins associated with CHD behave as heritable quantitative traits, 
and single nucleotide polymorphisms (SNPs) influencing their variance are now being identified 
both by candidate gene and genome wide studies [159,160]. Unlike the associations between 
blood proteins, or the association of blood proteins with CHD risk, genetic associations are 
protected from reverse causation because genotype is a fixed characteristic such that there is a 
unidirectional flow of information from common genome variation to mRNA to protein to complex 
phenotype and disease (see Figure 7.2). Moreover, since genotype is determined at random at 
conception, blood proteins residing off the causal pathway from SNP to disease should be 
balanced evenly among the different genotypic groups, as they are in a randomised clinical trial, 
thereby minimising confounding in genetic associations (see Figure 1.1). Therefore, SNPs that 
affect the variance in blood proteins linked to CHD could be used as unbiased tools with which to 
understand their aetiological relevance. This principle has been referred to as Mendelian 
randomisation and when applied to assess the potential causal role of blood proteins, genetic 
studies are utilised as a type of natural randomised trial. [22,23,120] 
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Figure 7.2. Exploiting unique properties of genetic associations to map causal relationships 
among blood proteins (BP). 
(A) Unidirectional flow of biological information 
Gene ý mRNA --r 
Blood 
ýi Complex trail --o. 
Surrogate Clinical event 
Protein end-point 
Random allocation Non-random allocation 
(B) The associations between two blood proteins (BP) explained using genotypes as instruments 
(i) BP1 (ii) BP1 
6 P2 G-BP1 BP2 
The causal nature and direction of the association of one Identification of an allele in gene (G-BPI) encoding the BPI allows 
blood-protein (BPI) with another blood-protein (BP2) is this to be used to explore the unconfounded association between BPI 
often not readily established and BP2 
(iii) 
BPI 
(iv) Observed association 
BPI 4---------- G-BP2 
/hanisrn 
for 
.. 
A 00 sociation 
G-BP1 BP2 G-BP1 BP2 
Absence of an association of G-BPI with BP2, in an An allele in gene ( G-BP2). which encodes BP2 is associated with 
appropriately powered analyses, suggests that BPI does both BP2 and BP I establishing a causal effect of 8P2 on BPI 
not lead to an alteration in BP2 
In this chapter, I describe how to integrate and overlaying genetic information can be used to 
disentangle causal pathways among blood proteins by using SNPs (cis-acting) in the gene 
encoding the blood protein of interest (pQTSNPs: protein quantitative trait SNPs). The integration 
of SNPs and blood proteins information in a large prospective study can be used to help address 
the problem of identifying causal links between correlated blood proteins and between blood 
proteins and CHD risk. For this I utilised the available gene-centric data generated in the NPHS-2 
study (This study has been described previously in methods section in Chapters 4 and 5). 
7.2 Methods 
7.2.1 Study design and phenotypic measures 
As described in methods section in Chapters 4 and 5, the Northwick Park Heart Study 2 (NPHS-2) 
is a prospective study of 3012 healthy middle-aged men aged 50-64 years at recruitment, 
sampled from nine UK general practices between 1989 and 1994 [99]. Men were free from 
disease at the time of recruitment, and information on lifestyle habits, height, weight, blood 
pressure were recorded at baseline and on subsequent prospective follow-up. Measures were 
made of at least 15 circulating blood factors associated with CHD risk, [12,129,161,162] including 
six single blood proteins (CRP, fibrinogen, Lp-PLA2, apolipoprotein-A1, apolipoprotein-B, and 
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Factor-VII), seven complex biomarkers (Total-cholesterol, HDL, LDL, triglycerides, BMI, systolic 
and diastolic blood pressure) and two metabolites (homocysteine and folate). All the measures 
were obtained before the development of clinical events. A DNA repository was established using 
samples from 2775 men obtained at the time of recruitment. 
7.2.2 Genotyping 
The gene variants utilised in this chapter are derived from two sources; (a) an Illumina 768 SNP 
custom array and (b) gene-variants previously typed in NPHS-2 study for a range of different 
projects. Briefly, the Illumina 768 SNP custom array use gene-variants from a customised design 
assembled to comprehensively capture common genetic variation in more than 76 genes. The 
SNPs from the Illumina 768 custom array were chosen for: (i) their involvement in the following 
pathways linked to CHD risk; lipid metabolism, inflammation, oxidative stress, thrombosis and 
haemostasis; (ii) a previously described association with the risk of CHD or type 2 diabetes 
mellitus, including SNPs from a recent whole-genome analysis of T2D which marginally failed the 
p<10-7 significance threshold for genome wide significance (personal communication, Prof 
Philippe Froguel, London); or (iii) their ability to tag copy number variation. [1631 Tagging (t) SNPs, 
optimised for the Illumina platform, were selected using HapMap, applying an r2 threshold of 0.8 
with a minor allele frequency threshold of 0.04. Where possible, coding SNPs were included in 
the tag set. 
From the two previous sources of genetic variants (Illumina 768 and variants previously typed in 
NPHS-2), in this chapter I only utilised the gene-variants within genes that encode for each of the 
six blood proteins available to the NPHS-2 study (CRP, fibrinogen, Lp-PLA2, apoliporotein-Al, 
apolipoprotein-B and Factor-VII). Overall a total 124 gene variants were used as follows: 4 SNPs 
from CRP gene, 18 SNPs from Fibrinogen alpha (FGA), beta (FGB) and gamma (FGG) chains, 
13 SNPs from PLA2G7 gene (cognate protein: Lp-PLA2), 36 SNPs from the gene cluster ApoA5- 
A4-C3-A1,42 SNPs from APOB gene and 11 SNPs from F7 gene. See Table 7.1 for specific 
details of gene variants. 
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7.2.3 Statistical analysis 
In order to illustrate the degree of clustering among blood proteins associated with CHD risk, pair- 
wise linear relationships between blood phenotypes were tested using Pearson correlation. 
Initially, all continuous phenotypes available in NPHS-2 and then restricted to blood proteins. In a 
second stage, the effect of all the cis-variants on their respective cognate proteins (e. g. CRP 
gene-variants on CRP levels) was evaluated in order to detect the most strongly associated SNP 
(judged as the variant with the lowest p-value) that could serve as unconfounded proxy for the 
cognate protein. Then, in order to investigate the nature of the associations between blood 
proteins the effect of the selected SNP on the blood proteins was obtained using a standardised 
scale in order to allow direct comparability across blood proteins. For all the genetic associations 
a model free approach was used. If the blood protein was measured once in the study, an 
ANOVA was used to test for its association with genotype. Where more than one measurement 
was available for the blood protein, a mixed model was fitted through the data using indicator 
variables. The regression coefficients obtained for the indicator variables compared to the 
reference category were assessed for significance using a Wald test. 
7.3 Results 
7.3.1 Between-phenotype correlations 
To delineate the potential for confounding in the associations of biomarkers (including blood 
proteins) with CHD, the correlations between-phenotype was assessed (Figure 7.3). Seventy-two 
of the 105 possible pair-wise correlations between phenotypes were significant with ap value <_ 
0.05 (68 traits significant with ap value <_ 0.01), which significantly exceeds the five expected by 
chance alone (p < 1x10 -8 for observed versus the expected). This illustrates the clustering of 
altered phenotypes among individuals at higher risk of CHD, which makes it challenging for 
observational studies alone to identify the independent causal effect of any one phenotype. When 
the analysis was restricted to blood proteins a similar scenario emerged with 12 out of the 15 pair- 
wise correlations being statistically significant (Figure 7.4). In some cases the magnitude of the 
correlation was large as that observed between CRP and fibrinogen (r= 0.43; p<0.001). Notably, 
some of the pair-wise correlations were between blood proteins from nominally different pathways, 
e. g. correlations were identified between markers of lipids, inflammation and coagulation, 
consistent with the view that some of these pathways may be causally linked. 
115 
rn 
ö> 
L LL 
cu 
(1) = 
a> 
o 
"- O ÜV 
w 
C 
N 
UN 
N 
UC 
C 
W 0) 
N 'C 
co 
>O 
3O 
O N 
L 
NV 
U) 
=O 
O 
Z 
cu vi 
cu L E Co 0 0) 
COC 
(ß 
E U) E 
NC- 
E 
0 
UQ 
O a) N cu 
he Y 
-C 
N cu 
a) N 
O CU 
CU Q) 
0-m 
C_ 
O to O cu 
E E 
*0 
OL 
C 
OOý 
Xv 
cc 
N 
E. 
C-Q 
OC0 
cU "O O 
a) 
O 
t= .0 
C 
V° 
U- 
ti O cc 0) 0 
LL 
LL 0 tr- 
u) 
L 
E 0 
U 
y 
f0 
0 
CU 
0 
0$ o 
wO0 
vööö 
0d 
r4 0> OOö 
ööÖ 
-n 
000 0 OD LCN O 
0öýQ 
m8ý 
(C) 
Figure 7.4. Correlations matrix between blood proteins linked to CHD in 2775 men from the 
NPHS-2 study. Values in cells indicate Pearson's correlation co-efficient r. * p<0.01, ** p<0.001. 
The intensity of the colour within the cells reflects the degree of correlation evaluated by using 
Pearson's correlation coefficient. 
Blood proteins only 
7.3.2 pQTSNPs as tools to distinguish causal from non-causal associations between 
blood proteins 
Because cis-acting variants in a gene encoding a blood protein (pQTSNPs) provide the most 
specific instrument with which to investigate the causal effects of the encoded protein (utilising the 
principles of Mendelian randomisation), I identified the most strongly associating pQTSNPs for 
each of the blood protein available in NPHS-2 (CRP, fibrinogen, Lp-PLA2, apoliporotein-Al, 
apolipoprotein-B and Factor-VII), results are described in the Table 7.2. 
From the set of pQTSNPs identified for each blood protein (Table 7.2), only the top-rank SNP was 
then used as unconfounded proxy to help distinguish causation from confounding in the directly 
observed association between these blood proteins, with the exception of apolipoprotein-B protein 
for which the second-best SNP was used due to low minor-allele frequency of the top-SNP. 
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Table 7.2. Associations of pQTSNPs with their respective cognate proteins. Only associations 
with ap value < 0.05 are presented. In bold the pQTSNP used as unconfounded instrument. 
Cognate protein Gene rs number P-value 
Apo-B APOB rs585967 0.000853 
APOB rs952275 0.000914 
APOB rs533617 0.005622 
APOB rs12714264 0.006086 
APOB rs10199768 0.025601 
Apo-Al APOA5-A4-C3-A1 rs1729410 0.000758 
APOA5-A4-C3-A1 rs4417316 0.005714 
APOA5-A4-C3-A1 rs603446 0.009762 
APOA5-A4-C3-A1 rsl 2285095 0.015973 
APOA5-A4-C3-A1 rs9804646 0.023318 
CRP CRP rs1205 0.00009559 
CRP rs3091244 0.00021787 
CRP rs3093077 0.00027444 
CRP rs1130864 0.00158698 
Lp-PLA2 PLA2G7 rs2216465 0.025633 
PLA2G7 rsl421378 0.03327 
FVII F7 rs6046 1.52E-180 
F7 rs555212 7.89E-36 
F7 rs3211719 1.04E-03 
F7 rs1475931 3.24E-03 
Fibrinogen FGA-B-G rs4508864 1.00E-07 
FGA-B-G rsl 800790 1.68E-07 
FGA-B-G rs4220 9.41 E-07 
FGA-B-G rs2070016 1.05E-05 
FGA-B-G rs6054 9.64E-04 
The Figure 7.5 a-f showed the effects (standardised mean difference) of each of the pQTSNP 
used as unconfounded instrument on the different blood protein phenotypes available in NPHS-2. 
As expected the association between each pQTSNP-and its cognate protein was strong, however 
none pQTSNPs was associated with any of the other blood proteins measured, despite 12 of the 
15 pair-wise correlations between the blood proteins themselves being highly significant (Figure 
7.4). 
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7.4 Discussion 
Utilising the principles of Mendelian randomisation, the results from the present analysis 
demonstrated that integrating evidence from cis-acting SNPs in a gene with their respective 
cognate proteins is an effective approach to distinguish causal effects from non-causal 
associations among blood proteins, and therefore serve to reconstruct biological networks of 
blood proteins of interest for CHD aetiology. 
The efficacy of this genetic approach was exemplified when applied to a limited set of six blood 
proteins available in NPHS-2 for which the observational evidence indicates the existence of an 
association with CHD risk for each blood protein, but their causal role and validity as therapeutic 
target remains unproven due to problems of reverse causation and confounding. Twelve out 15 
pair-wise comparison among the six blood proteins exhibited some degree of correlation (Figure 
7.4), in some cases as strong as that observed between CRP and fibrinogen (r=0.43; P<0.001). 
However, when using cis-acting variants as highly specific and unconfounded instruments, it was 
not possible to replicate any of the 12 between blood protein associations (Figure 7.5). 
Nonetheless, all the genetic instruments proved to have a strong effect on their respective 
cognate protein for which they intended to be a proxy. This discordance provides evidence that 
perhaps most of the 12 between-protein associations identified were more likely to be explained 
by a shared association with an unmeasured factor than by a direct causal effect of one protein 
on the level of another (scenario (ii), Figure 7.1). 
Some immediate translational application of this approach is in deciding which variables (blood 
proteins) adjust for when estimating the causal effect of a blood protein of interest. For example, 
CRP showed a strong correlation with fibrinogen (r=0.43). This association could arise because of 
a causal relationship (in either direction) or because of a common association of both these blood 
proteins with another factor (see Figure 7.1). This makes it difficult to assess whether CRP and 
fibrinogen lie on the same causal pathway to CHD, and makes it difficult to know whether it is 
legitimate to make statistical adjustment for fibrinogen in the many observational associations of 
CRP with CHD (and vice versa). For example, statistical adjustment, which is the orthodox 
approach to dealing with confounding in observational epidemiology, would be appropriate only if 
the association of CRP with CHD was not mediated (even in part) by an elevation in the level of 
fibrinogen. The absence of an association of CRP pQTSNPs with fibrinogen level (or F1BA-B-G 
with CRP level) (Figure 7.5), which is consistent with the findings from Chapters 4 (Table 4.3) and 
5 (Figure 5.5) and other studies of these variants [1081 indicates that CRP and fibrinogen do not 
exhibit a direct causal association with one another and that statistical adjustment is appropriate 
in observational studies of these biomarkers with CHD. 
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Some of the limitations and advantages of the approach described here deserved to be discussed. 
First, in theory, null associations observed using this pQTSNPs-blood protein integrative 
approach might be explained by insufficient statistical power to detect downstream effect. 
Although, that could be the case in the current study that includes a few thousand subjects, 
empirical evidence from this thesis as well as other studies confirms a null association for CRP 
(see Figure 5.5) and fibrinogen SNPs with multiple other phenotypic traits [108]. This limitation, 
however, could be overcome either by increasing the sample size or by using more potent genetic 
instrument. Another limitation to be consider is the presence of an effect modification in between 
blood protein association by a third factor (blood protein or complex trait) that may be in unnoticed 
to the investigators and therefore lead to exclude wrongly the absence of a causal effect. Such as 
the scenario described for the MTHFR/C677T-Hcy association by the folate intake (see Figure 
3.1). 
It is notable that most of the associations observed between the pQTSNPs and their cognate 
protein were highly significant despite the modest size of the data set. P-values were in the range 
of x10-4 to x10-180 There are several potential reasons for this. Variation in the level of circulating 
blood proteins is a much more proximal consequence of functional genetic variation (distal only to 
mRNA expression in the case of blood proteins) and so the signal to noise ratio in these 
associations is likely to be high. As a trait, the level of a blood protein is also likely to be 
influenced by a narrower range of genes and environmental factors than more distal biomarkers 
of CHD. 
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The approach described in this chapter can also be extended to include non-protein biomarkers. 
Whereas cis-acting SNPs in the encoding gene offer the most specific genetic instrument with 
which to assess the causal role of a protein, there may not be a single best instrument for a non- 
protein trait. Instead, SNPs from a range of genes (identified by gene centric or whole genome 
analysis) may be necessary. Although the approach described here took a gene-centric approach 
and focussed common alleles and a relatively narrow range of blood phenotypes, there is no 
theoretical constraint on the scope or breadth of the approach. For example, information on 
common genetic variation could be extended to incorporate rare SNPs. The phenotypes 
evaluated could be extended both proximally to include mRNA expression and more distally to 
include more complex phenotypes linked to CHD such as carotid-intima media thickness or 
measures of coronary artery calcification. The scope and breadth of the approach could also be 
extended laterally at the level of protein and non-protein phenotypes using proteomic and 
metabolomics respectively. The identification of SNP affecting the expression of an mRNA, its 
cognate protein, a more complex downstream phenotype and the risk of a clinical event would 
result in the mapping of a causal pathway, even though each element in the trail from protein to 
disease is likely to have additional, and increasingly complex, genetic and non-genetic 
determinants. [1641 However, The SNP with its unique properties (random allocation and 
unmodifiable) would act as the dissecting tool to generate evidence on biological pathways with 
high credibility that will serve for a more efficient generation of drug-target. 
In summary, findings from this Chapter demonstrate how integrating information on genotype and 
blood phenotypes in humans, can be used to construct association networks with a high-level of 
credibility, due to the particular properties of genetic variants, which are randomly allocated and 
unmodifiable by disease process, features which are not shared by any other natural biological 
exposure 
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Chapter 8. Discussion and conclusions 
Herein the findings of this thesis are summarised. I conclude by considering this work and the 
broader perspective of Mendelian randomisation in general as an inferential instrument to distinguish 
causal from non-causal associations. 
8.1 Homocysteine and stroke 
Regarding the role of Hcy in stroke, the most comprehensive synthesis of genetic evidence generated 
to date and reported in Chapters 2 and 3 indicated that the MTHFR genetic signal on both Hcy and 
stroke is more pronounced in areas associated with a low folate intake at population level, such as 
Asia. 
Nonetheless, since it has been reported, there has been a tendency for genetic studies conducted in 
Asia, and in particular in China, to systematically report stronger genetic signals for a wide variety of 
associations. [165] Therefore, there is the possibility that part of the findings on MTHFR-Hcy-Stroke 
could suffer from such overestimation, attributed to small-study bias. [165] Importantly, when the 
evidence was limited to large studies (defined as: MTHFR-Hcy >_500 individuals and MTHFR-stroke 
>_400 stroke events), the findings of a differential effect of the MTHFR gene on Hcy and stroke by 
region of folate supplementation remained largely unaltered. In addition, the only study with more 
than 1000 cases included in the analysis was conducted in Asia. [166] Although, far from definitive, 
this provides certain optimisms in the pronounced genetic effect observed in Asian studies. 
Despite being a consistent finding, the presence of a modifying effect of MTHFR-Hcy, and MTHFR- 
stroke by geographical region acting as proxy of the folate consumption, the use of this proxy 
encompass considerable imprecision. In support of the use of geographical regions as a proxy of 
folate intake, were the meta-regression analyses which indicated that the difference in Hcy levels by 
MTHFR genotype is reduced as the concentrations of folic acid increase. The number of studies that 
participate in such analyses was however limited, it was not possible to reproduce a similar analysis 
for the MTHFR-stroke association due to the absence of necessary information. Nonetheless, the 
ideal approach to evaluate the presence of a gene-environment interaction will require the uses of 
individual participant data from a single study, large enough to provide sufficient cases, or from an 
international collaboration involving multiples studies. 
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Figure 8.1. Uses of Mendelian randomisation. Underlined are the three particular uses of Mendelian 
randomisation that were employed in this document. 
Uses of Mendelian randomisation 
1. Proxy of external exposures 
e. g. alcohol, heavy-metal Poisoning, life-time risk of infection. 
2. Proxy to evaluate trans-generational effects 
e. g. early development of chronic diseases. 
3. Proxy of internal biomarkers to provide evidence on causality 
3. a. Gene -> Direct intermediate phenotype: CRP->CRP plasma->CHD 
3. b. Gene -> Indirect intermediate phenotype: MTHFR->Hcy levels->Stroke 
4. Proxies of drug interventions: 
Instrument Molecule target Outcome Potency 
Gene: Lp-PLA2 gene Lp-PLA2 enzyme CHD Small 
Drug: Lp-PLA2 inhibitor Lp-PLA2 enzyme CHD Large 
S. Dissection of biological pathways 
Although the genetic evidence is encouraging regarding a possible causal effect of Hcy in stroke, 
particularly in populations with low levels of folic acid consumption, genetic studies do not provide 
evidence on the reversibility of the risk that is associated with the exposure. Such evidence when 
possible, should come from randomised interventions. Evidence published to date on trials using Hyc- 
lowering interventions is almost entirely based on Europe, America and Australia, regions for which (if 
genetic studies are unbiased) the expected benefit for Hcy-lowering interventions is small or 
negligible. In contrast, no large trials using Hcy-lowering therapies is being conducted in areas with 
folic acid deficiency, despite genetic evidence (if free from bias) suggesting that the benefit is likely to 
be greater. 
Discussions of the differences between the randomised trials and genetic studies with particular 
emphasis to the Hcy-stroke example were presented in Chapter 3. A more general discussion of the 
differences between genetic studies and trials is provided in the section 8.5 of this Chapter. 
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8.2 CRP and cardiovascular disease 
Despite more than a decade of epidemiological studies and perhaps several more from incorporating 
basic scientific research focussed on CRP, its functions and the nature of its associations with 
cardiovascular disorders still remains to be established. 
The findings from Chapters 4 and 5 confirmed the multiplicity of associations of plasma CRP, not only 
with established, but also with emerging risk factors in CVD that restrain the utility of classical 
observational epidemiology to evaluate the nature of its associations. [1671 Other strategies to 
complement the observational evidence would therefore be ideal, see Figure 8.2. 
Figure 8.2. Strategies often used to investigate the causal role of a biomarker/exposure in disease 
development and the applicability of such strategies for the case of CRP. APR: Acute phase 
reactant. RCT: randomised clinical trial. 
Strategies to evaluate the role of CRP in CHD development 
Approach Limitation CRP 
Manipulation in vitro 
Genetically modified strain 
Human mendelian disorder 
RCT 
Isolated system 
Extrapolation to human 
disease 
Requires specific drug 
No known receptor 
CRP not an APR in mice 
None described 
None until recently 
As described in Figure 8.2 however, such additional strategies, in the case of CRP, are absent or of 
poor utility. [115] A genetic approach therefore offers a unique opportunity to evaluate the role of CRP 
while overcoming the limitations from observational epidemiology. Findings from a Mendelian 
randomisation applied to plasma CRP, whether using a single-variant or a tagging-haplotype from the 
CRP gene were generally concordant. Apart from the effect on its cognate protein (plasma CRP), no 
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single association was observed either for the CRP-variant +1444/C>T or for the CRP tagging- 
haplotypes. Since CRP is a protein with a gene that encodes for it, the utilisation of this gene, CRP 
(described in Chapter 7 as a pQTG) is therefore the most specific instrument that could be used to 
distinguish causal from non-causal associations of plasma CRP. This CRP example lies in the 
category of gene-direct intermediate phenotype (Figure 8.1) from the uses of Mendelian 
randomisation, and contrasts with the example of MTHFR-Hcy-stroke which lies in the category of 
gene-indirect intermediate phenotype. 
There are several possibilities that may explain the null effect of the genetic approach used for CRP. 
Firstly, the selected genetic instrument may not confer a sufficient difference in the concentrations of 
CRP. However, the effects on CRP concentrations of the CRP variant +1444/C>T (0.68 mg/L for TT 
vs. CC-genotype) and those from a CRP tagging-haplotype (42% relative difference for CGG vs. 
CAT-haplotype) confirmed the adequate selection of tools. These findings have received support from 
published studies evaluating individuals of European ancestry. [68] Secondly, the existence of a 
gene-environment interaction, that if not averted, may reduce or abolish the presence of a genetic 
signal. The observational evidence on CRP does not however support the existence of a gene- 
environment interaction. This scenario contrasts with that observed for the MTHFR-Hcy-Stroke 
example. Thirdly, a false negative result due to limited power to detect a small but causally important 
effect of CRP in cardiovascular disease. Results from this document (Chapters 4 and 5), plus the 
available evidence from several CRP-genetic studies, now including several thousands of CHD 
events indicates that this is perhaps unlikely. [111,112,114,122,123,168,169] However, the 
undergoing effort of the CCGC collaboration, which will include over 30,000 CHD events and 110,000 
controls using individual patient data will provide a unique opportunity to confirm or refute CRP as 
valid drug target for CHID. [1101 
8.3 Lp-PLA2 and CHD 
Findings from the Chapter 6 showed a graded and continuous association of Lp-PLA2 activity with 
CHD. The existence of multiple associations of Lp-PLA2 activity with cardiovascular risk factors 
however limits the utility of observational studies to infer a causal role on CHID. Randomised trials 
using a specific Lp-PLA2 inhibitor (darapladib) are underway and will be the final arbiter to evaluate 
the reversibility of the risk associated with Lp-PLA2 from observational studies. 
However, as way to increase the confidence in the Lp-PLA2 inhibitor, and reduce risk of a possible 
failure in phase-III trials, I presented how to use a genetic approach to evaluate the validity of a drug 
target. For this, I utilised the Lp-PLA2 gene (known as PLA2G7) to evaluate the utility of the Lp-PLA2 
enzyme as a valid therapeutic target. This example lies in the category of proxies of drug intervention 
from the uses of Mendelian randomisation (Figure 8.1). 
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This new extension of Mendelian randomisation will only be possible when the intervention and the 
gene, target the same molecule (numeral 4, Figure 8.1). Since these two instruments, also, share the 
characteristic of being randomly allocated (drug by trial randomisation process and gene due the 
Mendel's 2nd law) a "like with like" comparison is generated. However, a main feature that 
distinguishes these two approaches is the difference in the potency of their instruments (drug vs. 
gene) to modify the target molecule, Lp-PLA2 enzyme. While a dose of 160 mg of the Lp-PLA2 
inhibitor darapladib reduced the Lp-PLA2 activity by 66%, the best of seven common tagging-SNPs of 
the PLA2G7 gene (rsl051931) only reduced Lp-PLA2 activity by 7%. Yet, despite the differences in 
potency, neither the Lp-PLA2 inhibitor nor the genetic variant modified the concentrations of lipid 
particles. These findings contrast with the associations of Lp-PLA2 activity with lipid particles from 
observational studies. 
This gene-drug approach for Lp-PLA2 nonetheless serves to highlight two practical issues to be 
considered when conducting this analysis. Firstly, to consider the utility of gene-resequencing for the 
detection of rare variants with a greater genetic effect that could be used to mimic the effect of the 
intervention of interest. Secondly, the use of other ethnic groups with genetic variants (not present in 
European descent individuals) that possess an adequate genetic signal, such as the V279F variant 
in the PLA2G7 gene detected in subjects from Chinese and Japanese ancestry. 
8.4 Mendelian randomisation and biological pathways 
As described throughout this document for the Hcy, CRP, and Lp-PLA2 examples, the judgment of 
the nature of the multiple associations of these three biomarkers with other established and emerging 
risk factors is a challenging issue. The current strategy (non-randomised observations mainly from 
laboratory research in animals, cell and tissues) used to establish the nature of these associations is 
also prone to important biases (Figure 7.1). The magnitude of this problem, distinguishing causal from 
non-causal associations, is expected to grow exponentially with the development and refinement of 
OMICs technology. 
Capitalising on the unique properties of allelic variants (randomly allocated, unmodifiable and being 
the initial point of a unidirectional flow of information; see Figure 7.2), they are ideal instruments to 
distinguish causal from non-causal associations and therefore dissecting biological pathways that will 
finally lead to a more effective process of drug-target discovery. To describe a basic proof of principle, 
I focused on six blood proteins and utilised the most specific genetic instruments, cis-acting variants 
in gene encoding the blood protein of interest (pQTSNPs). 
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Findings from Chapter 7, also provide an immediate translation, which is to inform observational 
epidemiology if it is or is not appropriate to adjust for blood proteins when evaluating their role in 
disease development. The topical example of CRP, fibrinogen and CHD was utilised to exemplify this 
benefit. 
The theoretical limitations of this approach are not that different to those already described for 
Mendelian randomisation experiments (e. g. canalization, interactions, large-sample sizes). [22,23] 
Whilst, I restricted this approach to blood proteins, it could be applied to non-single protein, such as 
lipid fractions and metabolites, although the specificity of the gene-variant as a dissecting instrument 
would not be as high as it was in the pQTSNPs-cognate protein examples presented in Chapter 7. 
The breadth and depth of this genetic strategy to map biological pathways in humans will growth 
exponentially when current observational studies start to obtain information at large-scale on other 
biological levels, such as mRNA from micro-arrays, protein levels from proteomics or protein activity 
from metabolomics. It is envisaged that methodological developments will be necessary in order to 
exploit the maximum potential of this approach, especially when the different levels of biological 
information are considered to be integrated with one another. 
8.5 Mendelian randomisation as an inferential instrument 
Finally, I would like to conclude this document with a more general discussion of the Mendelian 
randomisation approach as an additional inferential instrument to those already in place for obtaining 
evidence on disease aetiology. 
Firstly, although the biomarker-outcome associations utilised as examples in this document may 
suggest a futility of observational epidemiology in providing evidence on causality, due to reverse 
causation and residual confounding, I would like to clarify that this will not necessarily be the case for 
all exposure and diseases as illustrated in Figure 8.3. The location of the exposure under 
investigation on the axis of randomness will subsequently affect its location on the axis of 
confounding. An exposure located in the extreme left of the axis of randomness (e. g. being 
vegetarian) indicates that to be allocated to that exposure (or the probability of acquiring this 
exposure) is far removed from being a random process, therefore the probability of confounding is 
extremely high. In consequence, results from an observational study investigating this exposure will 
have very low levels of credibility. On the contrary, in the extreme right appears an intervention used 
in randomised trial, a totally random process with very low (or almost absent) probability of 
confounding to occur. Thus, the credibility of these experiments is of the highest. This simplistic 
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example illustrates the fact that not all exposure-outcome associations using an observational design 
are precluded as an instrument to infer causation. Thus, Mendelian randomisation should be 
conceived as an "additional" instrument to infer causation, with certain scenarios (exposure-outcome 
association) in which its application will have greater benefits than others. 
Figure 8.3. Schematic representation of the utility of a genetic approach as an inferential instrument 
to distinguish causal from non-causal associations. 
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Secondly, although Mendelian randomisation experiments use the most personalised characteristic 
(genetic background), the inference on causation achieved by this approach are for all the individuals 
in a population regardless of their genetic background (Figure 8.4). Therefore, if (hypothetically) Hcy, 
is proved to be causal using a genetic approach, the benefit will be obtained through the well known 
strategies for prevention of disease: a population approach, high-risk approach (often with 
medications) or both in all individuals regardless of their genetic background (Figure 8.4). 
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Figure 8.4. Schematic representation of the inference obtained from Mendelian randomisation 
experiments in terms of the strategies for disease prevention. The x axis shows the Hcy 
concentrations in a hypothetical population. The right y axis shows the risk of disease (log-scale). The 
left y axis is the probability density. Light grey is the Hcy distribution in a population for subjects with 
CC-genotype of the MTHFR/C677T variant. Dark grey is the distribution of Hcy for subjects 
heterozygous and in black the Hcy distribution for subjects with TT genotype. This figure is a 
modification from that originally described by Prof. Geoffrey Rose in "Strategies for Disease 
Prevention". 
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Thirdly, it has been mentioned repeatedly throughout this document the similarities of genetic studies 
with randomised clinical trials, but there are some important issues that merits further discussion (see 
Figure 8.5). In particular I will mention several potential scenarios in which these two strategies may 
arrive at different results. For this I will assume that the sample size in both trials and genetic studies, 
as well as the potency of the genetic variant, are not an issue for consideration. 
Scenario-1 (trial-null and genetic-positive): randomised clinical trials are designed to test the efficacy 
(and safety) of an intervention (e. g. statins) on an outcome (e. g. CHD risk) and by inference provide 
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evidence on the reversibility of the risk associated to the exposure they intend to modify (e. g. LDL- 
cholesterol). In contrast, gene studies are by nature studies that evaluate the potential causality of a 
risk factor, but not the possibility of reversing the risk associated with the exposure. Thus, if a given 
risk factor is causal but not reversible, the trial and the genetic studies will obtain different findings. 
Scenario-2 (trial-null and genetic-positive): genetic studies can be conceived as lifetime randomised 
interventions contrasting with randomised clinical trials which often last for 5 years. Therefore, the 
benefit of certain interventions, in theory, may become more evident after longer periods of use. 
Figure 8.5. Schematic representation of the parallels and differences between genetic studies and 
randomised clinical trials. 
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Scenario-3 (trial-null and genetic-positive): randomised clinical trials are designed to test the efficacy 
and safety of an intervention. A wrong selection of the intervention may render the trial null and in the 
meantime the genetic study may give a positive result. Such could have been the scenario observed 
in the 1980's when available interventions to modify cholesterol were ineffective and their associated 
(using these interventions) were null. [170] In contrast, the genetic evidence from individuals suffering 
from familial hypercholesterolemia indicated the opposite. [221 
Scenario-4 (trial-positive and genetic-null): even if a risk factor is causal, a genetic study may be null 
due to the process of canalization or compensation that may occur between the actual moment of 
randomisation (gamete formation) and the experiment commencing (often several decades later), see 
Figure 8.5. In contrast, the randomised trial will give a positive result. 
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Summary 
Background Individuals homozygous for the T allele of the MTHFR C677T polymorphism have higher plasma 
homocysteine concentrations (the phenotype) than those with the CC genotype, which, if pathogenetic, should put 
them at increased risk of stroke. Since this polymorphism is distributed randomly during gamete formation, its 
association with stroke should not be biased or confounded. We investigated consistency between the expected odds 
ratio for stroke among TT homozygotes, extrapolated from genotype-phenotype and phenotype-disease studies, and 
the observed odds ratio from a meta-analysis of genotype-disease association studies. 
Methods We searched MEDLINE and EMBASE up to June, 2003, for all relevant studies on the association between 
homocysteine concentration and the MTHFR polymorphism, and until December, 2003, for those on the association 
between the polymorphism and the risk of stroke. Pooled odds ratios and 95% Cl were calculated by random-effects 
and fixed-effects models. Consistency between expected and observed odds ratios was assessed by interaction test. 
Findings 111 studies met the selection criteria. Among 15 635 people without cardiovascular disease, the weighted 
mean difference in homocysteine concentration between TT and CC homozygotes was 1.93 pmol/L (95% CI 1.38 to 
2.47). The expected odds ratio for stroke corresponding to this difference based on previous observational studies 
was 1.20 (1.10 to 1.31). In our genetic meta-analysis (n=13 928) the odds ratio for stroke was 1.26 (1.14 to 1 . 40) for 
TI' versus CC homozygotes, similar to the expected odds ratio (p=0.29). Consistency between the odds ratios was 
preserved in analyses by age-group, ethnic background, and geographical location. 
Interpretation The observed increase in risk of stroke among individuals homozygous for the MTHFR T allele is 
close to that predicted from the differences in homocysteine concentration conferred by this variant. This 
concordance is consistent with a causal relation between homocysteine concentration and stroke. 
Introduction 
Stroke is the third most common cause of death in more 
developed countries. ' About 80% of strokes are 
thromboembolic (ischaemic) in origin and the 
remainder are haemorrhagic. '-' In the UK, stroke is the 
largest single cause of severe disability with more than 
125 000 incident strokes and about 60 000 deaths due to 
stroke each year. ' Because treatments for stroke are 
limited, the best approach to reduce mortality and 
morbidity is primary prevention through modification of 
acquired risk factors (eg, high blood pressure, smoking, 
diabetes, and atrial fibrillation). ' 
Data from cohort and case-control studies suggest that 
a raised circulating concentration of homocysteine is 
associated with a higher risk of stroke. 4-6 However, 
homocysteine concentration is also related to smoking 
status, blood pressure, and social class and is higher in 
people with existing atherosclerosis than in those 
without. '-' Therefore, this relation could be subject to 
residual confounding, reverse-causality bias, or both. ' 4 
A common functional polymorphism, C677T, in the 
gene encoding methylenetetrahydrofolate reductase 
(MTHFR), an enzyme involved in homocysteine 
metabolism, has been associated with differences in 
hornocysteine concentration. d910 Since carriage of this 
variant is subject to the random assortment of maternal 
and paternal alleles at the time of gamete formation, 
according to Mendel's second law" associations between 
MTHFR genotype and hornocysteine concentration or 
stroke should not be subject to reverse-causality bias and 
should also he largely free from confounding by other 
determinants of homocysteine concentration or risk 
factors for stroke. ' Moreover, genotype is a fixed 
characteristic, so there is unlikely to be regression- 
dilution bias, which results from measurement error 
and biological variability of the exposure under 
assessment and leads to underestimation of the. associa- 
tion between a risk factor and disease. "" Therefore, if 
homocysteine increases the risk of stroke, carriage of the 
MTHFR polymorphism that exposes individuals to an 
increased homocysteine concentration should confer an 
increased risk of stroke proportional to the difference in 
homocysteine concentration attributable to variant and 
to the relative risk observed in non-genetic observational 
studies. 
The investigation of consistency between risk esti- 
mates obtained from genotype-disease studies and 
those from phenotype-disease studies, to provide 
insight into the nature of the observed associations, has 
been referred to as "mendelian randomisation". -" This 
approach has been used to test the nature of the 
association between homocysteine concentration and 
coronary heart disease, venous thromboembolisrn, and 
stroke. 49 However, in the previous genetic analyses of 
124 
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the MTIIFR polymorphism and stroke, the number of 
available studies was small. Also, information on the 
relative effect of the MTHFR polymorphism on 
hornocysteine concentration in different geographical 
locations, ethnic groups, and age-groups was limited. ' 
Demonstration that homocysteine concentration is 
causally related to the development of stroke would have 
important implications in primary prevention, because 
administration of folic acid is known to lower 
hornocysteine concentrations, " and a policy of 
fortification of cereal with folic acid to lower the 
incidence of neural-tube defects has already been 
undertaken in North America. 
We have carried out two updated and comprehensive 
meta-analyses. In the first, we investigated the extent to 
which hornocysteirne concentrations are determined by 
the MTHF R C(771' polymorphism. We also assessed the 
effect of pre-existing cardiovascular disease, geograph- 
ical location, ethnic background, and age on this 
association. In the second meta-analysis, we estimated 
the odds ratio of stroke conferred by the 'l'l' genotype. 
Our meta-analysis of MY HFR C677T polymorphism and 
ho mocysteine concentration includes data from 48 more 
Studies than a previous meta-analysis' and extends the 
observation: to people without cardiovascular disease. 
Our meta-analysis of the M 1'11FR 0677 l polymorphism 
arid stroke includes data from 23 more studies than the 
previous meta-analysis' and assessed the robustness of 
the results by sensitivity analysis. 
reviewed journals. For duplicate publications the smaller 
dataset was excluded. 
For inclusion in the meta-analysis on M'THIR and 
stroke, studies had to involve unrelated individuals and 
to examine the associations between ischaernic or 
haemorrhagic stroke and the presence of the polymor- 
phism. For the main comparison, only studies published 
as full-length articles or letters in peer-reviewed journals 
in English were included. However, to assess the 
robustness of the association, we did a sensitivity 
analysis that included silent brain infarction as an 
outcome, non-full-text papers, and papers published in 
languages other than English. In all searches, when 
relevant information was not reported or there was 
doubt about duplicate publications, we contacted the 
authors to obtain the required information. 
Data extraction 
Data for analysis (country of origin, study design, mean 
age of participants, frequency of genotypes and alleles, 
homocysteine and folate concentrations, ethnic back- 
ground, and frequency of cardiovascular risk factors) 
were extracted and entered into databases by two of us 
(JPC and PS). The results were compared and disagree- 
ments resolved by consensus. 
Statistical analysis 
We obtained a summary estimate of the effect of raised 
plasma homocysteine concentrations on risk of stroke 
from a recently published meta-analysis by Wald and 
others of eight prospective studies, which included 
676 stroke cases, mainly ischaernic in aetiology, in 
white people, carried out in European and North 
American countries. ' In that analysis, a difference of 
S µmol/L in plasma homocysteine was associated with 
an odds ratio for stroke of 1.59 (95% Cl 1 . 29 to 1.96) 
adjusted for confounding variables and for regression- 
dilution bias. ' We did a meta-analysis to obtain the 
weighted mean difference in plasma hornocysteine 
concentrations between individuals homozygous for 
the T allele and those homozygous for the C allele. The 
weighted mean difference was obtained separately for 
people with and without known cardiovascular disease 
(ischaernic heart disease, stroke, or venous thrombosis) 
and for both groups combined. For these analyses, a 
random-effects model" was used to allow for any 
heterogeneity across studies. Estimates of the weighted 
mean difference were obtained for different age- 
groups, by geographical location, and by ethnic 
background. We then did a second meta-analysis of all 
published studies to obtain a summary odds ratio for 
all strokes for individuals homozygous for the T allele 
compared with those hornozygous for the C allele. 
Fixed-effects summary odds ratios and 95% Cl were 
calculated by the Mantel-Haenszel method, '" and 
DerSimonian and Laird's method" was used to 
calculate random-effects summary odds ratios and 
Methods 
Two electronic: databases (Mhl lNl and EM RASP. ) were 
searched up to June, 20)3, for all studies on the 
association between the MTHFR 06771' polymorphism 
and homocysteine concentrations and up to December, 
2O03, for studies on the association between the MTHFR 
0(771' polymorphism and stroke. For the first search, we 
used the text words, which were also McS}I terms, 
1, polyrncrrphisrn", "mutation", "genes", and "cardiovas- 
cular disease" in combination with "homocysteine". For 
the second search, the terms used were "stroke", "brain 
infarction", "cerebral isch(a)emia", "h(a)emorrhagic 
stroke" and "silent brain infarction" in combination with 
4 genetic", "polyrnorphisrn", "mutation", or "genes". Both 
literature searches were limited to "human" and "English 
Ianguage". We searched for any additional studies in the 
references of all identified publications, including 
Previous relevant meta-analyses . 
4. B, 16 
Selection criteria 
For inclusion in the meta-analysis on homocysteine 
concentrations and the MTHFR polymorphism, studies had to have an analytical design (case-control, cohort, or 
Cross-sectional) and had to examine the association between homocysteine concentrations and the polymor- 
Phism. Studies were included only if they were 
Published as full-length articles or letters in peer- 
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their 95% Cl. Also, to test the robustness of our 
findings, we calculated different odds ratios according 
to outcome (ischaemic stroke confirmed by MR1 or CT, 
haemorrhagic stroke, or silent brain infarction), ethnic 
background (white and non-white), publication 
language (linglish and other), and type of publication 
(full text or abstract). 
We used the DerSimonian and Laird Q test"' to assess 
the degree of heterogeneity between studies, and funnel 
plots and hgger's regression asymmetry test to assess 
small-study bias, of which publication bias is one 
potential cause. " In addition, the influence of individual 
studies on the summary odds ratio was investigated by 
re-estimation and plotting of the summary odds ratio in 
the absence of each study. Meta-regression was used to 
assess the extent to which different variables explained 
heterogeneity in the weighted mean difference and in 
the surmnary odds ratios. ' Hnally, we used the weighted 
mean difference in homcxystcinc concentration by 
MT111 R (6771' polymorphism to estimate an expected 
increase in the risk of stroke assuming that an increase 
of S µrnol/l, in plasma hornocysteine would be associ- 
ated with an odds ratio for stroke of 1- 59 (1-20--l . 96) 
and that this association follows a log-linear relation. ' 
'Pie uncertainty surrounding the expected odds ratio is a 
function of the variability of the weighted rrrcan 
difference in homocysteine by genotype and the 
variability of the summary odds ratio from Wald's meta- 
analysis' arid cannot be directly calculated. 't'herefore, to 
obtain a 95% CI for this odds ratio, we generated a 
million values from a normal distribution with mean 
and SI) equal to the weighted mean difference and its 
Slh, and a million values from a normal distribution with 
mean and SI) equal to the natural logarithm of the 
summary odds ratio from Wald's meta-analysis' and its 
5k (calculated from its 95% CI). We used the simulated 
values to calculate a million estimates of this odds ratio 
and took the 2.5% arid 97.5% centile values of the 
created empirical distribution as 95% confidence limits. 
Then the expected odds ratio was compared with the 
summary odds ratio obtained from the meta-analysis of 
genetic studies by means of an interaction test. " 
Consistency between the two odds ratios would indicate 
that the association between plasma homocysteine 
concentration and stroke seen in non-genetic 
Results 
The primary search for studies on hotnocysteine and the 
MTFIFR C677T polymorphism generated 104 
potentially relevant studies (see webreferences, nurn- 
bered wl-w145, at http: //itnage. thelancet. cotri/extras/ 
03art11437webreferences. pol) of which 81 met the 
selection criteria (wl-w81). Of the 23 articles excluded, 16 
(w82-w97) did not provide sufficient data for us to 
calculate the weighted mean difference between the 
genotypes, and the relevant information could not be 
obtained from the authors. Two (w98, w99) were 
discarded as probable duplication, and five (w1(X)-wI 04) 
reported only the homocysteine concentrations for `I'l' 
homozygotes and C-allele carriers but not for the CC 
genotype alone. 
Of the 81 studies included (31 355 individuals), 
information for the main comparison ('I'l' vs CC 
genotype) was available for 15 635 people without 
known cardiovascular disease, 6312 with cardio- 
vascular disease, and for 9408 reported only as the 
combination of individuals with and without cardio- 
vascular disease. 
Among individuals without cardiovascular disease 
(webreferences wl-w41), the weighted mean difference 
in plasma homocysteine between those homozygous for 
the'I allele and those homozygous for the C allele was 
1 -93 µrnol/l. (95% CI 1 -38 to 2.47; p<O. 0001, figure 1). 
'T'here was significant inter-study heterogeneity (p for 
heterogeneity <0.0001). l'rorn the variables examined 
in a meta-regression analysis, the only major source of 
heterogeneity detected was the mean concentration of 
serum folate. The weighted mean difference in plasma 
homocysteine concentrations comparing the `I'T and CC 
genotypes was 0.048 µrnol/L less for each 1 nmol/1, 
increase in mean serum folate (p-) 035). 't'he weighted 
mean difference in homocysteine concentration was 
lower in studies done in North America than in those 
done in Europe or other continents (table 1). 
Conversely, the weighted mean serum folate concentra- 
tion was higher in North American (25 .3 nmol/L (7.3 
to 43.3j) than in huropean studies (13.6 nmol/L X11 .4 
to 15.60 and those conducted in other continents (15.3 
nrnol/L 19.0 to 21-61). No other sources of hetero- 
geneity by age (p=0.94), ethnic background (white vs 
other; p=0.62), smoking status (p=0.41), or sex 
(p=0- 57) were observed in a meta-regression analysis of 
studies in which these variables were reported. 
The distribution of the weighted mean difference in 
relation to its SD in the funnel plot was symmetrical, 
and the result of Egger's test was not significant 
(p=O. 72) providing no positive evidence for small-study 
bias. Visual assessment of a graph of the individual 
weighted mean difference for each study showed that 
none of the studies had an undue influence on the 
overall weighted mean difference. 
Among people with cardiovascular disease (w2, w4, w7, 
w11, w16, w21, w26, w27, w29, w32, w37, w39- wSS), the 
epidemiological studies is unlikely to be severely 
affected by residual or reverse-causality bias. Data were 
analysed by use of the Review Manager software (version 
4.2) from the Cochrane Collaboration 2003 and Stata 
(version 8.0). 
Role of the funding source 
No funding source had any role in study design; 
collection, analysis, or interpretation of data; or the 
writing of the report. All authors had full access to all the 
data in the study, and all took full responsibility for the 
decision to submit the paper for publication. 
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Figure 1: Weighted mean differences in plasma homocysteine concentration according to the MTHFR C677T genotype (TT vs CC) among people without 
known cardiovascular disease 
Iorwebretwr'rxes%(-vhttp: //image. thelancr'tcorfextras/03 art 11417webreferences. pdf. I hetotal number of people without known orrdiovas ular disease included 
in thi" meta analysis was 1S 63S (11 18R/, (16496, CC 7752). 
mean hornocysteine concentration was 4.35 µrnol/l. 
(3.22 to S- 41); p<O " (XX)1) higher for those homozygous for 
tF1 i allele than fror those hornoiygous for the C allele. A 
ºnc ta"regressirm analysis indicated that the greater 
difference in homo cysteine by genotype among people 
with cardiovascular disease was explained partly by lower 
serum feýlate concentrations (the crude 13 co eiºci(, nt for 
disease status was 3.04; after adjustment for serum folate 
it was 2.73). 
When the data from all studies, including those that 
investigated individuals with and without cardiovascular 
disease without distinction, were combined (wl-wXl), 
the weighted trx"an difference for homozygotes for the 
'I' allele against ho)rnozygotes for the C allele was 
3.10 µmol/l, (2.54 to 3.65; p<O (X)01). 
According to a previous meta-analysis of prospective 
studies, ' a plasma hornocysteine concentration higher by 
5 µmol/I. corresponds to an odds ratio for stroke of 1- 59 
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Numberof Number Weighted mean p 
participants of studies difference, µmol/L 
-- -- - 
(9S% (I) 
--- - 
All %Iudu's 9139 43 1.93 (1-38 to 7.47) <0.0001 
Ethnic background 
Whit, ('948 3) 196 (1.41 to 2.51) '0 W01 
rnh, i 2191 11 1.83 (0 "to 3.09) 0.004 
Mean age 
40yr"dnuroldk't 8515 3b 196 (146 to 2.47) <O M01 
I- Iturl40yr"ars 564 7 166(00 3 31) ()(N, 
Geographical location 
I <top" /0 31 26 2.04 (1 4S to 2.64) <o-(Y )1 
NorthArrr'f%a 1071 8 0.57(-0.28 to 1.42) 0.19 
Other (ontin nts 1081 9 797 (1.72 to4.22) <0-0001 
European and 7742 79 1-84 (1.29 to 2 39) <0.0001 
North American, 
mean age 40 years 
or older 
White people 6747 29 1.95 (1 39 to 2.51) <0-(X)01 
twin aw 40 
yl", u. T I. Ililr"i 
Table 1: Weighted mean difference in plasma homocysteine 
concentrations according to the MTHFR C677T genotype (TT vs CC) 
among people without cardiovascular disease 
(1 "29 te> 1 . 96). A 
difference in h(>rnocystvine 
cemccnlratiem of 1 "9.1 µrne>I/I. (1 - *48 te> 2.47) in 
healthy 
individuals with Ihc'I'I' genotype would therefore result in 
an expected , Kid., ratio for stroke of 1 20 (1 "11) to 1 "31) 
e (>rnpared with individuals homozygous for the C. allele, if 
the ass>>ciatie>n I>c"twc"Vn he>m>x-ysteine and risk c>f stroke 
f(>II>>ws a 1>g-linear relatiem (tal>k" 2), and is free from 
re>nfenmding and reverse-causality bias. l xpe"ded (Kiels 
ratio-,, f(ir streike derived from dine-re na"s in he>rno ysteitic 
by genotype in all individuals without cardiovascular 
disease, and also separately by ethnic background, 
g>-ogjaphiral Ioxation, and mean age are summarised in 
table, 2. 
( )f the 49 potentially relevant studies identified in the 
primary search for the meta-atralysis on the MII II R 
(; 677I' p lynurrphisrn aril stroke, i0 met the sclecticm 
criteria (w40, w47, w5i, w59, w71, wl05-w]28). Of the 
19 articles excluded for the purpose of the main 
> utnrarison, three (w129-wl il) were rnl>lishe el in non- 
Expected odds ratio for stroke Observed genetic odds ratio pt 
(95%(I)" (95% (I)t 
Main comparison 
AII0nu^. 1 )II(1111In1 31) 1'( /1 to 14u) rt; rl 
Secondary comparisons 
St ttifi wit I x-. v ,it p- 4oynars or (AtI)0 (1.101u 1.111) 1.16(114 Irr 140)S 0311 
Imop. rr lN, ohArni-ii, tooly 11/(1,04trr1)/) 111(1LU)Irr141) l) I/ 
WlIII, "J)", Jilt- oIlly 1)0(110A, 1 31) 1.19 (10) tu 1 39) 1r 1) 
MIisiklsfat 1,6ate hasen on rr nparlsrals d 11 v. ICgenayprs 'n(ktstat mwere raknlalenlonly tot lrxlNldllalswit hout 
rartliovasrulardisease Meanrxtx"rtedoddsrationwere rakulaledwith the lorntula expected cxklsratio 1 S9raisedtothe 
pimerol d/,, whered wrx1hlwI nr"an dittererxein Iwmrxysteinl" bygrrnrrylx", mit he as+umpkmthat a5 trntdIL increase in 
homncystelneisass'xiatedwith anraidsratiufrxstrokerd 1 59'tOdMtat iosobtainedfromIhe meta analysis of 
yrrruylx' disease asxxlalrm %I IKII's (AM I NI I 161/1 and sl tribe It a the tomparisun by use of an interau mit test St he 
welghted rnean aqr was 5(1 yr'a n t,,, , 'n,. s and SI yr'ars tar o Hit mh 
Table 2: Assessment of consistency between odds ratios derived by extrapolation from 
phenotype-disease studies and those derived from meta-analysis of genetic studies 
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English journals, two (w132, w133) reported the 
outcome silent brain infarction, and five (w134-w138) 
were published only as abstracts. 'I'hough excluded from 
the main comparison, these studies were used in a 
sensitivity analysis. Of the remaining nine publications 
excluded, five studies (w62, w139-w142) encompassed 
some duplication. Pour (w103, w143-w145) did not 
report the genotype frequency, and the relevant 
information could not be obtained from the authors. Of 
the 40 studies (a total of 6324 cases and 7604 controls) 
included, 19 were in white people, ten involved Asian 
participants, and one included both white individuals 
and people of Afro-Caribbean origin. 
The summary odds ratio, under a fixed-effects model, 
indicated that individuals with the 'I'I' genotype 
compared with those homozygous for the C allele had an 
Odds ratio for stroke of 1.26 (1-14 to 1.40; p<O "(N)01; 
figure 2). 'liiere was significant heterogeneity among the 
results of individual studies (p for heterogeneity=0.034). 
A sensitivity analysis showed that the study by Morita 
and colleagues (w47) was the main cause of the 
heterogeneity. After exclusion of this study, the 
heterogeneity was no longer significant (p=0.32) but the 
estimate of the overall effect changed very little and 
remained significant (odds ratio 1- 20 11 -08 to 1 "34); 
p=0.0006). Similarly, a random-effects model that took 
into account the variability within and between studies 
resulted in a similar overall estimate (1 "2( 11 . 07 to 
1 . 47); p=0.004). A meta-regression analysis showed that 
ethnic background (white vs other, p=0-23) and the 
presence of risk factors such as age (p=)" 38), sex 
(p--4). 46), hypertension (p=0-15), smoking (p=0.43), 
and diabetes (p=11.10) were not significant sources Of 
heterogeneity in a group of 20 studies (w47, w53, w59, 
w105, w108, w109, w1l1, wl16-w127) with infnrrnation 
on all these variables. 
'I'll(, distribution of the adds ratio in relation to its SD 
in the funnel plot was symmetrical, and the result of 
Jigger's test was not significant (p=0.32) providing no 
positive evidence of small-study bias. No individual 
study had an undue influence on the summary odds 
ratio. A sensitivity analysis showed a robust association 
between the M'1'1II-I (6771' pc)lyrnorphisrn and stroke 
(figure 3). No significant changes in the summary odds 
ratio were detected after addition of studies published in 
languages other than English (w129-w1 31) or in abstract 
form (wl 34-w138), or those that used the outcome silent 
brain infarction (w132, wl33). Similarly, no differences 
in the summary odds ratio were observed when the 
'ý. 
analysis was restricted according to ethnic background 
or to studies in which the outcome was solely ischaetnic 
stroke (figure 3). Data from five studies (w106, w110, 
will, w118, w129; 611 cases and 240S controls) for 
which information was available on the association of 
the M'171FR 06771' polymorphistn and haemorrhagic 
stroke (l'l' vs CC) gave a summary odds ratio of 1-16 
(0.90to 1" SO; p=0.25), under a fixed-effects model. 
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Estimates of odds ratios for 'l"I' homozygous 
individuals in comparison with those who had the CC 
genotype, extrapolated from the genotype effect on 
homo ysteine and the homocysteine-stroke association, 
were mathematically very similar to those fron our 
genotype-disease meta-analysis (table 2). 'I'he p value for 
interaction for the main comparison of the study, the 
non-genetic and genetic odds ratios for stroke in 'I'I' 
versus CC individuals, derived from all the data, was 
11.29. 'Ilierefore, there was no evidence of a significant 
difference between the expected odds ratio estimated 
from the increment in the hornocysteine concentrations 
by genotype- (M I I11 R C6771) and that observed from 
the genotype-disease meta-analysis. Moreover, no sig- 
nificant differences between estimated odds ratios were 
observed when similar comparisons were done among 
more ht>tn4>geneous groups defined by geographical 
location, ethnic background, or mean age (table 2). In all 
the comparisons, the expected odds ratios were within 
the 95% CI of the corresponding observed odds ratio 
obtained from the genetic association studies. 
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Discussion 
the main finding of these tneta-analyses was that the 
odds ratio for stroke conferred by the MT111 K 'I'I' 
gene>tyTx" was similar to that e"stimate"d by use of the- 
honiocysteine difference by gem )type and In mccysteine- 
strokce odds ratio, from phenotype-disease studies. 
Indeed, aller c"xelusic>n of the study of Morita and 
e<>Ileat; ues (w47) which was the cause of much of the 
heterogeneity in the genotype-strukce analysis, the 
sunitnary cxlds ratii> for the M'I'l IFR 'I'I' genotype was 
1 "LO (95% (; I 1 "OS to 1" 4), identical to the predicted 
e"f ect of the T(>lynu>rphisrn estimated from the studies of 
gent type-hc>tnocyste"ine differences and horncxyste"ine- 
stroke risk. Because of the random allocation of genotype 
in advance of disease development, these results imply 
that the ii latiun I twc"e"n hutn()ystceine" concentration 
and Stroke seen in phe"nuype-disease studies is not 
subject to substantial residual confounding or reverse- 
causality bias. Thus our study provides evidence for a 
tole for hc>rnocysteine in stroke pathugvnesis. 
Our first meta-analysis of studies examining the 
association between hurncxyste"irne cc>nceentration and 
MTI IFR genotype, involving m >rce than 31 (XX) people, 
allowed us to refine the size e"stitnate of the effect of the 
Mii II R C677l polymorphism on plasma hotnocysteine 
e'c>nce"ntralic>n and to explore potential sources of 
hc"teruge"ncity. 'Ill(- absolute difference in humocysteine 
concentration conferred by the g(-notyTx-, though 
consistent in direction, was great( T in people with 
established atherosclerosis than in individuals who were 
healthy at the time of measurement. A trreta-analysis of 
individual patients' data had similar findings. ` In that 
study, among individuals with coronary heart disease, 
there was a difference in hutnocysteine concentration between 'I'I' and CC individuals of 2.2 µtnol/l:, the 
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Figure 2: Odds ratio for stroke in individuals with the TT genotype compared with those homozygous for the 
C allele of the MTHFR C677T polymorphism 
I or wrhn4 "n"iu ", hllp: //irnayethi-lanu"t i oni/extras/O3art1143/wr4ar411irn o,. Fxll 1 ls total Wundher nl 
stroke caves was 6 324 (11 1041, (1 )85), CC ) 431) and the total number of controls was /604 (T1 1140, (1 
3393, C( 30/1). 
difference among healthy individuals was smaller, but 
still significant (1-5 µrnOI/I. ). ` Therefore, our data 
suggest the presence of an additional effect of disease 
status on the association between homocysteine 
9U; lit. 6s 'aa4ncso11 ax 
a: eF . 
A. " Il ýý ]"ýOj 
f 7 7ühs34/i 
: iiebWJF IR-rlit. t s' .. ý. _. r... a'ilax-ý*Mi 
Figure 3: Sensitivity analysis of the MTHFR C677T polymorphism and stroke association 
Summary odds ratio of stroke lo. II INDNIDUAIS compared WITH CC INDIVIDUALS by publication tyim, tit oke 
classification or type, and ethnic ynwp. 
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concentration arid MT11FR genotype, partly explained by tools (eg, Frarrringham risk equation) will require further 
lower serum folate concentrations in people with investigation. 
atherosclerotic disease. We therefore used estimates nur analyses must be interpreted in the context of 
from healthy individuals only when calculating the the limitations of the available data. In the meta- 
predicted odds ratio for stroke among TI' homozygotes. analysis of the MT11FR variant and hornocysteine 
In estimation of an association between genotype and concentrations, we found significant heterogeneity. 
intermediate phenotype, the potential modifier effect of This finding is perhaps not surprising, because 
disease status should be examined. "'', expression of the mutation is likely to depend on 
The second genetic meta-analysis (M'I'}IF'R C6771' and environmental factors such as folate concentrations, as 
stroke), which included about 14 0(X) individuals, allowed detected in our meta-regression analysis. ']'his idea is 
us to obtain a precise estimate of the effect of MT1 f FR supported by the smaller effect of the MT1 I PR (: 6771' 
genotype on stroke risk. Individuals homozygous for the polymorphism on the hornocysteine concentration in 
T allele had an odds ratio for stroke of 1 -26 (1 -14 to 1 "40) studies in North America, in which the mean 
compared with those homozygous for the C allele. 'T'his concentrations of serum folate were higher. I lowever, 
difference in risk is similar to that expected from the an overview of data from individual patients will be 
difference in homOxysteine concentrations by genotype required for more precise quantification of this 
in healthy individuals (1 . 20 11 - 10 to 1- il 1). Moreover, potential gene--environment interaction. ", " l'or this 
when the comparison was restricted to white individuals reason, only the estimates of weighted Mean difference 
or to studies done in liurope or North America, within a derived from a random-effects model were used in this 
similar age range to the population included in the meta- report. 
analysis of prospective studies of hornocysteirie and Publication bias or small-study bias was considered as 
stroke risk, ' similar results were obtained. an explanation for the observed associations between 
Clinical studies have shown that supplementation with the MIl I'R polymorphism, hornocysteine conccntra- 
folic acid and vitamin 1312 lowers homocysteine tion, and stroke risk, but the results obtained from the 
corncentrations by about 3 µrnol/l .. "" If hotnocysieine is funnel-plot analysis and Ggger's tests did riot provide 
causally associated with an increased risk of stroke, positive evidence- for such bias. Although confounding 
nutritional interventions to lower concentrations might is less likely irr analyses of an association of a genotype 
be expected to produce a relative-risk reduction in the with disease, some imbalance in the distribution of 
incidence of stroke of about 23%. ` Several randomised cardiovascular risk factors by Mii IIR genotype cannot 
clinical trials are currently investigating the effects on be totally excluded. I lowever, previous studies that have 
cardiovascular outcomes of lowering homocysteine investigated the effect of the M`f 11FR variant on 
concentration by administration of R vitamins. "" One coronary heart disease have suggested that there was no 
clinical trial in North America" did not detect a beneficial major systematic confounding frort other cardiovas- 
effect of high versus low folate doses in secondary cular risk factors (eg, age, sex, hypertension, diabetes, 
prevention of stroke. I low(-v(-r, as suggested by the trial obesity, or alcohol intake). " 
investigators and the results of oUT study, a larger sample The Mendelian randomisation approach used here is 
size, longer periods of intervention, and targeting of the a potentially useful tool to assess the nature of the 
intervention to populations with low folate observed associations between putative risk factors and 
concentrations might all be required to show any disease. This approach overcomes some potential 
potential benefit of this intervention. Such randomised limitations of observational studies, such as con- 
inte"rvention trials of the effect of lowering hornocysteirre founding, reverse-causality bias, and regression- 
concentrations are important for several reasons: the dilution bias. " '' "'- I lowever, it also has theoretical 
type of study we have done has several potential limitations, such as the potential for confounding of 
limitations; intervention trials are necessary to assess the association between genotype and intermediate 
reversibility arid could establish precisely the magnitude phenotype by linkage disequilibrium with other genes. 
of any treatment effect; and they could ascertain whether Similarly, associations of the genotype with environ- 
there are any unexpected adverse effects of such Mental exposures that regulate the concentrations of 
therapies. the intermediate phenotype could lead to spurious 
Despite the association found between the MT11FR genotype-disease association. hinally, population 
(6771' polyrnorphisrn, hornoýcysteine concentration, and stratification (confounding of gene-disease association 
stroke risk, the size of the effect is modest compared with by ethnicity), multiple disparate (pleiotropic) effects of 
those of classic cardiovascular risk factors arid does not gene polymorphisms on more than one biological 
necessarily provide a rational basis for screening for the system, or compensatory biological adaptation to its 
polymorphism or for the measurement of hornocysteine effects on disease risk (canalisation) could distort the 
concentration in isolation, in the prediction of stroke . observed genotype-disease association s in one or other Whether either of these measurements would add usefu l direction. 1-11 There are other practical limitations. 
predictive information to more established risk prediction Since the estimated relative risk arising from genotype 
www. thelancet om Vol 365 January IS, 200S 
(eg, MI'IIFR variant) on the intermediate phenotype 
(eg, homocysteine concentration) will in many cases be 
small, very large genetic association studies or meta- 
analysis of smaller studies will be needed to assess the 
nature of such associations. Unless careful 
consideration is given to the inclusion or exclusion of 
studies used in any meta-analyses, and to the potential 
for publication bias, the comparison of genetic and 
Tion-genetic odds ratio estimates could become 
distorted. 
Adequately powered randomised controlled trials of 
supplcmeritatitm with folic acid (with or without 
13 vitamins) will 1w necessary trr validate the therapeutic 
approach of lowering hornocysteinc concentrations to 
Prevent stroke and other cardiovascular ('vents. '' The 
findings of this study and previous analyses of the 
same type emphasise Ih(- potential importance of such 
trials. The tnendelian randc, rnisation approach we and 
others have used for hornocysteine might also be 
useful in assc"ssrnent of whether other "novel" risk 
factors for cardiovascular disease could have 
aeli<iii gical mikes. 
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Background II is unclear whcathcr the association between C-reactive protein (CRP) and 
incident corunarv events iS tree front bias and confounding. Individuals 
homoýtygous lot a ß-1444C>T polymorphism in the CRP gene have higher 
circulating; concentrations A CRP. Sincc the distribution of this polymorphism 
occurs at randonn during gamete torntaticm, its association with coronary events 
should not be biased or contnundcd. 
Methods We cakLIhlle 1 the weighted mean ditlrrcnce in CRP bctwecu individuals with 
variants o( the --14440 T polymorphism in the CRP gene among 4659 
tiuropean mvn hnmt six Studies (gvnotypv-inicrmcdiate phenotype studies). We 
used this diflcrence together with data from previous observational studies to 
ccm pute an expeetcd enteis ratio (OR) for nun-fatal myocardial infarction (MI) 
allloin individuals hoitioiygotis for the 1' allele. We then performed tour new 
genetic aSSOciatiun studies (6201 litn-u wan raten) to obtain a summary OR tor 
the association between the -1444(;: >T polyntorlthistn and non-fatal MI 
(gcnoiypr-disease studies). 
Results t; R1' was 0.68 ink; /I 195°I, confidence interval (45°x, (i) 0.11-1.10; P-0.0001] 
higher aunnuig stih. lrcls luunwiyguus for the +1444-T allele, with no 
cunI(nutlding by a range of covariales. The expected ORs among TI" 
subjects fur nun-fatal MI currcespouiding lo this dillerence in CRP was 1.20 
195% Cl 1.07-1.1Hl using the Reykjavik Heart study data and 1.25 (1.09-1.43) 
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for all observational studies to 2004. The estimate for the observed adjusted-OR 
tor non-fatal MI among Ti' subjects was 1.01 (95(1/,, Cl 0.74-1.38), lower than both 
expected ORs. 
Conclusions A comtmo i CRP gene polymorphism is associated with important differences in 
CRP concentrations, tree from confounding. The null association of this variant 
with coronary events suggests possible residual confounding (or reverse causation 
in the CRP- oronary event association in observational studies, though the 
confidence limits are still compatible With a modest causal effect. Additional studies 
of genotype (or haplotype) and coronary events would help clarify whether or not 
the fink between CRP and coronary events in observational studies is causal. 
Keywords C-rcaclivc >>roicin, cardiovascular disease, genclirs, po lyinorphisiii, 
III( a-analysis 
Prospective studies indicate a robust asstrcialion, in healthy 
intlivicittals, between lrvcls of the acute phase reactant 
Cl-reactive protein (CU) and later coronary events, 
t-i and it 
has been proposed that tnca%urrnu"nt of C. RI' tray be a useful 
adjunct to coronary risk assessment and that CAW could he 
causally involved in atherosIciosis, I However, CR1' concvntra- 
tiun5 are rurrclated with smoking statttti, blood pressure, 
obesity, diabetes, physical activity, social class, low birth 
weight, and other products of the inflanttnatnry response and 
are also higher in individual', with clinical cardiovascular 
disease. 5 Despite statistical adiiisi ew, this aswriatit»t may, 
tliert'furt", he sulrjt"(I lo icsiiittal trrnG+nttdittl; or bias due to 
reverse rautiatiun, where the disease even it it,, sult -clini(al 
slate It"atls to elevation in the level of CAP. 
5_8 
A rantit, tni, ed controlled clinical trial of a selective 
intervention to reduce CR1' would provide an In biased insight 
into the nature of Ihr assi. t alitrn. Unfortunately, no such 
selective intervcntitrn currently exist,,. Although inhibitors of 
to 11M(; -('. trA rrtlttrtasr (titatin, ) and f; litarc, nc; reduce C121'. 
they also have major effects on lipid profile and glucose 
turtaltttli, tn. Ali alternative approach to ctmtrul for ctmfttunti- 
ing and reverse causality is to identify a common polymorph- 
kin in the CR1' gene reliably a, tinc iated with differences itt 
circulating CR1' concentration. The inheritance of such a 
variant sitotlld be subject to Iht, rancittm assortment of maternal 
and paternal alleles at tltc time 01 kartiere formation, according 
it) Mendel's second law. 11 If CRP actually increases the risk of 
coronary events then carriage of an allele that exposes incii- 
vidnals it) a long-term elevation in CRY should confer an 
increased risk of coronary events proportional to the difference 
in t: RP attributable In the allele. This relationship should be 
largely muonfound d and free of reverse causality hias. 12,11 
Therefore, if non-genetic observational studies were unbiased, 
the increase in risk estimated from these studies should be 
consistent with the increase in risk conferred by Carriage of the 
allele. 12.1 { , Phis approach, known as 'Mendelian randomiza- 
tion', has been used recently to investigate the link between 
htntrcysit'lI1C, fibrinogen, and cardiovascular disease. 14-I7 
CRP concentration is a heritable trait. 18,! ') In three small 
st tidies we found that htrtntrzygosity for the rarer T allele of a 
I444C=->'1' {nilymurphisnt in the 3'-tin translated region of the 
CR1' gene was associated with higher basal and/or stimulated 
CRP cw (Lwratit)ns. 
2o'21 We have now g notypcd a large 
illlm1wr of Caucasian mc'n u) test whether tile' increasr in risk 
of coronary events in individuals Iutmon-gotis for this 
polytnt)rpllisnl i5 cltltir tol that predicted under thce assumption 
that the CRP-coronary event association from previous non- 
genetic oliservatirntal studies is free from residual confounding 
and bias fate to reverse causation. 
Methods 
Study populations 
After obtaining ethical approvals, genotyping for the CRP 
polymorphism and measurement of plasma CRY concentration 
were conducted in samples obtained from a number of crcs- 
sectioittal or prospective studies, o randomized controlled trials 
summarized in Table I and in supp1emetitaryy rnatrrials 
available online. 
21-27 To test the association of i 14440>T 
gemiotyfýcwith CRP concentration, tttale subjects without 
clinically evident cardiovascular disease from six studies 
with available DNA and plasma samples were studied f1 _2 1.25-? 7 (Table I ). ý A second analysis was conducted to 
evaluate the assuriatiom between genotype and risk of 
myocardial infarction (MI) in male subjects from four studies 
1), 22-25 (Table 
Data collection 
Data on sex, mean age, systolic and diastolic blood pressure, 
body teas' index (BMI), smoking status. glucose, lipid profile, 
alcohol consumption, fibrinogen, and plasma CRP values were 
obtained from the orisinal studies. Subjects were classified 
using unified definitions of hypertension, liypercholestero- 
]aemia, type-2 diabetes mellitus, and obesity from the 
guidelines on primary prevention of the American Heart 
Association. 2 For the studies relating genotype and coronary 
events, 22-25 note-fatal MI according to the WHO criteria` was 
considered the primary outcome, as this end-point had been 
uniformly used across all studies- Analyses of genotype and 
CRP were limited to male subjects tu preserve consistency with 
available studies of genotype and coronary events, which were 
all conducted in men. 
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Laboratory analyses 
All studies included in the present report used high sensitivity 
assays to measure plasma CRP concentrations. For specific 
details of the assays used please see supplementary materials 
provided online. 
CRP genotyping and examination of linkage 
disequilibrium 
The- CRI'/ i* 1444(7. >7' single nucleotide polynnorphistn (SNP; 
rsl 130864) was genntyperi by PCR and RUIP analysis using 
primer pairs described hrrvicrusly21 and the restriction enzymes 
541111 or 13sh12861 that cleave the 181 hp PCR product into 21hp 
and I Sthlr Ira); rnents only in the presence of the common C 
allele. All DNA analysi, was performed by staff unaware of the 
clinical status of the subjects. A public domain resecluencins; 
resource (Seattle SNNs; lilt p: /Ipgatubl. washinglou. r(iu/) was 
accessed ter 111Vestigalc associations between the rsl 1 30864 and 
other SNI's in the CRP ); ene, and ter ascertain haplotvpc 
structure. MUDI INU. was altirr searched to ids ntily published 
studies rcportint; linkage rliscquilibrium (l. l)) between CRI' 
SNl's and haplrriv), r strncturc. 
Statistical analysis 
Genotype and CRP concentration 
To quantify the effect of the ("; RI' gene polymorphism on CRII 
tonct"ntration, we genotyped 4659 nett from six studies 
(Table I). ýt We calculated the within-study mcan 
difIcrvI c in CRI' <<lcrnlratiun between individuals hunnrtxv- 
t; ort« for the 1' allele anti carriers of the C. allele and tlren 
weighted each mean by the inverse of its variance to obtain an 
overall weighted mean difference (WMD). In the calculation Of 
the WMI), we limited the analysis In tiuhject% without known 
rrronar or periflhrral artery disease at the time Of blond 
sampling in order to avoid the potential for established disease 
tit modify the tiu" of the genotype-CRI' as«Uciali<NL16 
linwr"ver, an analysis including all subjects was alsot conducted. 
Therefore, for prospective st iies, baseline CRP data were used 
fron, all available subjects without clinically evident athero- 
sclerosis. For case-control Sttidies, genotype-CRI' associations 
were analysed solely using control subjects. Because of its 
Skewed (list rihution, CRI' values were log-transformed before 
the analysis. For m ethods used to calculate the absolute 
geometric-WMI) in CXI' ctmcenirations by genotype please sec 
suhplemneniary materials available at 1.111 online. Random and 
fixed effect models were used for these analyses. ; tl'31 
Genotype and non-fatal nryocardial infarction 
To examine the effect of CKI' genotype on risk of non-fatal MI, 
We t; enrttyperl 6201 then from four studies (Table 1). 22-25 We 
obtained the adjusted odds ratios (ORs) and 95% ronfidencr 
intervals (95%, CIs) for subjects homozygous for the T allele 
compared with carriers of the C allele from each study. In 
addition, for the two intervention trials 21,24 the potential 
interaction of the genotype , MI association with the active 
therapy was also evaluated. We then pooled the within-study 
ORs ter Obtain a summary adjusted-OR and 95`% CI for non- 
fatal M1, under both fixed and random effect models. Fixed 
effect sunltnary-ORs were calculated using the inverse 
variance-weighted method, '` and the DerSimonian and 
Laird Q tesL13 was used to evaluate the degree of heterogeneity 
between studies. 
Consistency between the ORs from genetic and front 
non-genetic observational studies 
We estimated the expected OR for non-fatal Mt, corresponding 
to the WMI) in CRP between TT subjects and C allele carriers, 
based on data from prior non-genetic observational studies that 
examined the CRP-coronary event association. To do this we 
used information from the most recent theta-analysis of 
observational studies of CRI' and coronary events as well as 
data from the Reykjavik Heart Study, a very large study in 
which more extensive control for potential confounders was 
made. The first estimate, based on an OR of 1.58 (95% CI 1.48- 
1.68), for the top vs bottom textiles of the CRI' distribution, 
canto from the recent meta-analysis3't of 22 prospective studies 
with 7068 cases with different degrees of adjustment for 
traditional cardiovascular risk factors across the studies 
included and no adjustment for regression dilution bias. The 
second estimate was based on an OR of 1.45 Cl 1.26- 
1.68) between top and bottom tertiles of the CRY distribution 
reported ill the Reykjavik 1leart Study'-' "I the largest single 
prospective observational study of CRI', which contributed 
2459 cases to the meta-analysis and also undertook it 
comprehensive adjustment for potential confounders (age, 
sex, period of recruitment, smoking, systolic blood pressure, 
total cholesterol level, triglyceride levels, BMI, forced 
exlriratury volume in one second, diabetes, and 51 ioecotnoth is 
status). The third estimate from the Reykjavik Heart Study3't 
was based on an OR of 1.92 (95`7,, Cf 1.68-2.18) for top vs 
bottom fertile of CRI', based on a snore limited degree of 
adjustment (age, sex and period of recruitment). The final 
estimate also from the Reykjavik sttrdy31 was based on the 
adjusted standard tO year follow-up risk of 1.84 (95% Cl 1.49- 
2.29) for lop vs bottom tertile of CRY. 
For these estimates we assumed equivalence between 
relative risk and OR, that the usual mean difference in CRP 
between the individuals in top and bot torn textiles was 
1.4 tug/Iand that the CRY coronary event relationship was 
loglinear. The expected OR for TT homozygous subjects with 
reference to C allele carriers was calculated using the formula: 
expected OR pjZtwna I' 
D: 1 
PWOI 
The 95"16 
nur gerctic ýwdiýýs' 
Cl for this expected 
OR was obtained by simulation, 
16 
and it was compared with 
that observed by an interaction test, 
35 For details, please see 
supplementary materials available at 1.1/i online. Consistency 
between the observed genetic and expected (non-genetic) ORS 
would suggest that the association between CRP and coronary 
events identified in prior observational epidemiological studies 
would be unlikely to be the result of residual confounding or 
reverse causality bias. Data were analysed using the Review 
Manager software (version 4.2) from the Cochrane Collabora- 
tion 2003 and Stata 8.2 (Stata Corporation, College Station, 
TX, 2003). 
Results 
Allele and genotype frequencies, and LD with 
other CRP SNPs 
The allele and genotype frequencies of the 114440>T 
polymcirptiism were in }lardy-Weinberg equilibrium for all 
926 INIINNV11"', 'I 
Study 
TT CT+CC 
N Log-mean (SD) N Log-mean (SD) 
TT vs (CT+CC) 
Difference in log-CRP value Difference in log-CRP value 
(95% Cl) (95% Cl) 
WOSCOPS' 99 0.64 (1.07) 919 0.62(l. 07) 0.02 1-0.20.0.241 
WOSCOPSt 35 1.00 (0.87) 281 0.89 (1.05) 0.11 [-0.20.0.421 
NPHSII 230 1.08 (1.01) 1991 0.88 (1.01) 
+ 0.20 [0.06,0.34] 
UDACS 42 0.58 (0.78) 306 0.30 (0.85) 0.28 [0.03,0.53] 
HIFMECH 37 0.69 (1.18) 428 0.34 (0.94) 0.35 [- 0.04,0.74] 
EBCT 6 0.26 (0.93) 66 -0.22 (1.08) 0.48 (-0.31,1.271 
Army 13 0.04 (1.32) 206 -0.60 (1.06) 0.64 [-0.09,1.37] 
f 
Total (95% Cl) 462 4191 0.19 [0.09,0.29] 
Relative diterence 
Test for overall efted P=0.0001 Geometric WMD" 
1.21 [1.09,1.34] 
0.68 mg/l [0.31,1.101 
-1 -0.5 0 0.5 1 
Lower CRP Values Higher CRP Values 
Figure 1 Wan log-CRP and mean diHrreme in log-(. RP (eng/1) by study anic ng subjects without known cardiovascular disease. *, represents 
data for control subjeck; j, represents data for subjects with 
later non-fatal MI; $, represents relative difference was obtained hs- antilog of the 
differente in log-t: RP values; and "", represents Geometric WMD - l(rvialive diftrren<e in CRP <oncentration between TT homoz. ygoles and 
(1-allele carriers x ntean-CRP concentration in C-allele carriers) mean-CRP concentration in C-allele carriers] 
studies included in the present report, apart from a marginal 
distortion in the NI111S-11 study (please see Table I in stipple- 
mentary materials available at 0F online). The frequencies 
of the rare allele in disease-free subjects from all studies were 
very similar (range: 26-33%). Data from the Seattle SNPs 
reýcyurncin resource (lit tp: //pga. gs. washington. cduldata/crp) 
indicate, that four 1utnuwn CRP lIaplOtypes (approximate 
frt-quencies 0.3,0.3,0.3, and 0.05) account for >90% of 
ehronwumtes among sufijectS of I uropean descent. The 
1 I444T allele lies on ime of the three common hapl(ilypes 
(approximate frequency 0.5), which also contains the T allele of 
a common tri-allelic poolyin rrpliisni (-286C'>T/A; rs309l244). 
Prior studies also report a strong 1.1) between minor alleles at 
11444 and -286 poAymorphistns; reported D' values in 
Caucasians being 0.97,36 0.91,17 0.91 (unpublished data) and 
with an ? -valor of 0.97. 
tx In functional studies in vitro, the 
-286C>T/A SNP appears to account for increased transcrip- 
tional activity in studies using protimter-reporter assays. The 
union, haplotype containing minor alleles at -286 and 1 1444 
has been associated with higher CR1' values in Iwo published 
Studies, 16,39 and we have identified concordant population 
haplotype frequencies and associations with CRl' in mir 
own recent studies in the NI111S dataset of -2700 men 
(unpublished data). 
CRP/--1444C--T polymorphism anti CRP 
concentrations 
Iltiiiig data (rinn 4659 men from six sti iit ý, the weighted mean 
CRP concentration its C-allele carriers without known cardio- 
vascular disease was 2.01 mg/1 (95% Cl 1.94-2.07). Under a 
fixed effect model. the ge(nnetrii-WM1 in CRP (onceniration 
between individuals honnuzygotis for the T allele compared 
with carriers of the C allele was 0.68 tng/1 (95% CI 0.31-1.10; 
/' - 0.0001 ). There was no significant between-study 
heterogeneity [Y-value for heterogeneity (Pttr, ) - 0.47; 
Figure 1]. When alternative models of the effect of genotype 
on CRP were evaluated, only the TT vs CC comparison was 
significant (WMI) - 0.78 tng/I (0.41-1.20); P<0.0001 1, 
while heterozygosity (CT vs CC) was not (WMI) - 0.06 
(-0.24 - 0.44); P-0.661. When subjects with coronary or 
peripheral atherosclerosis at the time of blood sampling were 
included in this analysis (n - 5658), the WMD between 
individuals homozygous for the T allele compared with 
carriers of C was very similar 10.74 ntg/l (95% CI 0.37-1.10); 
P<0.00011. The values we have obtained are concordant 
with those obtained from other studies examining associations 
of CRP SNPs with CRl' concentration, taking into account 
known 11). 3( 0 
To evaluate potential Confounding of the genotype-CRI' 
association, we quantified the association between TT genotype 
and age, systolic and diastolic blood pressure, 13M1, current 
smoking, glucose, alcohol intake, fibrinogen, triglyceride, total 
and H1)1. cholesterol. No significant difference was observed 
for any of these risk factors, with the exception of a slightly 
higher I1MI among TT subjects (mean difference - 0.34 kg/m2; 
P-0.02; fable 2). In view of the multiple comparisons made, 
however, this significance level is not particularly extreme. 
Moreover, this apparent association was not significant when 
subjects with and without coronary heart disease were 
considered together, and it is likely, but not yet certain, to 
reflect the lpla)ul chartre. 
OR estimated from observational studies and the 
expected mean difference in plasma CRP 
1'. xpected ORs for nun-fatal MI among TT hutnozygotes 
compared with C allele carriers based on a between-genotype 
WM]) difference in CRP of 0.68 rng/l (95% C. l 0.31-1.10) were 
1.37 (95'/, Cl 1.14-1.68), 1.20 (95'%, CI 1.07-1.38), 1.34 (95% 
CI 1.12-1.67), and 1.25 (95% CI 1.09-1.43) based, respectively. 
on the Reykjavik Heart Study minimally and maximally 
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Table 2 Cardiovascular risk factor distribution according to thr t'RP/+1444(1>1 polymorphism 
Variable Subjects (studies) 
Weighted mean difference 
(TT minus C"carricrs) (9S% Cl) P-value 
Age (years) 6358 (7) 0.17 ( 0.19 to 0.52) ll. l 
Systolic blood pressure (mm 11g) 6356 (7) t). 31 1.78 to I. I6) O. MMS 
Diastolic Wood pressure (nun IIg) 6356 (7) 0.70 1.56 to 0.16) 0.1 
Bodv mass index (kg/m2) 6359 (7) 0.34 (0.06-0.62) 0.02 
Total cholesterol (mmol/1) 6115 (6) 0.01 ( U. OS to 0.06) 0.87 
IIDL-cholesterol (tnntol/1) 4714 (5) 0.01 (- 0.04 to 0.011 0.32 
Triglyceride Immolil) 6041 (5) 0.03 ( -0.11 to 0.06) 0.51 
Fibrinogen (g/l) 5656 (4) 0.03 (---0.02 to 0.08) 0.20 
Glurone (nunul/I) 1913 (3) 0.01 (- 0.1 3 to 0.12) 11.91) 
Alcohol intake (U/week) 4549 (4) 0.01 ( 1.18 Io 1.39) 0.99 
Current smoking` 6) 32 (6) 1.00 (0.84-1.20) 0.98 
C-reactive protein (mg/1) 4659 (6) 0.68 (0.31-1.10) 0.0001 
Comparisons are made between rl homozygotes and C-allele carriers. 
a for this variable instrad of the WMD. the value reported is the weighted odds ratio 
Study Cases Controls 
TT vs (CC+CT) 
Adjusted 
Odds ratio 
9500 Cl 
Odds ratio 
95°o CI 
HIFMECH 491 517 1.14 JO. 55.2.35) 
LEADER 43 1023 1.48 [0.57,3.811 
NPHSII 103 2573 a 0.33 [0.12,0.91] 
WOSCOPS 348 1103 
- 1.01 10.73,1.60] 
Total (95% CI) 985 5216 1 . 01 [0.74,1.38] 
Test for heterogeneity P= 0.14 
Test for overall effect: P= 0.95 
0.1 0.2 0.5 125 10 
Decreased risk Increased risk 
Figure 2 Adjusted odds ratio (a multivariate logistic regression model was used to adjust the OR from each study by age, total choleswrol, 
alcohol intake, body mass index, hypertension, diabetes, and smoking) for non-fatal MI among subjects with the +1441T-genotype in 
comparison with carriers of the +14440 allele 
adjusted models, the Reykjavik study 10 year estimate, and on Consistency between the ORs estimated 
the meta-analysis ui studies up to 2004. from the mean difference in CRP level 
and the OR from the genetic study 
OR of non-fatal MI for the CRP/-1444C>T 
polymorphism 
Data from four new studies involving 985 subjects with non- 
fatal MI and 5216 control subjects were pooled to obtain a 
summary adjusted OR. After combining the studies under a 
fixed effect model, subjects homozygous for the T allele 
compared with C allele carriers had no significant increase in 
the risk of non-fatal MI [summary adjusted-OR= 1.01 (95% CI 
0.74-1.38); P-0.95] (Figure 2). No significant inter-study 
heterogeneity was observed (PH,, - 0.14). When alalysis of the 
risk of non-fatal MI conferred by homozygosity for the T allele 
was restricted to prospective genetic studies, there was still no 
significant association with non-fatal MI [OR - 0.98 (95% CI 
0.70-1.38); P=0.93]. No significant increase in risk was 
observed in the individual studies, and there was no significant 
interaction between treatment and genotype-outcome associ- 
ation in the two clinical trials involved in this analysis: for 
LhADFR, P=0.53 and WOSCOPS, P-0.44. 
The eslitnatc tf the observed OR from the tcnelic study 
11,01 (95% Cl 0.74-1.38)] was mathematically smaller 
than the expected OR 11.37 (95% CI 1.14-1.68) or 1.34 
(95% CI 1.12-1.67)], calculated using data from the 
minimally adjusted estimate or the 10 year estimate from 
the Reykjavik Heart Study. 34 lt was, however, closer to 
estimates based on data from the maximally adjusted 
model of the large Reykjavik Heart Study [1.20 (95%, CI 
1.07-1.38)] and to an estimate based on an updated tneta- 
analysis of studies to 2004 11.25 (95% CI 1.09-1.43)]. 
Indeed, most of the 95% confidence limits of these latter 
two estimates lay within the tipper bound of the 95% 
confidence limit of the genetic estimate (Figure 3). The 
P-value for interaction for the comparisons of the minimally 
and maximally adjusted estimates from the Reykjavik 
study. and from an updated meta-analysis of studies to 
2004 with the observed genetic estimate is outlined in 
Figure 3. 
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odds ratio P-value for comparison with 
Study Number of CHD cases (95% Cl) Genetic study 
Reykjavik study minimum adjustment 2459 
Reykjavik study full adjustment 2459 
Meta-analysis 2004 7068 
Present genetic study 985 
ý- 1.37 (1.14-1.68] 0.10 
1.20 [1.07-1.38] 0.24 
1 1.25 [1.09-1.43] 0.18 
1.01 [0.74-1.38] 
0.5 0.7 1 1.5 2 
Decreased risk Increased risk 
Figure 3 Comparison of expected and observed odds ratios for non-fatal MT for individuals homozygous for the CRP +1444(: >T polymorphism. 
Expet ted ORs were calculated assuming a log-linear association between CRP and nom-fatal Ml, and that a 1.4 mgll difference in CRP corresponds 
to an OR for coronary events of 1.92 (951iß Cl I . 68-2.18) and 1.45 (95`! CI 1.25-1.68) based on the minimum and 
fully adjusted models 
from the Reykjavik fit-art Study published in 2004 and 1.58 (95'ßi, Cl 1.48-1.68) based on an update 1 meta-analysis published in 2004, 
jl)ata derived front rrterences (6) and (34), respectivelyl 
Discussion 
Using pooled data Inoin 4659 individuals, we found that ntrn 
homor. yguus for the T allele of the - I444C; -T polymorphism 
of the human CRP gelte had a circulating CRP concentration 
0.68 mg/I (95% CI 0.31-1.10) higher than carriers of the C 
allele, confirming the results of earlier smaller studies. 
20.21 Cltl' 
genulype, therefore, contributes to the variation in CRP 
concentration observed in the population. This association 
probably reflects 1.1) with a putative functional SNP in the gene 
promoter (-286C>T/A; r% ! t091244), although an effect of 
i I444C>T on RNA stability cats of be ailed out. 
We estimated that this difference in CRP of 0.68 utg/l (95% 
Cl 0.31-I. 10) would confer an OR for non-fatal MI of 1.25 
(95%, CI 1.09-1.43) or 1.20 (95%, CI 1.07-1.38) using data 
from a meta-analysis of prospective cohort studies published in 
2004,; 't and front the maximally adjust cd Illodel of tile 
Reykjavik Heart Study, ' M respectively, assuming the observa- 
tional associations have been unbiased and free from residual 
confounding. However, despite possessing a genotype that 
would have exposed them toi a long-term elevation in CRP 
concentration, for men wit lt the TI' genotype, the point 
estimate of the OR for non-fatal MI was 1.01 (95% Cl 0.74- 
1.38). 't'his finding is important since, in contrast to the 
reported association between CRP and coronary events in 
previous studies, the association between CRP genotype and 
events should not be subject tot reverse causality bias, 
regression dilution bias, or to confounding by other 
cardiovascular risk factors related to CRP, though some 
doubt about a marginal effect of the genotype on 13M1 remains 
to be evalttated. 7'K't441-47 This is supported by the data in 
Table 2, which indicate that certain established cardiovascular 
risk factors and some inflammatory starkers, that are known to 
be associated with CRP, were not associated with I444C>T 
genotype. 
The estimate of risk derived from the genetic association 
studies of CR1' reported here should not be biased or 
confounded, but it is currently much less precise than the 
estimates obtained from classical observational epidemiology. It 
is likely that for this reason an interaction test, which has low 
power, did not provide formal evidence for heterogeneity 
between genetic and non-genetic ORs at the 5% level of 
significance (Figure 3). Approaches for evaluating consistency 
of genetic and non-genetic disease risk estimates from 
Mendelian randomization studies have been reviewed 
recently. 48 it is clear, however, from visual inspection of the 
Forest plot, that the genetic risk estimate is closer to more 
recent estimates of the CRY-coronary event association 
reported in an updated meta-analysis of observational studies 
published in 2004,31 and in the maximally adjusted model of 
the large Reykjavik Heart Study. 4 Thus, recent results from 
prospective observational studies in which the random error 
has been reduced substantially by considering more studies in a 
theta-analysis, and in which more extensive statistical 
adjustment has been conducted, as exemplified in the 
Reykjavik Heart Study, indicate that the association of CRY 
with coronary heart disease risk has decreased substantially in 
comparison to earlier estimates. 
34 The strong potential for 
confounding in observational studies of the measured 
phenotype (CR1') and the utility of genotype as a proxy for 
CRY was illustrated by a recent study40 in which a range of 
covariates that exhibited strong correlations with CRY were 
distributed evenly among >3500 British women separated 
according to genotypes for a 1059G>C polymorphism that is in 
l. t) with the variant reported here. 36 
Although a null association was identified between CRY 
genotype and coronary events in this study the width of the 
confidence limits is such that our observation could be 
compatible with a modest but potentially important causal link. 
It is estimated that a dataset of -10000 cases and similar 
number of controls would be required in a genetic association 
study to exclude a small effect of CRP on coronary heart disease 
aetiology. 49 However, evidence froth different sources indicates 
that, if anything, the discrepancy observed between the genetic 
and non-genetic ORs is likely to be greater, rather than smaller. 
First, the observational estimate of the CRP-coronary event 
association3't on which we based the non-genetic OR, did not 
adjust for regression dilution Was and so may have been 
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underestimated. However, this bias is unlikely to affect the 
genetic estimate. 12 Second, emerging evidence supporting the 
current null genetic estimate comes from three genetic studies 
to Caucasians, with an additional I S98 cases and 1347 
Controls, 37,50,91 where carriers of the C allele of the 10596>C 
Variant (in LD with the + 1444/C>T variant) did not have an 
increased risk of cardiovascular events despite having a CRP 
concentration that was 0.3-0.6 mg/I higher than GG 
hotnozygous subjects. Moreover, recent data from two other 
genetic studies in Caucasians (703 cases and 1053 controls) 
found no association of the - 1444/C>T variant with 
cardiovascular events despite a similar effect of this variant 
Oil CRP concentration. 37'33 An additional approach in future 
Mendelian randomization studies is to genotype several SN1's at 
the CRP locus to generate all common haploiypes and to 
ensure inclusion of SNPs with demonstrated functionality [rota 
in vitro studies in such analyses. Since there is extensive 
LI) across the CRP gene, only a small number of 'tagging' SNPs 
(3-5) require typing to capture most of the genetic variation at 
this locus. '-1 '5'; In addition to -286C>T/A, published and public 
domain data indicate that four common haplotypes identified 
by these tagging-SNPs account for >9(1% of chromosomes in 
subjects of European descent. 
It is important to note that there is evidence for an additional 
fcnrctioual CRP promoter SNP found at high frequency in 
subjects of African origin. 16,54 
It is important to make clear that our study was limited to 
male Caucasian subjects and that additional studies will be 
required to ascertain whether similar findings pertain to 
women and also to other ethnic groups. However, recent 
evidence suggests that a similar effect of the i I444C>T 
polymorphism on CRP concentrations would be expected to 
occur in women as recently reported in British and American 
Wooten. 19'55 This is also supported by the effect of the 1059/ 
G>C variant on CRP levels, and the 0.42 mg/I difference in 
CRP concentrations among C carriers compared with women hotnozygous to the G allele is very similar to the effect observed 
here in rnen. 38"40 
Our finding using a genetic approach also needs to be set in 
the context of recent mechanistic studies that have investigated 
a potential pro-atherogenic effect of CRP on vascular cells and 
, issues. 56-61 It is becoming clear now that many of the pro- 
atherogenic effects demonstrated in vitro in initial studies could 
have been due to the presence of pro-inflammatory substances 
contaminating commercially sourced recombinant CR]' from 
62-70 bacterial sources, or to the sodium azide preservative. 
More recent experimental studies, using pure CRP prepara- 
tions, have failed to confirm the proposed pro-atherogenic 
actions of CRP on vascular tissues and would be concordant 
With our own data from genetic epidetniology, c'2-7o as would 
the recent experiments in atherosclerosis-prone mice, which 
showed that in contrast to earlier studies transgenic 
overexpression of human CRI' did not enhance development 
of atherosclerotic lesions. 71-73 
In conclusion, Caucasian men with a genotype that would 
have exposed them to a long-term elevation in CRP 
concentration [0.68 mg/I (95% CI 0.31-1.10)] were not at 
increased risk of non-fatal MI (OR 1.01; 95%, Cf 0.74-1.38), 
though the confidence limits currently encompass substantial 
Uncertainty. Taking this into account, it is at the very least 
likely that unbiased and nutz-confounded estimate., of the effect 
of CRP can coronary events are smaller than earlier studies 
estimated, a finding that is in agreement with tltr latest 
evidence derived from prospective observational studies and 
also with more refined and carefully conducted mechanistic 
studies. 71 If Our null point estimate of time genetic effect is 
stabler with the addition of further studies, it Might lead tai the 
re-evaluation of CRP both as a risk QtarkerI and as a potential 
therapeutic target. s Additional studies with data ein CR1' 
genotype, CRP levels, and coronary events will be essential tu 
obtain more precise genetic risk estimates and to hell) clarify 
whether or not CRP plays a causal role in atltcýnýthrnibýýsiti. 
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Estimation of Bias in Nongenetic Observational Studies Using 
"Mendelian Triangulation" 
LEONELO E. BAUTISTA, MD, MPH, DRPH, LIAM SMEETH, MRCGP, MSc, PET, 
AROON D. HINGORANI, FRCP, PiiL), AND JUAN P. CASAS, MIS 
PURPOSE: Phenotype-disease odds ratios calculated from the effect of a genotype on its phenotype and 
on disease risk ("Mendelian triangulation") can he used as a standard to assess bias on the corresponding 
odds ratio from nongenctic studies. Statistical tests are commonly used to compare these odds ratios. We 
propose a method to estimate the magnitude of the bias and judge the validity of the phenotype-disease 
association. 
METHODS: For four published examples, we Obtained 10,000 random values from distributions of the 
odds ratios from hoch genetic and nongenetic studies. A range of values compatible with an unbiased 
odds ratio was then calculated from the empirical distribution of the differences between both odds ratios. 
RESULTS: We show that estimating a range of likely values for an unbiased odds ratio is useful to judge 
the effect of the phenotype and identify cases for which information from genetic studies adds little to the 
evaluation of the phenotype-disease association. Conversely, statistical tests could be misleading. 
CONCLUSIONS: Estimating a range of values for an unbiased odds ratio is more informative and appro- 
priate than statistical tests when using the Mendelian triangulation approach for assessment of bias in 
phenotype-disease association studies. 
Ann EI, idiemiol 2006; 16: 675-680. n 2006 Elsevier Inc. All rights reserved. 
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INTRODUCTION 
Observational epidemiologic studies are a useful tool to es- 
tablish causal associations and have had A considerable im- 
pact on public health stmt clinical practice. However, recent 
discrepancies with results from randomized clinical trials 
have brought to focus the need for careful design to control 
bias in ohscrv, tticmal studies (1). Spurious associations in 
these studies are frequently the result of uncontrolled con- 
founders and reverse-causality bias. Assessing the likelihood 
and magnitude of such biases is complicated because some 
confounding factors may he unknown or difficult to measure, 
and ascertaining the start ing time for exposure and disease 
may not he possible. 
Assuming that the effect of a gene variant on disease is 
mediated exclusively through its influence on the interme- 
diatc phenotype (IP) of interest, the odds ratio from studies 
of the effect of the genotype on disease risk (ORgd) and the 
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between-genotype difference in IP (AIP) can he used to cal- 
culate an unconfounded odds ratio (ORgpd = ORgdtk/4tt't) 
for the effect of k units of the IP on the risk of disease (Fig. 1) 
(2). The fundamental concept behind this approach is that 
the inheritance of genetic variants is subject to the random 
assortment of maternal and paternal alleles at the time of 
gamete formation, according to Mendel's second law (3). 
Because the presence of the genotype is unlikely to he re- 
lated to other risk factors for the disease, genotype-disease 
and genotype-IP studies should he largely free of confound- 
ing. They also should he free of reverse-causality bias be- 
cause genotype is a hereditary fixed characteristic (2,4). 
Therefore, the ORgpd also should he unbiased and could 
be used as a standard to assess whether odds ratios fron non- 
genetic observational studies of the association between an 
IP and a disease (ORpd) are biased. If ORgpd and ORpd are 
of a similar magnitude, this offers support for the validity of 
results from nongenetic observational studies. However, if 
ORgpd and ORpd differ to a substantial degree, this suggests 
that results from nongenetic observational studies may be 
biased. 
Although the ORgpd is supposedly unbiased, in some 
cases, it would not provide a conclusive picture of the 
phenotype-disease association. This would happen mostly 
when genetic studies are not large enough to produce a pre- 
cise estimate of ORgpd. In those cases, the ORgpd still could 
he used to assess the validity of ORpd and improve our esti- 
mates of the strength of the phenotype-disease association. 
© 2006 Elsevier Inc. All rights reserved. 
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Selected Abbreviations and Acronyms 
IP = intermediate phenotype 
ORgd = odds ratio from studies of the effect of the genotype on disease 
risk 
01P = between-genotype difference in intermediate phenotype 
ORgpd = unconf ounded odds ratio of the intermediate phenotype on risk 
of disease 
ORpd = odds ratios from nongenetic studies of the association between 
an it tertnediare phenotype and a disease 
MI IIFR = methyleneretrahydrotolate reductase 
G= conhdence interval 
CRP =C -reactive protein 
ApoB = apc lipoprcmtein ß 
A proper assessment of the phenotype-disease association in 
these cases can he conducted only if both the random vari- 
ability of the C)Rgpd and of the ORpd is taken into account 
when comparing both estimates. 
Calculation of the C)Rgpd has been called "Mendelian 
randomization" (2), an acknowledgment of the underlying 
biologic process of random allocation of genetic traits during 
gamete formation. Because the approach is basically an 
indirect calculation of the association between an IP and 
risk of disease, we prefer to call it "Mendelian triangulation" 
(2,4). This term has been used previously (2,4) and conveys 
the fact that a "triangulation" is applied to data from studies 
of the effect of the genotype on risk of disease and on 
IP levels to indirectly obtain ORgpd, an unbiased estimate 
of the effect of phenotype levels on disease incidence 
(ORpd). For example, a common polymorphism, C677T, in 
the gene encoding methyleneteirahydrofolate reductase 
(MTHFIZ) has been associated with significant differences 
in homocysteine levels. We st tidied the effect of this polymor- 
phistn and found that subjects homozygous for the T allele 
had greater homocysteine levels (SIP = 1.93 µmol/L) and 
Intermediate Phenotype 
G>IP studies 
(IP) 
IP->D studies 
Mean (IPýC-IPgo)=DIP ORpd 
otentially biased" 
Genotype Disease 
(ß) G>D studies (D) 
ORgd 
ORgpd 'Unbiased", associated with ak unit change in IP ORgpd= ORgd(w Al) 
F 
ORgpd - ORpd ? 
GG Genotype at nsk, associated with high levels of the IP 
gg Wild type genotype, associated with low levels of the P 
FIGURE 1. Components of the Mendelian triangulation 
strategy. 
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greater risk of stroke (ORgd = 1.26) compared with subjects 
homozygous for the C allele (5). A meta-analysis of prospec- 
tive studies showed that an increase of 5.0 pmol/L in plasma 
homocysteine level increases the risk of stroke by 59% (ORpd 
= 1.59) (6). Based on results from our genetic study, the 
increase in risk for stroke corresponding to a difference of 
5.0 tmol/L in homocysteine levels would he ORgpd = 
1.26(5/193) = 1.81. By comparing ORpd = 1.59 with ORgpd 
= 1.81, one could evaluate whether results from nongenetic 
observational studies are distorted by confounding or reverse- 
causality bias. 
In this report, we consider two aspects of Mendelian tri- 
angulation that have received relatively little attention to 
date. First, we consider the random variation in the various 
estimates used in the Mendelian triangulation strategy, in 
particular, variability in the estimate of the effect of the ge- 
notype on its IP. Second, we ponder the nature of the com- 
parison between the estimate of effect of the IP on disease 
risk obtained from nongenetic observational studies 
(C)Rpd) and the estimate derived from genetic studies 
(ORgpd). Novel approaches are presented that use reliable 
estimates of uncertaimy derived from multiple simulations 
and integrate the information from both genetic and nonge- 
netic studies in the evaluation of the IP-disease association. 
Uncertainty in Estimates of the Effect of 
Genotype on IP 
To date, most studies using Mendelian triangulation have 
paid little attention to the sources of random error in the es- 
timation of the ORgpd. In particular, uncertainty in the 
measurement of the between-genotype difference in pheno- 
type level (DIP) has been ignored (7). A failure to incorpo- 
rate the variability in AIP results in overestimation of the 
precision of the ORgpd and may lead to misleading infer- 
ences. Because discordance between ORgpd and C)Rpd 
could result from random and/or systematic error, a sound 
evaluation of bias can he conducted only when random error 
has been properly accounted for. Assuming a log-linear rela- 
tionship between the IP and risk for disease, ORgpd can be 
calculated as ORgd(kj°tt') (7). If ORgd and DIP come from 
large studies, it would he reasonable to assume that 
log(ORgd) and DIP itself are both normally distributed. If 
ORgd and DIP come from different studies, a practical 
approach to estimate the standard error of t7Rgpd would 
he to generate a large number of random values from the dis- 
tribution of log(ORgd) and AIP and use those values to cre- 
ate an empirical distribution of ORgpd values. Although the 
formula of Fieller (8) for the variance in the ratio of two 
normally distributed variables could be used to obtain valid 
confidence intervals (Cls) and statistical tests for the 
ORgpd, a simulation approach has the additional advantage 
of providing a simple way to estimate the magnitude of bias 
AEP Vol. 16, No. 9 
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in ORpd and combine data from genetic and nongenetic 
studies. 
Comparing the Estimate of the Effect of IP on Disease 
Risk Obtained From Nongenetic Studies With That 
From Genetic Studies: Judging Agreement versus 
Hypothesis Testing 
Judgments on the magnitude of residual confounding and 
reverse-causality bias in nongenetic IP-disease association 
studies have relied largely on hypothesis tests of the differ- 
ence between ORpd and ORgpd (2,5,9,10). Considering 
solely the size of the ORpd - ORgpd difference can he mis- 
leading because large or small differences could result from 
random variability in either of the two quantities. As sug- 
gested previously (2,9), a t-test of the hypothesis ORpd 
= ORgpd can he constructed as (11): 
(C)Rpd ORgpd)/I(standard error ofORpd)2+ 
(si ndard error of CRgpd)211 
lt is possible to incorporate the variability of AIP into such 
a test and thus avoid a spuriously precise result. However, 
even if correctly calculated, use of a statistical test to judge 
the magnitude of bias in observational studies can be ques- 
tioned on theoretical and practical grounds (12 ). When us- 
ing the Mendelian triangulation strategy, we take ORgpd as 
a standard and compare it with ORpd. The underlying prin- 
ciple is that departures of ORpd from ORgpd are caused by 
systematic errors, largely confounding and reverse causality. 
However, statistical tests aim to evaluate whether the differ- 
ence between ORpd and ORgpd is caused by random error. 
Because l values depend on the magnitude of the difference 
(bias), as well as on the precision of ORpd and ORgpd, small 
differences may he statistically significant (p < 0.05) if esti- 
mates of ORpd and ORgpd come from studies with large 
sample size. This may lead to the erroneous conclusion 
that ORpd is significantly biased, even if its value is close 
to that of the ORgpd. Conversely, large differences between 
ORpd and ORgpd could be statistically nonsignificant (p 
0.05) if estimates of ORpd and/or ORgpd come from small 
studies. In this case, one would erroneously conclude that 
ORpd is unbiased, even if it is very different from ORgpd. 
Thus, the significance of a statistical test, regardless of the 
chosen significance level, is not the most appropriate mea- 
sure of degree of bias in ORpd. 
The likely validity of IP-disease association studies can 
be assessed by how close the potentially "biased" estimate 
(ORpd) is to the theoretically "unbiased" estimate 
(ORgpd). We propose that the degree of consistency be- 
tween ORpd and ORgpd is a matter of estimation and judg- 
ment, rather than hypothesis testing. This is analogous to 
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deciding whether material confounding is likely to he pres- 
ent when comparing crude and adjusted odds ratios in an ep- 
idemiologic study of a putative risk factor and a disease. 
Significance testing in such a setting is inappropriate and 
unhelpful. However, when comparing different estimates 
of effect, it remains important to consider their precision. 
Thus, methods to assess the degree of uncertainty caused 
by random error in these estimates are needed, although hy- 
pothesis testing is inappropriate. 
An average estimate of the bias can be obtained by gen- 
erating a large number of random values from the distribu- 
tion of both log(ORgpd) and log(ORpd). Also, a range of 
values compatible with an unbiased ORpd can he calculated 
from the empirical distribution of calculated ORpd -ORgpd 
differences. This approach is similar to the method of Bland 
and Altman (13) of limits of agreement used to compare 
clinical tests. An assessment based on the size of the bias 
(or agreement for the Bland-Altman method) and the range 
of reasonably unbiased ORpd would depend on the particu- 
lar phenotype-disease association being studied. 
METHODS 
We used data from a study of the association between homo- 
cysteine level and stroke that used Mendelian triangulation 
for the C: 677T/MTHFR genotype (5) to illustrate the con- 
sequence of ignoring variability in &IP in the estimation of 
the precision of the ORgpd. We drew a random sample of 
10,000 values from the distribution of log(ORgd) and OlP 
and used them to calculate an equal number of values for 
ORgpd. A 95% CI for C)Rgpd was constructed by excluding 
values greater than the upper and less than the lower 2.5% 
percentiles of its distribution. The standard error of ORgpd 
is given approximately by: (upper 95% Cl limit - 
lower 95% 
Cl limit) -= (2 * 1.96). We compared results obtained de- 
pending on whether variability in &1P is taken into account. 
To show the effect of variability in LIP, results were oh- 
tained for cumulative results of studies published between 
1998 and 2003. 
Using four other published examples of studies that used 
the Mendelian triangulation strategy (2,9,10), we randomly 
drew 10,000 values from the distribution of log(ORpd) and 
log(ORgpd) (sample means and standard errors). We used 
these values to estimate the likely degree of bias in the 
ORpd compared with the ORgpd by calculating: 
I. Mean relative bias = mean of (ORpd; ORgpd, ) 
ORgpd; 
2. Smallest and largest relative bias = 2.5% lowest 
and upper percentile values for the relative bias 
(ORpd; -- ORgpd, ) = ORgpd, 
3. Range of reasonable unbiased ORpd = mean 
ORpd; = lowest and largest relative bias 
678 Bautista et al. 
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These provide a range of reasonable values for ORpd if it 
were unbiased. 
For comparison purposes, we also present for each exam- 
ple results of standard statistical hypothesis tests of a differ- 
ence between ORpd and ORgpd that do not take into 
account variability in DIP. All analyses were performed 
using Stara 8.2 (Stata Corp., College Station, TX). 
RESULTS 
In our previous study of the association between homo- 
cysteine level and stroke incidence using Mendelian trian- 
gulation for the C677T/MTHFR genotype (5), SIP and its 
standard error varied with the accumulation of data from 
new studies (Table 1). The phenotype difference corre- 
sponding to ORpd was 5 pmol/L. With data available up 
to 1998, a CI for ORgpd that correctly accounts for random 
error in NNP was almost three times wider than an interval 
calculated ignoring the variability of SIP. By 2003, the sam- 
ple size was more than 12 times that in 1998, and the stan- 
dard error of OIP was considerably reduced. However, 
a correct Cl was still 9% wider than the interval obtained 
ignoring the variability of AIP. 
Results of using repeated simulations to estimate the 
magnitude of bias in ORpd are listed in Table 2. In example 
1, coronary heart disease is the outcome of interest, homo- 
cysteine is the IP, and the MTHFR/C677T variant is the 
polymorphism associated with both phenotype levels and 
disease risk (2). Mean relative bias was 0.975, i. e., ORpd 
was underestimated on average by 2.5%. However, accord- 
ing to the data at hand, ORpd could he underestimated by 
13% or overestimated by 9%, and the range of reasonable 
values for an unbiased ORpd was 1.04 to 1.29. Because 
TABLE 1. Mendelian triangulation estimates of the odds ratio 
for stroke for a 5-pmol/L difference in plasma homocysteine 
level with and without correcting the variance for uncertainty 
in the association between MTlIFR/C677T genotype and 
homocysteine level 
Studies Sample 
up to size A11 
SE 
(All')" 
Odds 
ratio 
95% Cl 
ignoring 
SE(Oll')h 
95% CI 
accounting 
for SE(&IP) h 
Ratio 
of width` 
1998 730 2.10 0.5996 1.73 1.37---2.23 1.31-3.82 2.92 
1999 935 2.72 0.3725 1.53 1.27-1.86 1.25-2.00 1.27 
2000 2515 2.18 0.2282 1.70 1.35 2.16 1.332.28 1.17 
2001 3619 1.94 0.2237 1.81 1.40-2.38 1,38-2.55 1.19 
2002 5847 1.86 0.1620 1.86 1.42 2.47 1.40 2.57 1.11 
2003 9139 1.93 0.1477 1.82 1.40-2.39 1.38-2-46 1.09 
MTF-iFR - methylenererrahydrofolare reductase; Cl = confidence interval. 
"Difference in plasma homocysteine levels between individuals with genotype Tl 
and CC for the MTHFR/C67T1 polymorphism. 
'Standard 
error of the between-genotype phenotype difference in plasma homocys- 
reit e levels. 
'Ratio of the width of the 95% CIs that takes into account and the one that ignores 
the standard error of the between-genotype phenotype difference in plasma homo- 
cysteine levels. 
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this range of values for ORpd does not include 1, we are in- 
clined to conclude that greater plasma homocysteine level 
increases the risk for coronary heart disease. In other words, 
even if ORpd is biased, the bias is small and it is unlikely that 
the observed phenotype-disease association is caused mostly 
by confounding or reverse-causality bias. Therefore, results 
of genotype-disease and genotype-phenotype association 
studies provide additional support for the association be- 
tween phenotype and disease quantified in nongenetic 
observational studies. In this example, p value from a t-test 
of a difference between ORpd and ORgpd that does not 
take into account variability in DIP was 0.69. This nonsig- 
nificant p suggests that the difference between the two esti- 
nmates could be attributed to random error. However, it 
provides no insight into evidence underlying the judgment 
of lack of bias because it could be the result of a small 
ORpd - ORgpd difference and/or 
large variability in either 
of the two estimates (i. e., lack of power). The test is con- 
ducted under the assumption that the difference between 
ORpd and ORgpd is not the consequence of bias. 
Example 2 is of coronary heart disease, fibrinogen level, 
and the -148 Hindill variant (2). There was an average pos- 
itive bias of 17%. Taking random error into account, ORpd 
was overestimated by 7% (smallest relative bias) to 27% 
(largest relative bias). These figures correspond to values 
of 0.94 to 1.12 for a range of unbiased ORpd. Therefore, 
available data from both nongenetic observational studies 
and genotype-IP and genotype-disease studies point to 
a very small or a null effect of fibrinogen level on risk for cor- 
onary heart disease. The effect reflected by the ORpd seems 
to he mostly a result of bias. The p from a t-test for a differ- 
ence between ORpd and ORgpd that does not take into 
account the variability in AIP was highly significant 
(p < 0.001). This small p value results from a large differ- 
ence between ORpd and ORgpd and very precise measurements 
of both estimates. However, contrary to the estimation ap- 
proach, the p value does not allow us to explicitly combine all 
data from genetic and nongenetic studies to make a judgment 
on the phenotype-disease association. 
Example 3 is of coronary heart disease, fibrinogen level, 
and the -148 HindIIl variant (9). The relative mean bias 
was very small ( 0.6%), suggesting the ORpd may be unbi- 
ased. However, the range of plausible unbiased ORpd values 
was very wide (0.70 to 1.64), reflecting the large uncertainty 
in estimation of ORgpd. In this case, a conclusion regarding 
the effect of plasma fibrinogen level on coronary heart 
disease is not warranted because the range of values for 
unbiased ORpd is too wide. Briefly, if ORgpd from the Men- 
delian triangulation cannot he calculated with sufficient 
precision, it will be of limited use to assess whether ORpd 
is biased. The p value from a t-test for a difference between 
ORpd and ORgpd was nonsignificant (p = 0.80). This could 
have led to the inappropriate conclusion that ORpd was 
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TABLE 2. Examples of comparison of odds ratios from nongenetic observational studies (ORpd) and odds ratios 
from genotype-phenotype disease studies (ORgpd) 
Exposure (phenotype/ 
disease/gene variant) ORpd ORgpd 
Relative 
mean bias 
Smallest 
bias (%) 
Largest 
bias (%) 
Smallest 
ORpd' 
Largest 
ORpd, p 
1_ Homo ysteine/('HD/MTHFR/C677T2 1.13 (1.08-1.19) 1.16 (1.05-1.28) 0.975 0.874 1.09 1.04 1.29 0.69 
2. Fihrinogen/CHD/-148 ] lind 1W 1.20 (1.13 1.26) 1.03 (0.96 1.10) 1.17 1.07 1.27 0.94 1.12 <0. Ot31 
3. Fibrinogen/0 ID/-148 Hind 11124 1.07 (1.01- 1.11) 1.08 (0.71 -1.65) 0.994 0.653 1.52 0.70 1.64 0.80 
4. Apo B/Apo Al/MI Apo-E (2/( 3/01" 1.63 (1.58 1.68) 1.11 (1.07 1.36) 1.36 1.20 1.54 1.06 1.36 <0.001 
CHU = coronary heart disease; Apo B= apolipoprotein B; MTHFR = methylenetetrahydrofnlate reductase. 
'Calculated using the 95% confidence limits of the relative bias, 
"p from a t-teat for a ditference between ORpd and ORgpd that does not take into account the variability of AIP 
unbiased. However, the estimation approach clearly illus- 
trated that there was absence of evidence of bias, rather 
than clear evidence of absence of bias. 
Example 4 is of myocardial infarction, apolipoprotein 13 
(ApoB)/ApoAl, and Apo-E E2/s3/E4 variants (10). The 
ORpd was biased substantially, with a relative mean bias 
of 36%. Despite the large bias, the range of unbiased values 
for the ORpd (1.06 to 135) suggests that the ratio of plasma 
Apo B/Apo Al is associated with increased risk for myocar- 
dial infarction. However, the increase in risk is likely smaller 
than that reported in nongenetic observational studies. The 
p value from a t-test for a difference between ORpd and 
ORgpd was highly significant (p < 0.001). This would lead 
to a conclusion that ORpd was biased. However, the more 
subtle interpretation that whereas there was likely to be sub- 
stantial bias in the estimate of ORpd, the association was still 
likely to he present could not he drawn from the p value. 
DISCUSSION 
We have shown that simulations can help correctly interpret 
combined results from nongenetic studies and Mendelian 
triangulation studies. Random variation in AIP and thus 
ORgpd can he estimated reliably, avoiding the problem of 
spurious precision that arises when such variability is 
ignored. More important, simulations also are useful to ob- 
tain an estimate of the likely degree of bias in ORpd, which 
cannot be accomplished with statistical tests. We propose 
that the comparison between ORpd and ORgpd be based 
on their degree of consistency and is a matter of estimation 
and judgment about the level of systematic error in the 
ORpd, rather than of hypothesis testing. The most reason- 
able way to evaluate bias in this context is to estimate its 
magnitude and judge whether it is sufficiently large to 
make us believe that confounding or reverse-causality bias 
were so substantial as to shed doubts on the validity of 
ORpd. Even if random error is negligible, proper quantifica- 
tion of the magnitude of the bias is essential to assess whether 
the nature of the phenotype-disease association is likely 
valid and possibly causal. By calculating a range of plausible 
unbiased values for the phenotype-disease association, 
taking into account results from genotype-disease and geno- 
type-1P studies, one can make full use of the information 
available to learn what should he reasonably expected in 
the case of extreme underestimation or overestimation 
bias. This may help identify cases in which the IP is still likely 
associated with the disease, even if considerable bias is pres- 
ent. This cannot he accomplished by using the "yes" or "no" 
decision rules attached to statistical tests and the use of single 
cutoff values. In addition, the range of plausible values for an 
unbiased ORpd allows us to identify studies in which the 
ORgpd obtained by Mendelian triangulation is so uncertain 
that it is practically of little use to assess the validity of ORpd. 
In these cases, the range of values for the ORpd could be too 
wide to reach a conclusion, and inspection of the Cl for 
ORgd, AIP, and ORpd would help its define what type of 
additional information should be gathered in future studies. 
This cannot be accomplished with statistical tests. 
Alternative approaches to the problems we highlight in- 
clude the use of bioequivalence tests and instrumental vari- 
ables. Bioequivalence tests have been proposed as a method 
to measure the degree of residual confounding in ORpd (7). 
Because these tests evaluate the probability of getting a dif- 
ference equal to or larger than a preset value, they pertain to 
the evaluation of random error, and their use in evaluating 
systematic error (residual confounding and reverse-causality 
bias) is questionable. Large differences between ORpd and 
ORgpd could be statistically nonsignificant simply because 
of lack of study power. This could happen if the estimates 
of ORpd and/or ORgd come from small studies. Conversely, 
a small ORpd -ORgpd difference, which will indicate little, 
if any, systematic error, could he statistically significant if 
both ORpd and ORgpd are measured with high precision, 
such as would he expected in large studies. Briefly, p value 
from a statistical test by itself will tell very little about the 
magnitude of the bias in ORpd regardless of the level of sig- 
nificance used for interpretation. 
Another approach to control for unmeasured con- 
founders in the context of genetic studies is the use of 
instrumental-variable methods (14,15). For example, the 
instrumental variable approach was used to estimate an un- 
biased effect of plasma C-reactive protein (CRP) level on 
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hypertension, taking advantage of the association between 
the 10590/C polymorphism in the human CRP gene with 
CRP levels (16). Genetic variants may be treated as instru- 
mental variables if they are unrelated to other risk factors for 
the disease under study, correlate with the 1P, and are related 
to disease risk only through their association with the IP. An 
estimate of the effect of IP on disease risk can be obtained as 
the ratio of the genotype-disease effect/genotype-IP effect. 
Hausman's (17) specification error test frequently is used to 
evaluate whether the regression coefficient from a model in- 
cluding the instrumental variable differs from a model not 
including the instrumental variable. Because the goal of 
the instrumental variable approach is largely to evaluate 
and control for systematic error, not for random error, use 
of statistical tests in this context is as questionable as its 
use in Mendelian triangulation. In addition, the instrumen- 
tal variable adjustment for confounding can be particularly 
unreliable if the genotype-IP association is weak and when 
the genotype-disease and the genotype-IP associations 
have been measured with considerable uncertainty (14, 
15). When results from an instrumental variable analysis dif- 
fer from those of a standard analysis, the judgment of bias be- 
comes subjective (18). An approach based on estimation, 
rather than statistical testing, such as the one we propose, 
may be useful in these cases. 
We recognize that our approach should he used with cau- 
tion and tested with additional data. If data from overlap- 
ping studies are used to estimate ORgd, &IP, and C)Rpd, 
the nonindependence of the observations trust he taken 
into account in the calculation of the variability of the 
ORgpd. Also, when any of these estimates come from small 
studies, the assumption of normal distribution may not ap- 
ply. In such situations, the values of ORgpd and ORpd 
should he generated by sampling random values from the 
proper distributions of ORgd, SIP, and ORpd. 
Despite its potential value, the Mendelian triangulation 
strategy should be considered as an emerging additional 
source of evidence about the effects of environmental expo- 
sures on disease, not as proof of causality. A number of 
caveats may apply. First, if the studied genotype has 
alternative splicing leading to the production of two differ- 
ent 1Ps, the Mendelian triangulation approach may not be 
appropriate. Second, it is assumed that the lifetime geneti- 
cally determined difference in an IP does not lead to com- 
pensatory changes in other systems that may confound the 
genetic estimate. Third, the genotype-IP and genotype- 
disease associations may be confounded by linkage disequi- 
librium with other causal genes or by ethnicity, population 
stratification. Fourth, cases and controls in genetic studies 
are rarely random samples from their population, and rela- 
tively small samples frequently are used. In consequence, as- 
sociations between a genotype and risk factors for a disease 
can occur in genetic studies and can result in selection 
AFT Vol. 16, No. 9 
Septemhen ? i)c)O 675-680 
bias and confounding, even if they are not expected to occur 
in the entire population (19). 
In conclusion, Mendelian triangulation is a promising 
strategy for the study of disease cause, but adequate methods 
to compare ORgpd and ()Rpd are needed to avoid mislead- 
ing assessment of the causal role of an IP on disease risk. The 
simulation methods presented here provide a useful ap- 
proach to attain this goal. 
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This editorial refers to 'C-reactive protein gene haplo- 
types and risk of coronary heart disease. The Rotterdam 
Study't by I. Kardys et at., on page 1331 
In the last decade, there has been a burgeoning interest in 
associations between concentrations of various circulating 
biomarkers and later coronary disease. ' Of these, the 
acute phase reactant, C-reactive protein, has garnered the 
greatest attention. This spotlight on C-reactive protein 
reflects the strength and consistency of the observed associ- 
ations, the fact that C-reactive protein is a stable and 
readily measured analyte, and the focus on the link 
between inflammation and atherosclerosis. The findings 
led initially to the proposal that its measurement might 
provide useful predictive information on coronary disease 
risk. 2 Later, the proposal was made that C-reactive protein 
might even play a contributory role in atherogenesis. 2 
Associations identified between C-reactive protein and inci- 
dent blood pressure, diabetes, and metabolic syndrome 
were used in support of this, and experimental data from 
studies of vascular cells and tissues in vitro and from infu- 
sions of C-reactive protein provided preliminary evidence 
for pro-inflammatory, pro-adhesive, and pro-thrombotic 
actions. 3 These data are exciting because it was through a 
similar mix of observational and experimental work that 
cholesterol was first identified as a potential causal factor 
in atherosclerosis, a link which randomized clinical trials 
of cholesterol-lowering drugs subsequently confirmed to be 
causal. If the same is true for C-reactive protein, it would 
represent a new therapeutic target for coronary disease 
prevention. 
More recently, however, evidence has emerged, which 
questions the role of C-reactive protein in both the predic- 
tion of clinical events and in the pathogenesis of athero- 
sclerosis. A meta-analysis of the prospective cohort studies, 
including a very large new study, indicated that the strength 
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of the C-reactive protein-coronary event association may be 
smaller than initially supposed and that C-reactive protein 
may offer limited predictive information, particularly after 
levels of traditional risk factors are taken into account. 4 
This is because C-reactive protein is itself associated with 
a range of established risk factors for cardiovascular 
disease including smoking, blood pressure, diabetes, as well 
as HDL-cholesterol. Once these are measured, it has been 
argued, there is little additional predictive information in a 
C-reactive protein measurement. 
Associations among established risk factors and biomarkers 
also limit inference on causation in observational studies 
because associations of any one factor such as C-reactive 
protein with incident disease could be affected by confound- 
ing (where the link arises because of the common association 
of the biomarker and the disease outcome with other causal 
risk factors like smoking, or with an enlarging list of other 
biomarkers of less certain causal relevance). Statistical 
adjustment can limit confounding, but rarely overcomes it 
completely. Adequate adjustment can only be made for 
those risk factors or biomarkers that have been measured. 
In a recent review, perhaps 100 biomarkers or exposures 
(including C-reactive protein) were listed as having shown 
association with coronary risk in observational studies. ' 
Importantly, most of these correlate to a greater or lesser 
degree with one another. However, no study has adjusted 
for them all. Even if all were assayed, the inherent biological 
and analytical variability in any measure generally limits the 
ability to make complete adjustment. Despite this, the 
persisting association of C-reactive protein with disease 
risk, after adjustment for a generally limited range of risk 
factors or other biomarkers, referred to as 'independent 
association' in statistical parlance, has sometimes been over- 
interpreted as equating with causation. The possibility of 
residual confounding by unmeasured exposures remains 
however, and the link with the disease may not be causal. 
There is an additional problem. Observational studies may 
not well define the direction of causation, should it exist. 
Reverse causation (where atheroma leads to an elevation 
of C-reactive protein rather than vice versa) could provide 
an alternative explanation for the link between C-reactive 
protein concentration and disease risk. Although this is 
more of a problem in case-control studies, it may still 
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affect prospective studies of initially healthy subjects, 
because atherosclerosis has such a long subclinical phase. 
Against this setting, another prospective observational 
study demonstrating the association of C-reactive protein 
with coronary events is reported by Witteman et a(. 
5 This 
association, which diminishes but persists after adjustment 
for a range of potential confounders, is insistently concor- 
dant with prior work. So what is different about this 
study? The beauty of the current work is that, in line with 
a growing number of similar studies, it takes the observa- 
tional analysis, with its inherent limitations, a stage 
further by incorporating a genetic approach. Taking advan- 
tage of its recent resequencing (http: //pga. gs. washington. 
edu/data/crp/ and Carlson et a(., 6), Kardys et at. type 
three common genetic variants (single nucleotide poly- 
morphisms; SNPs) in the gene that encodes C-reactive 
protein. Through their association with the 12 or so 
additional untyped variants in the gene, these three 
'tagging' SNPs adequately capture almost all the genetic 
diversity at this locus in European subjects. All the SNPs, 
as well as the haplotypes inferred from them, are associated 
with differences in C-reactive protein concentration of 
about 0.6 mg/L between the most extreme categories, 
representing nearly 25% of the interquartile range of the 
C-reactive protein distribution in this population. Seasoned 
readers of the journal may have become wary of positive 
findings from genetic association studies with disease 
end-points, because of their inconsistency. Nevertheless, 
they can be reassured that, in this case, the association 
between C-reactive protein genotype and C-reactive 
protein concentration (an intermediate phenotype) is 
almost certainly correct. The genotype-C-reactive protein 
associations identified by the Rotterdam study are closely 
concordant with other studies of C-reactive protein 
SNPs. 6-8 In general, genotype biomarker associations 
appear to be more readily established than genotype 
disease associations perhaps because: (a) a change in level 
or property of the biomarker is the immediate consequence 
of the genetic variation, so the 'signal-to-noise ratio' is 
greater in such studies; (b) a given biomarker is likely influ- 
enced by a smaller range of genes and exposures than the 
disease; (c) biomarkers are continuous traits, so power is 
enhanced greatly over studies where the outcome is categ- 
orical (e. g. disease event); and (d) biomarker levels are less 
prone to misclassifcation error than commonly used disease 
end-points such as 'myocardial infarction' or 'angiographic 
coronary artery disease (CAD)'. 
So why bother to study gene variants when one can 
measure C-reactive protein itself? Even if genotype contrib- 
utes to differences in C-reactive protein concentration, it is 
only one of the many factors to do so, and the genetic con- 
tribution to the variance in C-reactive protein is likely to be 
much smaller than that due to the combined effect of 
acquired exposures such as abdominal obesity, smoking, 
blood pressure, and so on. The answer is that, there is one 
particular property of genotype that distinguishes it from 
all the acquired exposures that influence C-reactive 
protein. Genotype is determined at random at conception 
according to Mendel's Laws, because of the independent 
assortment of alleles during meiotic cell division and the 
reconstitution of the diploid genome during fusion of 
gametes. In effect, allocation to a low-C-reactive protein 
genotype (or haplotype) at conception is analogous to 
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being randomized to a specific C-reactive protein-lowering 
drug in a clinical trial. This natural Mendelian randomization 
should ensure that factors that could confound associations 
of C-reactive protein itself with coronary disease should be 
distributed evenly among individuals with differing 
C-reactive protein genotype (or haplotype). 9'10 lt is clear 
from Kardys's study that this is indeed the case. Although 
a whole range of measured (and by extrapolation unmea- 
sured) exposures relevant to coronary risk varied by quartile 
of measured C-reactive protein, none differed among the 
four common haplotypes or genotypes of the C-reactive 
protein gene, despite a substantial genetic influence on 
C-reactive protein concentration. Moreover, as genotype/ 
haplotype is determined prior to the disease, reverse causa- 
tion should also be overcome. Thus, studying the effect of 
C-reactive protein indirectly through its gene, counter- 
intuitively, provides a less biased and confounded assess- 
ment of its influence on disease risk than studying C-reactive 
protein itself. If a high C-reactive protein actually contri- 
buted causally to coronary disease risk, individuals with 
genotypes that raise C-reactive protein concentration 
should have a higher risk of coronary disease, commensurate 
with the effect of genotype on C-reactive protein level. In 
the current study, however, no such increase in coronary 
risk was observed. 
So is the case now closed? Has a causal role for C-reactive 
protein in atherosclerosis been unequivocally refuted? The 
answer is no, but evidence such as this is forcing a more cau- 
tious and critical approach. The null point estimate from the 
current genetic study is concordant with genetic risk esti- 
mates from other work7'8 and consistent with recent experi- 
mental studies in vitro, which have indicated that the 
apparently pro-atherogenic actions of C-reactive protein 
observed in earlier studies may have been mediated by bac- 
terial peptides and sodium azide present in commercial 
recombinant C-reactive protein preparations rather than 
by C-reactive protein itself. " Because the genetic effect 
on C-reactive protein is small, a very large genetic associ- 
ation study with about 10 000 cases would be required to 
exclude a small but, in population terms, extremely import- 
ant causal effect of C-reactive protein on coronary out- 
comes. Accumulating this number of cases may be beyond 
the capacity of individual research groups, but could be 
achieved through a collaborative effort to pool studies of 
the type reported here. The development of networks of 
genetic investigators may help facilitate this and, in the 
absence of a selective C-reactive protein-lowering drug, 
may provide the only currently practical way of providing 
randomized evidence on the effect of C-reactive protein- 
lowering on disease risk. 12 Although statins lower C-reactive 
protein, this is neither their primary nor main action and it is 
unclear if this effect is achieved independently of or through 
cholesterol reduction. 
What of C-reactive protein and disease prediction? 
C-reactive protein might still provide useful information 
on coronary risk even if it does not play a causal role in 
coronary disease, because its concentration might capture 
information on the extent of exposure to orthodox risk 
factors, inflammatory signals from adipose, or the burden 
or inflammatory state of atheromatous plaques. However, 
the finding that common variation in the C-reactive 
protein gene influences C-reactive protein concentration 
both in health and during acute inflammation has potentially 
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important implications for risk prediction. Two individuals 
with contrasting C-reactive protein genotype but the same 
measured C-reactive protein concentration might have 
different underlying levels of risk factor exposure or inflam- 
matory activity. If it is these that influence disease outcome, 
the prognostic value of a given C-reactive protein measure 
may need to be considered in conjunction with genotype 
or haplotype. Additional work will be required to assess if 
the predictive utility of a C-reactive protein measurement 
is modified by genotype. 
Combining genetic and observational approaches as 
Kardys et at. have done, offers the possibility of better 
distinguishing causal from confounded associations of 
biomarkers and coronary disease and may, in future, help 
prioritize new therapeutic targets. Rich and expanding 
databases of human genome variation are providing the 
genetic tools for this type of work, but of no lesser import- 
ance are the existence of well-phenotyped cohorts, of which 
the Rotterdam study is an excellent example. 
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Modestly elevated baseline concentrations of 
C-reactive protein (CRP), the classical acute phase 
protein, are associated with the long-term risk of coro- 
nary heart disease in general populations, whilst the 
major acute phase response of CRP following 
myocardial infarction is associated with death and car- 
diac complications. The pathogenic and clinical sig- 
nificance of these associations is controversial. Here 
we critically review the evidence and describe large- 
scale epidemiological studies, novel experiments and 
possible specific therapies which will rigorously 
inform the debate. We distinguish between the poten- 
tial pathogenicity of high acute phase circulating CRP 
concentrations in individuals with substantial tissue 
damage and modest but persistent increases in base- 
line values in generally healthy subjects. 
Keywords: coronary heart disease, (:. -reactive protein. 
Introduction 
Inflammation has been proposed to contribute to dif- 
ferent stages in the pathogenesis of coronary heart 
disease (CHI)), including the lifelong process of ath- 
crogcnesis, the acute atherothrombotic event, which 
causes ischaemic necrosis in acute myocardial infarc- 
tion (Ml) and the myocardial damage following 
ischaemia (1-51. C-reactive protein (CRP), the classi- 
cal acute phase protein, is the most extensively stud- 
ied systemic marker of inflammation (61. Since the 
original demonstration of an association between even 
modest increases in baseline circulating CRP and sub- 
sequent cardiovascular outcomes in patients with 
unstable angina at the initial examination [7,81, CRP 
has been the focus of intense investigation (51. 
Several population-based prospective studies of CHD 
(defined in this paper as non fatal MI or coronary 
death) have reported on associations of subtle, pro- 
longed increases in baseline CRP levels with CHD 
risk [9]. Also, CRP has been known for more than 
25 years to bind to LDL [10,111 and it has been 
detected in atherosclerotic plaques [121. These obser- 
vations have collectively raised the possibility that 
CRP may play a direct causal role in CHD (and, by 
implication, could be an important therapeutic target), 
although there is debate about the interpretation of 
both epidemiological and experimental observations 
[13-15]. There is also uncertainty about the separate 
issue of the value of measurement of CRP in the 
long-term prediction of cardiovascular outcomes [16, 
171. A completely distinct possibility is that, in con- 
trast to modest long-term differences in baseline CRP 
values, the major acute phase response of CRP trig- 
gered by MI may contribute acutely to severity and 
outcome of the ischaemic lesion [1R}. The objective 
of this article is to provide a critical review of the 
© 2008 Blackwell Publishing Ltd 295 
available evidence on associations of CRP with CHD 
and to highlight emerging approaches that may help 
clarify the uncertainties described above. 
Structure of CRP 
('-reactive protein is a nonglycosylatcd circulating 
plasma protein which together with the distinct but 
closely related protein, serum amyloid P component 
(SAP), comprises the pentraxin family of proteins 
[19,201, which belong to the lectin fold superfamily 
[2Ii. Each pentraxin is composed of five identical 
noncovalcntly associated subunits arranged with cyc- 
lic pentameric symmetry in a disc-like configuration 
and has characteristic calcium-dependent binding to 
specific ligands (Fig. 1). lach CRP protomcr has the 
flattened f1-jcllyroll lectin fold and hears on one face, 
the B or binding face, a pocket which contains two 
calcium ions hound just 4A apart by coordination 
with protein carhoxylatc and amide side chains 
derived from loops that congregate on one face of 
the protomer core. 'I hcsc calcium atoms are essential 
for all physiological ligand binding by ('RP and also 
markedly stabilize both the structure of the protomcr 
[221 and the integrity of the native pentamcr. 
Calcium is, of course, always present in the cxtiaccl- 
lular environment in vivo in which ('RP exists, 
and inappropriate omission of calcium in handling 
r 
' 
«lýýiý 
CRP for in vilru experiments produces misleading 
observations. 
In the absence of calcium, even if pH and ionic 
strength are physiological, CRP readily aggregates, 
loses its physiological ligand binding and the normal 
secondary effects thereof, dissociates into protomers 
which then readily misfold, and becomes susceptible 
to proteolytic cleavage. In marked contrast, native 
CRP in the presence of physiological conditions of 
calcium, pH and ionic strength is remarkably stable. 
Although isolated pure CRP can aggregate if subjected 
to violent turbulence, it is otherwise very stable, unaf- 
fected by repeated freeze-thawing, remains in its nor- 
mal pentameric assembly and is highly resistant to 
proteolysis [231. It does not dissociate into protomets 
even in the presence of the very strong anionic deter- 
gent, sodium dodecyl sulphate, unless boiled. CRP is 
also stable in serum which enhances greatly its utility 
as a clinical marker. In view of these robust observa- 
tions, speculations about physiological or pathophysio- 
logical effects of denatured CRP subunits, so-called 
modified CRP, or of proteolytic cleavage fragments of 
('RP are unlikely to he correct and the evidence for 
existence of such moieties in viva is unconvincing. 
The critical importance of appropriate handling of 
('RP is strikingly exemplified by recent observations 
Fig. I 3D X-ray crystal structure of the human ('-rcacti%e protein (('RP) molecule with hound calcium (left) and of a hhus- 
phocholine molecule bound in the ligand binding pocket of one ('RP prototner (right), showing the intennolecular interactions 
responsible for binding 1197 1. X-ray crystallographic structures provided by Dr. Simon Kolstoe. 
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on the putative binding interaction between 
CRP and 
complement regulatory protein, 
factor H (fH). One of 
the two major polymorphic variants of fH is a highly 
significant risk factor for age-related macular degener- 
ation [24-261, and the amino acid substitution 
(Y402H) is in the seventh short consensus repeat, the 
region of fH reported to bind to CRP [271. Recent 
reports of binding between CRP and fH were all 
based on solid phase studies in which CRP was 
immobilized, usually from calcium-free solutions and 
thereby destabilized, by nonspecific adherence to plas- 
tic surfaces, conditions in which such immobilized 
proteins arc inevitably at least partly denatured [291. 
When these studies were repeated using CRP in the 
presence of calcium, no interaction with fH was 
detected (S. Hakobyan, C. L. Harris, C. W. van den 
Berg, M. C. Fernandez Alonso, F. Goicoechea de 
Jorge, S. Rodriguez de Cordoba, G. Rivas, P. Man- 
gione, M. B. Pepys and H. P. Morgan, unpublished 
data). Further extensive controlled studies with fluid 
phase proteins and different configurations and meth- 
ods of immobilization of CRP or fH confirmed that 
there was no detectable interaction between fH and 
native CRP either in solution or on a solid phase 
(S. Hakobyan, C. L. Harris, C. W. van den Berg, M. C. 
Fernandez Alonso, E. Goicoechca de Jorge, S. Rodri- 
guez de Cordoba, G. Rivas, P. Mangione, M. B. Pepys 
and BY. Morgan, unpublished data). Binding was 
only seen when the CRP was denatured and since, as 
noted above, evidence for the existence or at least 
persistence of denatured CRP in vivo is not com- 
pelling, a pathophysiologically relevant interaction 
between CRP and f-I is questionable. 
Ligand binding by CRP 
C. -reactive protein was discovered and named for its 
binding to pneumococcal somatic C-polysaccharide 
[291 in which it recognizes the phosphocholine resi- 
dues which are present in this ribitol teichoic acid 
[301. Phosphocholine is the natural ligand to which 
CRP binds with highest affinity and this key ligand is 
ubiquitous as the polar head group of phosphatidlyl 
choline in cell membranes and plasma lipoproteins. 
Phosphocholine is also present in constituents of 
many bacteria, fungi and parasites and plants and the 
importance for mammalian biology of its recognition 
is exemplified by the fact that a significant proportion 
of the germline antibody specificities are directed at 
it. However, CRP does not hind to all materials con- 
taining phosphocholine as the residues must be `avail- 
able' or in an appropriate sterochemical configuration. 
Thus CRP binds to dead or damaged cells in which 
significant amounts of lysophosphatidyl choline are 
present, but not the surface of living healthy cells 
[': )I]. Binding of CRP to apoptotic cells is controver- 
sial and the most rigorous evidence suggests that CRP 
only binds to so-called late apoptotic cells which are 
effectively necrotic [32-341. CRP also hinds to oxi- 
dized phospholipids (33}, platelet activating factor 
[351, modified L. DL [ß61, [S-VLDL, concentrated 
normal VLDL [371 and to small nuclear ºibonuclco- 
protein particles (which do not contain phospho- 
choline) when these are exposed in dead or damaged 
cells [39,391. 
Binding of CRP to its macromolecular ligands has 
many of the same effects as binding of antibodies to 
antigens, thus CRP precipitates soluble ligands, aggre- 
gates particulate ligands and activates the classical 
complement pathway [40-421. By analogy with anti- 
bodies, it is therefore possible that CRP might con- 
tribute both to host defence against infection and 
enhancement of inflammatory tissue damage. 
Functions of human CRP 
Despite many claims and assertions in the literature, 
neither the normal functions of human CRP nor its 
possible role in disease is known. This is because no 
deficiency or even structural polymorphism of human 
CRP has yet been reported, nor is any drug or other 
therapeutic manoeuvre yet available which specifically 
inhibits or depletes human CRP in vivo. The effects 
of absence, lack of function or inhibition of human 
CRP have thus so far not been tested. 
The notable evolutionary and phylogenetic conserva- 
tion of both the existence and the structure of the 
CRP molecule [20,43,44] suggest that it is likely to 
have a beneficial role and in view of its ligand bind- 
ing specificity and secondary effects, this role could 
© 2008 Blackwell Publishing Ltd Journal of Internal Medicine 264; 295-314 291 
he related to both innate immunity against infection 
and the appropriate safe handling and disposal of 
damaged autologous cells and lipids. However, testing 
these possibilities experimentally is extremely chal- 
lcnging because despite considerable structural 
similarity, the ('RP molecules in different species 
show major differences in normal concentration, in 
behaviour as acute phase proteins, fine ligand binding 
specificity and secondary effects after ligand binding. 
Extrapolation from animals to man is therefore diffi- 
cult and requires that putatively conserved functions 
must be compatible with these major differences. Fur- 
the more, effects of hetcrologous ('RP in vivo, follow- 
ing administration or transgenic expression of human 
('RP in animals. are not necessarily genuine effects of 
human ('RP in humans. Finally, any function pro- 
posed for human ('RP must he consistent with the 
remarkable speed and dynamic range of its plasma 
concentration, which can rise by over 1000-fold in 
24-48 h after a strong acute stimulus such as sepsis 
or acute Ml, and can fäll with a half time of about 
24 h when the stimulus is removed. These dramatic 
changes are not associated with any local or systemic 
vascular or inflammatory effects in patients other than 
those related to the pathology or treatment, which 
respectively triggered or alleviated the acute phase 
response. The fact that injection of even huge doses 
of isolated pure authentic human CRP into healthy 
animals has no adverse, inflammatory or tissue 
damaging etiects is consistent with these long 
well-established clinical observations. 
Synthesis of CRP 
The circulating ('RP is produced by hepatocytes. 
Reports of extra-hepatic ('RP synthesis by some other 
cell types have not always been reproducible [45,461, 
and although possibly relevant to potential local 
effects of ('RP, the contribution to plasma concentra- 
tions can only he minnte with respect to that from the 
liver. Hepatic ('RP synthesis is under exquisitely sen- 
sitive transcriptional regulation via pro-inflammatory 
cytokines including interlcukin (IL)-6, IL-1 and 
tumour necrosis factor-x so that almost any form of 
tissue injury, infection or inflammation, and indeed 
also most forms of adverse nonphysiological 'stress', 
are associated with increased circulating CRP values 
[471. CRP is apparently cleared from the plasma and 
catabolized exclusively by hepatocytes [481 and the 
plasma half-life in humans of about 19 h is the same 
in all individuals regardless of the presence of disease 
or the circulating concentration of CRP. The sole 
determinant of the plasma concentration is therefore 
the synthesis rate [491. 
lt is critically important for any interpretation of the 
significance and utility of CRP values to distinguish 
between modest increments in the very low normal 
baseline values of CRP and the massive rises of sev- 
eral orders of magnitude which occur very rapidly fol- 
lowing major stimuli, such as sepsis, acute trauma or 
tissue necrosis, and which may persist for months or 
years in individuals with chronic active inflammatory 
and tissue damaging diseases, such as chronic infec- 
tions, rheumatoid arthritis, Crohn's disease, lymphoma 
and many others. Furthermore the almost completely 
nonspecific nature of the CRP response means that it 
is neither possible nor medically appropriate to inter- 
pret CRP values in an individual in the absence of 
full clinical information on that person, including his- 
tory, physical examination and full results of all avail- 
able investigations (6j. 
Concentration of circulating CRP in healthy normal 
individuals and in general populations 
In healthy notmal subjects CRP is a trace plasma pro- 
tein. In the first substantial study of such individuals, 
the median value in 468 British Caucasian volunteer 
blood donors aged l8-63 years was 0.9 mg L 1, the 
ninetieth percentile of the distribution was 3 mg L 
and the ninety-ninth percentile was 10 mg L1 [501. 
Similar distributions have been reported from the gen- 
eral adult population of USA [51] and Northern hur- 
ope [52] although values are slightly higher overall in 
these unselected populations, more extreme high val- 
ties are present and concentrations tend to increase 
slightly with age. The markedly skewed distribution 
of CRP values is typically normalized by log transfor- 
mation. In USA 50% of individuals have baseline 
CRP greater than 2 mg L' and 33", % are between 3 
and 10 mg L1 [51]. Compared with people of 
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Northern European ancestry, higher baseline CRP 
values of CRP have been observed 
in people of Afro- 
Caribbean origin residing in North America and lower 
values in people of Japanese or Chinese ancestry 
[53, 
541. In the indigenous Japanese, baseline CRP values 
are about one-tenth of those seen 
in individuals of 
European ancestry [551 but the reasons for these dif- 
ferences are uncertain. In healthy individuals 
followed 
serially with monthly samples, most 
CRP values clus- 
ter at a level typical for that individual and generally 
within the range of 0.1-3 mg L 
1, but with occasional 
spikes unrelated to any obvious clinical pathology. 
About 50% of the individual variance in baseline 
CRP concentration is genetic and largely attributable 
to noncoding polymorphisms in the CRP gene (see 
below). The other major determinant, independent of 
genetic factors, is the level of adiposity, especially 
central abdominal obesity [561, reflecting production 
of pro-inflammatory cytokines by macrophages asso- 
ciated with such adipose tissue and by the adipocytes 
themselves [571 and possibly even some CRP pro- 
duction by adipocytes [581. The year-to-year within- 
pet-son variability of CRP in populations of initially 
apparent healthy adults is comparable with those seen 
for levels of blood pressure or serum cholesterol 
(Fig. 2a) and some other circulating markers of 
inflammation (e. g. fibrinogen, leucocyte count) [59- 
61]. For example, the intraclass correlation coefficient 
for CRP levels (calculated from two different mea- 
surements obtained from the same individuals a few 
years apart) is about 0.6 [62]. 
The term 'high-sensitivity' or `highly sensitive' CRP, 
abbreviated as hs-CRP, has been widely adopted in 
recent literature. It refers to measurement of CRP in 
serum or plasma samples using immunoassay methods 
with sufficient sensitivity to quantify CRP throughout 
its normal range in contrast to older less sensitive 
commercial assays which had detection limits in the 
range 2-10 mg L' and were suitable for measure- 
ment of acute phase responses of CRP rather than 
baseline values. It is very important to recognize that 
the analyte designated as hs-CRP is just CRP itself, 
not anything new or different and in particular is not 
a novel analyte with any special relationship to car- 
diovascular disease. hs-CRP is the same exquisitely 
(a) Within-person variability over 12 years (b) Odds ratios for coronary heart disease 
No. of paired No. of CHD 
Emerging markers measurements cases 
C-reactive protein 370 2038 
370 Interleukin-6 2138 -I-- 
Lipoprotein (a) 372 -a- 2047 ý- 
Triglycerides 358 2066 
Established risk factors 
' 
Total cholesterol 379 2078 
Systolic blood pressure 378 2078 
Current smokert 380 2078 
0.0 0.5 1.0 0.7 1.0 1.5 2.0 2.5 
Regression dilution ratio Odd ratios and 95% 01 
(95%01)- (top third vs bottom third)$ 
Fig. 2 Direct comparisons of C-reactive protein, several established cardiovascular risk factors and emerging markers in rela- 
tion to: (a) within-person variability over 12 years (expressed as the regression dilution ratio*) and (b) odds ratios for coronary 
heart disease (adjusted for established risk factors). *Regression dilution ratio calculated using Rosner's multivariate regression 
method, adjusted for baseline age, sex, smoking history, diabetes history, total cholesterol, log triglycerides, systolic blood pres- 
sure, and 
body mass index. 'Compared with not current smokers. 'Odds ratios (top third vs. bottom third) are adjusted for 
cohort, age, sex, period of recruitment, smoking status, history of diabetes, total cholesterol, log triglycerides, systolic blood 
pressure and body mass index. Data source: data have been derived from the 19 000-participants Reykjavik cohort study and 
collated from the following publications: [62,102,104,105j. 
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sensitive and entirely nonspecific systemic marker of 
infection, inflammation, tissue damage and/or almost 
any form of adverse nonphysiological stress as the 
CRP, which has been extensively studied and used 
clinically for over 75 years. Precisely the same con- 
straints apply to use of its values, notably that these 
cannot be interpreted in the absence of füll clinical 
information on the individual patient at the time the 
sample was taken [6]. An individual with an apparent 
baseline CRP value of, say 7 mg L 1, should not just 
he told that they have an increased risk of cardiovas- 
cular disease and be advised to alter their lifestyle 
accordingly, when the increased CRP concentration 
might reflect any of a very wide range of other seri- 
ous diseases which have not yet declared themselves, 
for example, Hodgkin's disease or renal carcinoma or 
any other condition which is often occult for some 
time before clinical presentation [6]. 
Long-term prospective epidemiological studies of 
CRP and CHD 
In 1996, the first population-based prospective study 
reported on associations of `baseline' CRP levels with 
CHD outcomes [63]. By 2008, over 40 further such 
studies had reported [62-101], typically involving 
middle-aged populations of European ancestry. A lit- 
erature-based meta-analysis was published in 2004 
involving 22 population-based prospective studies 
with a total of 7068 incident CHD cases with a mean 
follow-up of 12 years. The odds ratio for CHD 
adjusted for several established risk factors was 1.6 
(95% CI: 1.5-1.7) in a comparison of people with 
baseline CRP levels in the top third compared with 
those in the bottom third of the population distribu- 
tion (corresponding to values of about 2.4 mg L1 vs. 
1 mg L 1) [62]. This odds ratio is similar in magni- 
tude to those reported for some other nonspecific cir- 
culating markers of inflammation (e. g. fibrinogen 
[60], IL-6 [102], leucocyte count [103]) and some 
other emerging biochemical risk markers (e. g. trigly- 
cerides [104], lipoprotein (a) [105]) (Fig. 2b). By 
contrast, an odds ratio of 2.0 (1.6-2.5) for CHD was 
reported in a previous review of the 11 initial pro- 
spective studies of CRP [71] and even more extreme 
odds ratios have been reported in some earlier indi- 
vidual studies. This attenuation in ('HD risk associ- 
ated with CRP levels during the course of its study is 
likely, at least in part, to reflect the decrease in scope 
for random error and for selective publication in lar- 
ger and later hypothesis-testing studies. It is also pos- 
sible, however, that there may he important 
differences across studies in features related to popu- 
lation characteristics, assay procedures and statistical 
methods used. To help address such uncertainties 
more reliably, the Emerging Risk Factors Collabora- 
tion (ERFC) has collated and harmonized individual 
data from participants in 49 population-based prospec- 
tive studies of CRP involving a total of about 
120 000 participants and about ')500 ('HE) outcomes 
[9]. In contrast with literature-based reviews (which 
have access to only published or limited aggregated 
data), detailed pooled analyses involving primary data 
should provide: (i) precise analyses of CRP-CHI. ) 
associations under a range of various circumstances 
(such as at different ages, in women and men and at 
different levels of risk factors), (ii) reliable character- 
ization of the shape of any dose-response relationship 
curves, (iii) consistent approaches to adjust for possi- 
ble confounding factors, (iv) correction for within-per- 
son variability in levels of CRP and of possible 
confounding factors and (v) detailed investigation of 
potential sources of heterogeneity. 
Even analyses in the ERFC may not, however, distin- 
guish reliably whether CRY is mainly a causal risk 
factor in CHD or mainly a marker of established car- 
diovascular risk factors to which it is correlated, or 
mainly a marker of subclinical disease or some com- 
bination of these possibilities. The potential scope for 
confounding in studies of CRP is suggested by obser- 
vations that individuals with higher than average lev- 
els of CRP tend to have higher values of blood 
pressure, pulse-wave velocity, central arterial blood 
pressure, proatherogenic lipid fractions (LDL, apolipo- 
protein-B), higher body mass index and levels of 
abdominal obesity and a greater prevalence of diabe- 
tes and metabolic syndrome and smoking and lower 
socio-economic status and birth weight (106-109. 
CRP is inversely associated with a range of poten- 
tially protective risk factors in CHID, such as physical 
activity, HDL cholesterol, apolipoprotein-AI and 
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consumption of fruits and vegetables (100,1101. CRP 
levels are also associated with levels of several other 
emerging biochemical risk markers of uncertain 
relevance to CHD, such as fibrinogen, adiponectin 
and triglycerides X88,1001. The third National Health 
and Nutrition Examination Survey reported that in up 
to about two-thirds of Americans, a CRP level greater 
than 3 mg L1 could be attributable to elevations in 
at least one established cardiovascular risk factor such 
as those named above [111]. The many potentially 
relevant correlates of CRP make it difficult, therefore, 
to determine to what extent the observed associations 
of CRP with CHD risk are independent from estab- 
lished and emerging coronary risk markers. Statistical 
adjustment for confounding factors is potentially lim- 
ited because not all relevant confounders have been 
(or can be) measured in a study. Moreover, even mca- 
sured confounders may be incompletely adjusted for 
because allowances are typically not made for within- 
person variability in levels of confounders (e. g. blood 
pressure, serum lipid concentrations). Alternatively, 
statistical ove adjustment - the correction for markers 
in any causal pathway between CRP levels and CHD 
risk - could in principle obscure a potentially impor- 
tant aetiological relationship. In practice, however, it 
is difficult to judge the likelihood of over adjustment 
given current uncertainties about whether CRP exerts 
any vascular effects, as described in the next section. 
Experimental studies and animal models of CRP and 
atherogenesis 
The possibility that CRP might have proatherogenic 
actions was first suggested in 1982 by the discovery 
of its specific binding to LDL and VLDL [10,11] 
and was supported by its detection in atherosclerotic 
plaque [12]. Even before this it was well established 
that CRP can activate the classical complement path- 
way [40,411 and is therefore potentially pro-infla- 
mmatory. However, compelling evidence for a role of 
CRP in atherosclerosis has not emerged despite many 
reports describing a very large range of pro-inflamma- 
tory, pro-thrombotic, vasoactive and thus potentially 
pro-atherogenic and pro-atherothrombotic effects of 
CRP preparations on various cell types in vitro. 
Almost none of these reports, most of which use com- 
mercial preparations of CRP, have described any char- 
acterization of the integrity or purity of the protein, 
and very few included any controls. None of the early 
studies removed either the toxic sodium azide, present 
in all commercial preparations as a bacteriostatic, or 
considered the inevitable presence of bacterial endo- 
toxin (lipopolysaccharide) in CRP produced by 
recombinant Escherchiu coli. Careful studies with 
authentic pure CRP isolated from human material and 
with recombinant CRP produced by mammalian cells, 
and thus free of such biologically active contamina- 
tion, do not confirm claims for wide-ranging direct 
cellular actions of CRP [13,112-1191. 
There is now an extensive and controversial literature 
which extends to in vivo studies involving either 
injection of CRP in different species or transgenic 
expression of CRP in mice. Injection of even enor- 
mous doses (40 mg kg 1) of purified authentic human 
CRP into mice and rats neither elicited inflammation 
nor produced any clinical ill effects (including 
changes in blood pressure) [120]. This important 
observation is consistent with the fact that human 
CRP concentrations can cover a 10 000-fold range 
from less than 50 jig L1 to more than 500 mg L1 in 
the acute phase response and this is very unlikely to 
be compatible with significant effects of CRP on vas- 
cular tone, activation of inflammatory cells, triggering 
of coagulation or any of the other purported signalling 
functions lately ascribed to CRP on the basis of 
in vitro studies with commercial CRP preparations. 
Although there is one report of enhanced atherosclero- 
sis in apolipoprotein E knockout mice expressing 
transgenic human CRP [121] other and larger studies 
show no such effect [122-1241 nor any pro-inflam- 
matory or pro-thrombotic action even in aged athero- 
sclerotic animals [125]. In the more humanized model 
of atherosclerosis in LDL receptor knockout mice 
expressing apoB 100, transgenic human CRP was ath- 
eroprotective [126]. Indeed, the presence of CRP in 
human atheroma is no less likely a priori to be ath- 
eroprotective than it is to be atherogenic [36]. Extra- 
polation to humans from in vivo experimental animal 
studies of CRP function is not possible because, 
despite the considerable phylogenetic conservation of 
CRP structure, there are very substantial differences 
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between CRPs of different species with respect to fine 
details of ligand recognition, secondary effects of 
ligand binding including complement activation, 
normal concentrations and behaviour as acute phase 
reactants [44,127,1281. Introduction of human CRP 
into animals, wherein the protein is interacting with 
xenogeneic molecules, cells, physiological and patho- 
physiological processes, cannot be assumed to be a 
robust test for functions of human CRP in humans. 
Despite the claims to the contrary, the only rigorous 
conclusion at present is that neither the physiological 
nor the pathophysiological functions of human CRP 
are yet known. 
To address these questions, work is in progress in the 
Pepys laboratory in three areas: 
I C'-reactive protein knockout mice have been created 
using C57HL/6 embryonic stem cells in order to have 
genetically homogenous pure line C57BL/6 mice defi- 
cient in CRP. "These mice are fertile and so far have an 
apparently normal life span. Characterization of their 
phenotype in relation to atherogenesis and other chal- 
lenges will elucidate the functions of mouse CRP and 
may be informative about the human protein, even 
though the two have radically different concentrations 
and behaviour as acute phase proteins. Others have 
also lately reported production of a mouse CRP knock- 
out but not its genetic background [ 1291. 
2 Clinical `good manufacturing practice' grade 
human CRP has been isolated and purified from 
human plasma pooled from over 6000 comprehen- 
sively validated normal healthy donors. This is a con- 
siderable undertaking in view of the normal plasma 
concentration of CRP of less than I mg L1 and will 
he only the second reported human CRP preparation 
made from healthy individuals [491 rather than from 
diseased individuals mounting an acute phase 
response or produced in recombinant bacteria or cells. 
It is thus entirely physiological in addition to being 
highly purified, completely free of exposure to bacte- 
rial endotoxin or other contamination, sterile, nonpyr- 
ogenic, fully structurally and functionally intact and 
approved by the UK regulatory authorities for admin- 
istration to human subjects. This preparation will be 
used to test for effects of human CRP itself, on cells 
in vitro, on animals in vivo and finally in human vol- 
unteers, unrelated to any possible contamination or 
alteration in the native protein. This unique reagent 
will he made available for replication studies by oth- 
ers and should make a major contribution to resolu- 
tion of the present controversies. 
3 The first specific CRP inhibitor drug, 1,6 (bis)- 
phosphocholine hexane [1201 and related compounds 
are being developed for clinical testing. Although they 
are not orally bioavailable, have a very short half-life, 
and will thus he suitable only for short-term acute 
use, they should be informative about the role of CRP 
following acute Ml or in other acute clinical condi- 
tions characterized by tissue damage and a major 
acute phase CRP response. Development of new 
drugs able to specifically block CRP function for sus- 
tained periods will be required to establish robustly 
the role of human CRP in health and disease, as 
described in the final section of this review. 
Randomized trials of statins in relation to CRP and 
CHD 
The Justification for the Use of Statins in Primary 
Prevention: an Intervention Trial Evaluating Rosuvast- 
atin (JUPITER) randomized about 18 000 participants 
without evidence of cardiovascular disease, who had 
relatively high baseline levels of CRP (2 mg L1 or 
greater) and relatively low levels of LDL cholesterol 
(i. e. <3.36 mmol L 1), to receive either rosuvastatin 
20 mg once daily or placebo [ 130,1311. Based on a 
recommendation from an independent data and safety 
monitoring board, the trial was stopped early in Feb- 
ruary 2008 because there was unequivocal evidence 
of a reduction in cardiovascular morbidity and mortal- 
ity in patients treated with rosuvastatin compared 
with placebo (http: i/www. cardiosource. coni/rapidne%, s 
summaries/summary. asp? SumID=318). The JUPITER 
findings extend the known benefits of statins beyond 
those previously demonstrated in a meta-analysis of 
individual results on about 90 000 patients that 
showed cardioprotective effects across a wide range 
of predominantly intermediate-to-high risk individuals 
[132]. 
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The findings of the JUPITER trial, which have not 
yet been published in detail, have raised several 
questions. First, is the measurement of CRP and 
LDL cholesterol an optimum approach to target statin 
medication in individuals at low-to-intermediate risk 
of cardiovascular disease'' This topic is considered in 
a subsequent section of this review in relation to 
measurement of ('RP for the purposes of risk stratifi- 
cation. Second, might statins confer at least part of 
their benefits through lowering ('RP (or related anti- 
inflammatory activities)'? This question arises because 
statins are known to lower baseline ('RP concentra- 
tions by about 20% [1331. Unfortunately, this 
hypothesis is difficult to confirm or refute reliably in 
randomized trials of statins because these agents so 
potently lower the plasma concentration of L1)L cho- 
lesterol, a major known causative factor in (CHI). A 
third question suggested by the JUPITER findings is: 
might the cardioprotective benefits of statins be pro- 
portionally greater in people with higher baseline 
('RP levels than those with lower CRP levels (i. e. 
effect-modification of statin effectiveness), given the 
possibility that statins may have relevant anti-inflam- 
matory activities'? 1133--I361. The JUPI'FI: R trial 
itself may not he the optimum study to test this 
hypothesis because, as noted above, it was restricted 
to participants with ('RP levels 2 mg L' or greater. 
This question can, however, he readily addressed by 
measurement of (1R1' levels in the stored serum sam- 
ples of several existing large statin trials that 
recruited patients without reference to baseline CRP 
levels. For example, stich analyses of CRP are 
expected to emerge from the Heart Protection Study, 
which randomized about 20 (J00 high-risk patients to 
40 mg simvastatin or placebo and has recorded 
I'ig. 3 Conceptual parallels 
between a randomized controlled 
trial and a hypothetical Mende- 
lian randomization experiment to 
judge the causal relevance of a 
hiomarker associated with coro- 
nary haart disease (('1! D) risk. 
several thousand cardiovascular outcomes during 
follow-up [137,138]. 
Genetic studies 
An emerging approach to evaluate any causal rele- 
vance of subtle, prolonged increases in CRP levels to 
C'HU involves genetic epidemiology [139-1411. 
`Mendelian randomization' experiments attempt to 
minimize confounding and avoid reverse association 
bias by measurement of common polymorphisms or 
haplotypes in regulatory regions of the CRP gene that 
have been reliably associated with differences in cir- 
culating CRP concentration (but not with any known 
change in CRP function). According to Mendel's 
second law (1421, the inheritance of genetic variants 
should he subject to the random assortment of mater- 
nal and paternal alleles at the time of gamete forma- 
tion. So, if CRP levels actually increase the risk of 
('HU, then carriage of alleles (or haplotypes) that 
expose individuals to a long-term elevation of CRP 
should confer an increased risk of CHD outcomes in 
proportion to the difference in CRP levels attributable 
to the allele. Because of the randomized allocation of 
alleles from parents to offspring, potential confound- 
ers should he distributed amongst the genotypic clas- 
ses, and any bias because of reverse causation should 
be avoided because genotypes are fixed at conception 
and not prone to modification by the onset of disease 
[143,1441 (Fig. 3). This approach has been applied to 
the study of other emerging risk markers, including 
plasma levels of fibrinogen and homocysteine [139. 
1411, The potential limitations of Mendelian 
randomization analyses include the need for very 
large sample sizes because most genotypes have only 
RCT Mendelian randomisation 
Sample 
Randomisation 
Intervention Control 
Blo 
masker 
Blom) ker 
or higher 
CV 
i 
vent CV 
i 
vent 
rate lower rate higher 
Population 
Random allocation of alleles 
I 
Genotype as Genotype AA 
Biom' arker Biomarken 
loner higher 
CV 
I 
event CV event 
rate lower rate higher 
(c) 2008 Blackwell Publishing Ltd Journal of Internal Medicine 264; 295-314 303 
j. P. Casas et al. Review: C-reactive protein and CHD 
modest effects on concentrations of biochemical 
markers and, at least in principle, the scope for resid- 
ual confounding by unrecognized pleiotropic effects 
of genotypes and by developmental adaptation (`cana- 
lization') [ 1401. 
C-reactive protein concentration is a heritable trait 
156,145-1481 and several single nucleotide poly- 
morphisms (SNPs) within the CRP gene have now 
been identified (Fig. 4) (1491. Twelve common SNPs 
with minor allele frequency of >5% are present in 
a6 kb region encompassing the gene in people of 
European ancestry and there are around 22 SNPs in 
subjects of African descent. In Europeans, the 12 
SNPs are distributed amongst just four common 
haplotypcs that account for approximately 95%, of 
all chromosomes. A number of studies have reported 
consistent associations with CRP concentration of 
individual SNPs or subsets of SNPs, some of which 
have been typed for their ability to capture haplotype 
diversity (tagging SNPs) (108,150-1521. For exam- 
ple, a combined analysis of 25 reports involving a 
total of around 31 000 participants of European 
descent has yielded a difference in CRP levels of 
0.12-0.96 mg L' per allele, depending on the SNP 
studied, a difference that equates to between 0.3 
and 0.8 standard deviations of the CRP distribution. 
A meta-analysis of genetic studies involving a new 
Bayesian method (enabling integration of information 
across studies that had typed a partially overlapping 
set of CRP SNPs) has provided evidence of four func- 
tional SNPs at the CRP locus that influence its circu- 
lating concentration (149. Several initial studies have 
reported that although these CRP genotypes (and 
haplotypes) are clearly associated with CRP levels, 
they are not materially associated with any of a large 
panel of established or emerging cardiovascular risk 
markers, suggesting that these variants may well he 
unbiased proxies for CRP and suitable for use in 
Mendelian randomization analyses ("fable 1) [ 108, 
151,153-1551. Although such studies (which have 
collectively involved a few thousand CHD cases) 
have generally reported lack of strong association of 
these genetic variants with CHD risk, they have not 
been sufficiently powerful to realistically confirm or 
refute any moderate effect of CRP levels on CHD 
such as a 10-20% increase in risk per standard devia- 
tion increase in levels. As sample size calculations 
suggest that at least 15 000 CHD cases and a similar 
number of controls may well be needed to provide 
CRP levels by C RP gene variant 
Additive model 
CRP Gene variant No. Studies Traditional meta-analyses Bayesian model 
(individuals) Estimate Estimate 
(95% confidential intervals) (95% credible intervals) 
rsl 800947 (+1059G )C)' 10 (11045) --i- -0.38 (-0.50, -0.25) -0.26 (-0.46, -0.11) 
rs1205 (+2302G -AA) 10 (16942) -0.35 (-0.41, -0.28) -52 (-0.68, -0.36) 
rsl417938 (+194A >T) 5(7460) -i- 0.17 (0.03,0.31) N/A 
rs2794521 (-717A)G) 6 (5803) 0.12 (-0.10,0.35) N/A 
rsl 130864 (+1444C -J) 19 (21 674) 0.19 (0.14,0.25) -0.34 (0.20, -1.17) 
rs3091244 (-286C--J/A) 7 (7786) 0.20 (0 15,0.25) N/A 
rs3093077 (+48997 )G) 4 (6619) 
AV 
0.48 (0.33,0.62) 0.59 (0.37,0.95) 
rs3093059 (-757T--*C) 3 (3475) "-7}- 0.56 (0.37,0.78) N/A 
-0.7-0.5-0.3-0.1 0.3 0.7 
Fig. 4 The effect of eight common polymorphisms in the human CRP gene on CRP concentration (mg L`1). [nfonnation was 
obtained from published and unpublished studies, and analyses were based on traditional meta-analysis using an additive model 
as well as Bayesian meta-analysis. The figure is reproduced from Fig. 4 in Verzilli et al. Am J hum Genet, 2008; 82: 859- 
872, p 865. N/A refers to SNPs excluded from the Bayesian model. 
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Table 1 Cardiovascular risk fac- 
tor distribution according to the 
CRP/ i 14440-T polymorphism Variable 
Subjects 
(studies) 
Weighted mean difference 
[IT - C-carriers] (95(%1) Y-value 
Age (years) 6358 (7) 0.17 (-0.19,0.52) 0.35 
Systolic blood pressure (nimllg) 6356 (7) -0.31 (-1.78,1.16) 0.68 
Diastolic blood pressure (nmillg) 6356 (7) -0,70 (-1.56,0.16) 0.11 
Body mass index (kg m-') 6359 (7) 0.34 (0.06,0.62) (1.02 
Total cholesterol (rnmol L-1) 6115 (6) -0.01 (-0.08.0.06) 0.87 
1I17L cholesterol (nmtol L-') 4714 (5) -0.01 (-0.04,0.01) 0.32 
Triglyceride (nuuol 1. 6041 (5) -0.03 (-0.11,0.06) 0.51 
l"ibrinogen (g L-1) 5656 (4) 0.03 (-0.02,0.08) 0.20 
Glucose (tmnol L-1) 1913 (3) -0.01 (-0.13,0.13) 0.90 
Alcohol intake (U per week) 4549 (4) 0.01 (-1.38,1.39) 0.99 
Current smoking' 6132 (6) 1.011 (0.84,1.20) 0.98 
C-reactive protein (mg L") 4659 (6) 0.68 (0.31,1.10) 0.0001 
CRP. C-reactive protein. 
'For this variable instead of the WMD, the value reported is the weighted odds ratio 
Data source: Table taken from C'asas et a!., 2006 [l54]. 
Comparisons are made between TT homozygotes and C-allele carriers. 
such informative analyses, the CRP Coronary Disease 
Genetics Collaboration (CCGC) has been established 
[1561. This collaboration currently involves over 30 
epidemiological studies with a total of about 37 000 
cases of MI or coronary death and about 120 000 
controls. The objective is to conduct pooled analyses 
of individual participant data from these studies to 
examine the association between relevant CRP genetic 
variants and CHD risk under various circumstances, 
thereby helping to assess causality. 
CRP and risk stratification in acute coronary 
syndromes 
Several scores have been proposed to assess the 
short-term risk for recurrent events and adverse prog- 
nosis in patients presenting with acute coronary syn- 
dromes, such as the thrombolysis in myocardial 
infarction (TIMI) risk score, which is based on clini- 
cal and electrocardiogram variables [1571. As noted 
above, several studies have reported on associations 
between CRP levels and recurrent cardiovascular 
events in patients presenting with acute coronary syn- 
drome [7,8,158,1591. In 2003, the American Heart 
Association/Centres for Disease Control (AHA/CDC) 
recommended CRP measurement as an additional 
marker of prognosis in patients with acute coronary 
syndromes [161 on top of characteristics in the TIMT 
risk score [160,1611. Further studies have proposed 
the addition of troponin 'I and N-terminal pro-brain 
natriuretic peptide to the TIMI risk score plus CRP 
[1621. Interpretation of this evidence would be 
enhanced by pooled analyses of individual data from 
each of the available studies of acute coronary syn- 
dromes (which is currently outside the scope of the 
FRFC) and by consideration of how addition of CRP 
(and other markers) to risk alogrithms might lead to 
any change in the management of such patients. 
CRP and the evaluation of long-term risk of coronary 
disease 
Several risk algorithms have been proposed to help 
stratify risk of cardiovascular disease in general 
Western populations, such as Framingham, PRO- 
CAM, SCORE, Reynolds and QRISK [163-1671. 
Each of these algorithms involves a core set of the 
same established risk factors (e. g. smoking, blood 
pressure, total cholesterol) but differ in their inclu- 
sion of various other characteristics, such as HDL-C 
(in Framingham), triglycerides (in PROCAM only), 
CRP (in Reynolds only) and body mass index or 
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markers of socio-economic status (in QRISK only). 
As CRP levels display relatively limited biological 
variability (outside acute phase fluctuations) and can 
he accurately assessed using assays with internation- 
ally agreed standards, their measurement for risk pre- 
diction has been regarded as particularly practicable 
by some workers (although such advantages also 
apply to the measurement of some other nonspecific 
inflammatory markers that may be measured more 
cost effectively than CRP such as the leucocyte 
count and serum albumin). In 2003, a report of the 
AHA/CDC recommended that `CRP may be used at 
the discretion of the physician as patt of a global 
coronary risk assessment in adults without known 
cardiovascular disease', concluding that a CRP value 
above a cut point of 3 mg L1 was indicative of 
high risk [ 161. The report acknowledged, however, 
the need for further research to address several 
uncertainties in the evidence. By contrast, Euro- 
pcan authorities have not recommended measurement 
of ('RP to enhance cardiovascular risk assessment 
1171. 
Part of the uncertainty stems from the fact that 
although many published prospective studies have 
commented on the potential value of CRP in risk 
prediction, they have often reported only measures 
of association (e. g. odds ratios, hazard ratios), which 
do not directly address the issue of the utility of a 
marker in prediction or stratification. Furthermore, 
even studies that have involved statistics relevant to 
the assessment of risk prediction have involved dif- 
ferent metrics, including measures of discrimination 
(c. g. the C index 1168,1691 and the measure D 
(170, with the former related to the area under the 
receiver operating characteristic curve) and reclassifi- 
cation methods that aim to summarize the potential 
of a marker to re-assign individuals into more appro- 
priate risk groups [1711. Each of these approaches 
may impart somewhat different information. As rec- 
ommended by the US National Heart Lung and 
Blood Institute 2006 workshop report on CRP, fur- 
ther work is needed to compare and contrast the 
strengths and limitations of each of these approaches 
(172 to enable their use in the multiple study situa- 
tion (as in the ERFC. database) and to incorporate 
health economic analyses to help judge the value of 
any such measurements (http: //www. nlilbi. nih. gov/ 
meetings/work sh opsi crpi report. htm ). 
CRP in acute ischaemic tissue damage 
There is always a substantial CRP acute phase 
response following acute I [173,174. An associa- 
tion between sustained high values of CRP following 
acute Ml and adverse outcomes was first reported in 
1982 [1751 and subsequent large studies have shown 
that increased peak and postinfarct CRP concentra- 
tions are significantly associated with increased inci- 
dence of cardiac complications including heart 
failure and cardiac death, apparently independently 
of other predictors [14,159,176--1811. Acute M1 is 
invariably associated with acute inflammation around 
the lesion [11 and complement makes a substantial 
contribution to the size of experimental acute myo- 
cardial infarcts produced by coronary artery ligation 
in mammals [1821, including old world primates 
[1831. All human acute Ml lesions contain CRP and 
activated complement co-deposited in and around the 
infarct [2,1841. The rat provides an excellent model 
for testing the possible pathogenicity of human CRP 
in this situation because although rats have abundant 
CRP, their protein does not activate rat complement 
whereas human CRP potently activates both rat and 
human complement [1851. Effects of human CRP 
injected into rats can therefore reflect what human 
CRP may do in humans. Indeed, administration of 
authentic pure human CRP to rats after they have 
undergone coronary artery ligation or ischaemia- 
reperfusion injury causes significant worsening of 
cardiac function and increased mortality, which 
reflect increased infarct size [18]. The effect is spe- 
cific for human CRP and absolutely complement- 
dependent, and human CRP is co-deposited with rat 
complement in the infarct [181. The same pathogenic 
effect of human CRP is seen in the rat model of 
cerebral infarction produced by middle cerebral 
artery occlusion [1861. The adverse effect of human 
CRP in the acute MI situation is completely abro- 
gated by administration of the novel small molecule 
specific CRP inhibitor drug, 1,6 (bis)-phosphocho- 
line hexane [1201 (Fig. 5). Importantly, this drug has 
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Fig. 5 Chemical fonnula of 
his( phosphocholine)-hexane 
(above) and 3D crystal structure 
of the drug-C-reactive protein 
(CRP) complex (below); face on 
view (left) and side view (right) 
of two ('RP molecules cross- 
linked by five drug molecules 
11201. X-ray cry stallographic 
structures provided by Dr. Simon 
Kolstoe. 
no effect at all in rats subjected to coronary artery 
ligation which do not receive human ('RP and is 
thus not cardioprotective per se but only by virtue 
of its inhibition of ('RP [1201. 
The likely mechanism of ('RP pathogenicity is there- 
fore binding of abundant CRP to the ligands exposed 
in dead and damaged cells, triggering substantial com- 
plcmcnt activation with release of chemotactic factors 
and opsoni7ation of cells in and around the lesion, 
leading to enhanced infiltration by inflammatory cells 
and consequent bystander damage. The terminal com- 
plcment sequence may also directly kill cells which 
would otherwise survive and the end result is death of 
more myocardial tissue than would be killed by 
ischacmia alone. Development is now in progress 
towards clinical testing of ('RP inhibition in patients 
with acute vll. 
Conclusion 
Until specific ('RP inhibitor drugs suitable for long- 
term administration become available, the question 
of whether low level chronically increased CRP 
concentration is a risk factor for CHD, may be 
addressed by pooled analyses of data from prospec- 
tive studies of circulating CRP levels and from 
studies of CRP genetic variants. Uncertainties 
related to the separate issue of risk prediction in the 
general population can also be addressed in the near 
future by collaborative approaches involving large 
combined datasets. Meanwhile, it is very important 
to distinguish clearly between (i) the potential path- 
ogenicity of high circulating CRP concentrations in 
individuals with a substantial volume of damaged 
tissue in whom CRP binding to exposed ligands 
and consequent major complement activation can 
exacerbate injury and (ii) the possible actions of 
baseline or rather modestly increased CRP concen- 
trations which together with complement may assist 
in clearance and resolution of minor tissue injury 
and thus be beneficial. The cxpei mental evidence 
from animals indicates that human CRP can defi- 
nitely be pathogenic after ischacmic infarction, but 
any relevance to the slow process of atherogenesis 
remains unproved. 
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